<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:radx="http://radx.com/20260630"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="radx-20260630.xsd" xlink:type="simple"/>
    <context id="cref_138071911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:PlanAxis">radx:SharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-10</startDate>
            <endDate>2026-09-10</endDate>
        </period>
    </context>
    <context id="cref_1453202449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:AmericanDepositaryShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">radx:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-24</instant>
        </period>
    </context>
    <context id="cref_208507239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">radx:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-24</instant>
        </period>
    </context>
    <context id="cref_1391050674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">radx:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <context id="cref_1449520954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:PlanAxis">radx:SharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">radx:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <context id="cref_1085778750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_608536123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_17985243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:PlanAxis">radx:SharePurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1360674854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">radx:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-24</startDate>
            <endDate>2026-07-24</endDate>
        </period>
    </context>
    <context id="cref_2001163503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:GoingConcernMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1305557533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_198500851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1018615720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1345123180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_312638053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_540356014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_812473718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1591042892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">radx:TotalRemunerationForAuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_303504771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">radx:TotalRemunerationForAuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2100782799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">radx:AuditOfNASDAQRegistrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1346747018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">radx:AuditOfNASDAQRegistrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_825614241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">radx:AuditAndReviewOfFinancialStatementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_414897961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">radx:AuditAndReviewOfFinancialStatementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AuditAndOtherAssuranceServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_682156036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroNineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2001150217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyElevenTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_257140075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroOneZeroEightTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_126996007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroOneZeroSevenTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_718193669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1205521687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_675759352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_17681198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1672483521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1304073823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1358652047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:NineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_782284377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:NineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_450007838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyEightZeroEightTwoThousandAndTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_591779329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyEightZeroEightTwoThousandAndTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1551093248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyEightZeroEightTwoThousandAndTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1088531607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyFourZeroTwoZeroSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_520762590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyFourZeroTwoZeroSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_871342575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyFourZeroTwoZeroSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_317646948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyFourZeroTwoZeroSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1292143018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_619814595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1717370067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1685255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_374893698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyTwoElevenTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_160466343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyTwoElevenTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_366531594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyTwoElevenTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_455539713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyTwoElevenTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_611529629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroNineThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_981352347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroNineThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1622593116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_234220556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1981733187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1089707227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSixTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_341143700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSixTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_520622503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyElevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_72696819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyElevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1854211896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroEightTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_900522248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroEightTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1396836075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_65228173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_101105586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroNineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_589083587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroNineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_875875991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroNineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_959946701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1796366748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1827222556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_443616561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2128956856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2119408009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1242036386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_685861082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_284529348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1497542677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_893620482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1072549679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_775859418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoZeroTwoFourZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_927481683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoZeroTwoFourZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_460571520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoZeroTwoFourZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1495591169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoZeroTwoFourZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_749500879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeTwelveThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_421970489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeTwelveThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1899490176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeTwelveThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1008207822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeTwelveThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1300933542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1596448726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1728794886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1436931810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1266471380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1359085653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1275499145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1391377859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_519685270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_270637834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_724216223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_420995518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_759987645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_688984078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1269655552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1492498597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroSixZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_407099329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroFiveEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1107392644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroFiveEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1794744267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroFiveEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_730857818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroFiveEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1608534073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroTwoZeroSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1370650207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroTwoZeroSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1927572909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroTwoZeroSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1258967839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyThreeZeroTwoZeroSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_362113034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_317774168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_875420284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_412889581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1194433765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_927149939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1666552381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_172805993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoElevenSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2068080987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1674668432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_786507420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_878367649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1707518562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroFourTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1160084053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroFourTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1924206269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroFourTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_327000077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroFourTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1222503693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroThreeZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_777974110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroThreeZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1756325082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroThreeZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_119703658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyTwoZeroThreeZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1881161616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneTwelveTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1915052171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneTwelveTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1954644021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneTwelveTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1100805626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneTwelveTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1647359300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroEightZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1857311806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroEightZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1805944749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroEightZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2054622152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroEightZeroTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_121897300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSevenTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2000660802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSevenTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_930482778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSevenTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1739775018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSevenTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_100673349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSixTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_931133148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSixTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_51592759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSixTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_198631103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroSixTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1487221508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_501241957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2112097951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1443674035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1494728494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourZeroFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2017346239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourZeroFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1130058759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourZeroFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_816183465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroFourZeroFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1403356230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroThreeTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_548074793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroThreeTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1781408912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroThreeTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_360264480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroThreeTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_926930741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_530068751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_450697764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1034873053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_135083310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1941222514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_875901779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">radx:EmployeeOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_1677041325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:PaymentsToDirectorRelatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1783997132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:PaymentsToDirectorRelatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_493839153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:PaymentsToDirectorRelatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1767159501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:ForfeiturePaymentsExpenseToKeyManagementPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_403406822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:ForfeiturePaymentsExpenseToKeyManagementPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1632162546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:CancerResearchTechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2070317563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FDAINDAllowanceForATherapeuticProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1878796642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1178193810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:DeferredPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_252680283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:UponTotalWorldwideNetSalesOfAllLicensedProductsExceedingFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_358410001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:UponTotalWorldwideNetSalesOfAllLicensedProductsExceedingFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_412852398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:UponTotalWorldwideNetSalesOfAllLicensedProductsExceedingTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1314667924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:UponTotalWorldwideNetSalesOfAllLicensedProductsExceedingThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1703580672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:UponTotalWorldwideNetSalesOfAllLicensedProductsExceedingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1047837936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:UponTotalWorldwideNetSalesOfAllLicensedProductsExceedingOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_141722107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1404515809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAorEquivalentInANonUSJurisdictionForALicensedProductByTheChineseEquivalentOfTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1184592063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAorEquivalentInANonUSJurisdictionForALicensedProductByTheChineseEquivalentOfTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_6539201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAorEquivalentInANonUSJurisdictionForALicensedProductByTheJapaneseEquivalentOfTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_157759423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAorEquivalentInANonUSJurisdictionForALicensedProductByTheJapaneseEquivalentOfTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1301684061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAorEquivalentInANonUSJurisdictionForALicensedProductByTheEuropeanUnionEquivalentOfTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_315987104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAorEquivalentInANonUSJurisdictionForALicensedProductByTheEuropeanUnionEquivalentOfTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1488830671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAForALicensedProductByTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2107642178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:RegulatoryApprovalOfABLAForALicensedProductByTheFDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1217481479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FilingOfBLAorEquivalentInANonUSJurisdictionForALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_667332784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FilingOfBLAorEquivalentInANonUSJurisdictionForALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_840661265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:InitiationOfPhaseIIIClinicalTrialOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1067645943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:InitiationOfPhaseIIIClinicalTrialOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1873235144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:InitiationOfPhaseIIClinicalTrialOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2002430941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:InitiationOfPhaseIIClinicalTrialOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1009298097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:InitiationOfPhaseIClinicalTrialOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForAnyOtherLicencedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_191062219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:InitiationOfPhaseIClinicalTrialOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:AndersonForLicencedProductsThatTargetBSevenHThreeAndorAreCoveredByBSevenHThreePatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1902447576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:AggregateNetSalesWorldwideExceedingOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1846050054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:AggregateNetSalesWorldwideExceedingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_407034768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstCommercialSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_543436903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:GrantOfMAInTheEUorUKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_892197224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:GrantOfUSRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1284817183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:Phase3ClinicalTrialpivotalStudyCommencementLimitedToEachOfThe1st3IndicationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2024565384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:Phase2ClinicalTrialpivotalStudyCommencementLimitedToEachOfThe1st3IndicationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_754655235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:Phase1ClinicalTrialpivotalStudyCommencementLimitedToEachOfThe1stIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_10281060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:ClearingOfINDInTheUSOrAnyCountryInTerritoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:TherapeuticDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_424525606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:AggregateNetSalesWorldwideExceedingOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1222400261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:AggregateNetSalesWorldwideExceedingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_828513137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstCommercialSaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2132565912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:GrantOfEUorUKRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2041296158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:GrantOfUSRegulatoryApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_204932463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:Phase3ClinicalTrialCommencementLimitedToEachOfThe1st3IndicationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_324120889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:Phase2ClinicalTrialCommencementLimitedToEachOfThe1st3IndicationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1231890165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:Phase1ClinicalTrialCommencementLimitedToEachOfThe1stIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1954685255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_986665818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="cref_1405919732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhaseOneTherapeuticClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_748034023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:NanoMabTechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhase3TherapeuticClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1078079355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:NanoMabTechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhase2TherapeuticClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1939047493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:NanoMabTechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhaseOneTherapeuticClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_868429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:NanoMabTechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:INDSubmissionToTheUSFDAOrTheEMAOrTheNMPAForPDL1TherapeuticINDSubmissionForTheCamelidPDL1NewFormulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_225111429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:NanoMabTechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:INDSubmissionToTheUSFDAOrTheEMAOrTheNMPAForPDL1TherapeuticBindingLicenseAgreementWithAThirdpartyToImproveCamelidPDL1TherapeuticIndexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2015100241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1877994204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1406080744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhase3TherapeuticClinicalTrialOrApprovalOfALicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_17840321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhase2TherapeuticClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_786639730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientDosedInTheFirstPhaseOneTherapeuticClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1098967680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:INDAllowanceByTheUSFDAOrTheEMAOrTheNMPAforThePKT7TherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_108840067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:INDAllowanceByTheUSFDAOrTheEMAOrTheNMPAforEitherTheHER2OrTheTROP2TherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1210940666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:NanoMabIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="cref_1916309410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1769048956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:ApprovalAtFirstOfFDAEMAPMDAForDiagnosticTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1085754203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:SecondIndicationApprovalAtFirstOfFDAEMAPMDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_789149418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:PMDAApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_844937145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:EMAApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_444225272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FDAApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1509416075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FDASubmissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2032731225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:UponTheDosingOfTheFinalPatientInAPivotalStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_277748615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientPivotalStudyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1017328493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:LastPatientPhaseTwoBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1705760710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientPhaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_566554721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:LastPatientPhaseOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_485519371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:EquivalentOfEitherOfTheseThatIsSufficientToAllowDosingInHumansInAnyCountryInTheTerritoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1350153857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1410443802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1950371269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1162615470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="cref_1533494348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:AnyMarketingApprovalInTheTerritoryOtherThanInAustraliaTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1739428878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:LastPatientPhaseThreeTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1217508044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientPhase3TherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_562406285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:LastPatientPhaseTwoTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1411999849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:FirstPatientPhaseTwoTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_761094825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:LastPatientPhaseOneTherapeuticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1430221635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:AnyMarketingApprovalInJapanChinaHongKongOrTheUnitedStatesOf68GaTRIVEHEXINForDiagnosticApplicationDiagnosticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2125799627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">radx:CommencementOfPhase3DiagnosticClinicalTrialFor68GaTRIVEHEXINDiagnosticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_816128912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1189307281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="cref_965818673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1302339560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1569279335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1773416733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_175546384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:MDAndersonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1098178729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:RadiopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_766531602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:PharmaFifteenCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1639151071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:PharmaFifteenCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_587244859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2048871378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_346654251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:RadiopharmTheranosticsUSAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_126621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">radx:RadiopharmTheranosticsUSAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1963669158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1665656946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:Over5YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1217755389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:Between2And5YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1158695048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:Between1And2YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_199907254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2071746334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:NotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1399891170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:Over5YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1590527928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:Between2And5YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_308497697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:Between1And2YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1863492555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2130818383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">radx:NotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1848343351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_517081436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1912952120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">radx:GBPAUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_249693967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">radx:GBPAUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1832352150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">radx:EURAUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_710217859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">radx:EURAUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_656615078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">radx:USDAUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_334748240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">radx:USDAUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1455051567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ForeignOperationsWhoseFunctionalCurrencyIsNotExchangeableIntoPresentationCurrencyAxis">radx:GBPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_11673677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ForeignOperationsWhoseFunctionalCurrencyIsNotExchangeableIntoPresentationCurrencyAxis">radx:GBPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2044802928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ForeignOperationsWhoseFunctionalCurrencyIsNotExchangeableIntoPresentationCurrencyAxis">radx:EuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1769175827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ForeignOperationsWhoseFunctionalCurrencyIsNotExchangeableIntoPresentationCurrencyAxis">radx:EuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1885936551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ForeignOperationsWhoseFunctionalCurrencyIsNotExchangeableIntoPresentationCurrencyAxis">radx:USDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_218923996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ForeignOperationsWhoseFunctionalCurrencyIsNotExchangeableIntoPresentationCurrencyAxis">radx:USDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_259034637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1502965910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_686324981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_711082873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_404292157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1897982295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">radx:ContingentIssueOfEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_1445455089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">radx:ContingentIssueOfEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1794279675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1672975465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_327595348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1623135981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_996975840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1121416750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_435790906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_777909411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_208910529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_402616417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1659325166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_855609256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_958314475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1984381866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1342992216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1972543109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1712076956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_565546587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1052646885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1670218366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_495300227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2011796631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_723492209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_531204171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_301496185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_239281928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_362669200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_416724211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_815368052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1818709843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_2064533522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_124540725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_97917737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_418281911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:ShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_308524805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveTwelveZeroNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1307110558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveTwelveZeroNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_823319036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveTwelveZeroFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1457716369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveTwelveZeroFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1920512828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveTenTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_883977399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveTenTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1610866922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveZeroSixTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1135754045">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveZeroSixTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_974563778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:IssueOfPlacementSharesToLantheusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveZeroOneTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1113578005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:IssueOfPlacementSharesToLantheusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFiveZeroOneTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_962250976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:ForfeitureSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourTwelveSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_872043276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:ForfeitureSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourTwelveSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1540898789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:AchievementOfAMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourTwelveThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_123290324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:AchievementOfAMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourTwelveThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1673541035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:IssueOfPlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroNineOneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_786742383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:IssueOfPlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroNineOneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_346236073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LantheusInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_366909380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LantheusInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1103562920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">radx:Tranche2PlacementSharesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1529876341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:Tranche2PlacementSharesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1960491201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:Tranche2PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_692413006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:Tranche2PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2122001255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:IssueOfSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroSevenZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_276303662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:IssueOfSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroSevenZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1259894475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_1742620739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroFiveOneSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1621380337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroFiveOneSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_394609396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroFourOneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1104773571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroFourOneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_971503140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroThreeTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1446556830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroThreeTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_272871356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:Pharma15AcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroThreeZeroFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1115980466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:Pharma15AcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroThreeZeroFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_987834646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroTwoOneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1801638694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroTwoOneFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1083727377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueShortfallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroTwoZeroNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_713120193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LindAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroTwoZeroNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1316836734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueShortfallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroOneThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_522101770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueShortfallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroOneThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_235866821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LieuOfCashForServicesRenderedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroOneZeroFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_79226475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:LieuOfCashForServicesRenderedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyFourZeroOneZeroFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2062279520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:ForfeitureSharesAsPerEmploymentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyThreeTwelveMonthFourteenDaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_987019731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:ForfeitureSharesAsPerEmploymentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyThreeTwelveMonthFourteenDaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1354820612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyThreeTwelveZeroEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_276989555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">radx:RightsIssueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">radx:TwoThousandTwentyThreeTwelveZeroEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_442824516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="cref_233224037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">radx:PivalateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_194685560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">radx:MAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1940931547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1497733908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">radx:huPSAAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1698932143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">radx:AVb6IntegrinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_584156497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:OtherIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_481931119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:PivalateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_538344337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1886757926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:MAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2010781659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1617380781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:huPSAAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_489116657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:AVb6IntegrinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_61988382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:OtherIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_824292737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:PivalateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1124718144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1778718866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:MAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_260407272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1118946646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:huPSAAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1835989352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:AVb6IntegrinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2147404629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:OtherIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_236469634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:PivalateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_675422079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2111569484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:MAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_625013276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1328464632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:huPSAAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_7718076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:AVb6IntegrinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1665330828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:PivalateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_654635920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:MAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1111408546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1238301015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:huPSAAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_515724922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:AVb6IntegrinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1494054659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:OtherIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1480035372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:PivalateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_415298535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1008801451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:MAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_415814143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1424152838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:huPSAAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2011328152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:AVb6IntegrinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2113010095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_825383145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2028021515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:MDAndersonContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1841843539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:Pharma15ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_119581305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:NeoIndicateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1173656975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:PivalateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1424935193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:TRIMTContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1546656074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:DiaprostContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_298583932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:NanoMabContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_916272453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:MDAndersonContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_422981330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:PivalateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_865489246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:TRIMTContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_950767289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:DiaprostContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_36056968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:NanoMabContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1546356962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:MDAndersonContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_275006410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:MDAndersonContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_968227831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:TRIMTContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1682262865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:TRIMTContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_658631945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:Pharma15ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_476095383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:PivalateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1214084812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:PivalateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1304397351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:NeoIndicateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1430126581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:NanoMabContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1477221416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:NanoMabContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_58409172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:DiaprostContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_158447489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:DiaprostContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_387488510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:RDAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_858350249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:OtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_2027155156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:OtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_655907015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:OtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_705890069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_41466566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_861240918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:AccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1986429776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:AmountsDueToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1865531277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1595967763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_808852886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1763895519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">radx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1502821912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">radx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1446399978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">radx:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_71955621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">radx:AccruedReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_290225396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">radx:AccruedReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1493941943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">radx:AccruedReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_820677847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_560997269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:USTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_2051121825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:USTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1834664750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:USTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_879251327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:USTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1662401931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:USTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_898783114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:USTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1130774008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:AustralianTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_1315326579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:AustralianTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1699112522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:AustralianTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_585009615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:AustralianTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_2052780937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:AustralianTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1937830845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">radx:AustralianTaxExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_892721806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_993985842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1346579919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_109617195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:UCLAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_133146093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:UCLAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_467084138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:PivalateImperialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1664407651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:PivalateImperialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2088230386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:PivalateImperialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1521170066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:NeoindicateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_2040435642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:NeoindicateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_577038710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:NeoindicateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_484307968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1650050184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1668330041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:NanoMabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_662260166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:RDVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_270941582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:RDVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_680055745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:RDVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_293179339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1715402857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1828563044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:huPSAAntibodyDiaprostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1267373319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:huPSAAntibodyDiaprostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2074446413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:huPSAAntibodyDiaprostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_874894537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ConsultingFeesRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_891507282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ConsultingFeesRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1074339372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ConsultingFeesRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_745646697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AVb6IntegrinTRIMTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_897947490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AVb6IntegrinTRIMTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2021512896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AVb6IntegrinTRIMTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_292626312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1504167164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_58801058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1451871145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:TravelAndEntertainmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_192897766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:TravelAndEntertainmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_630773908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:TravelAndEntertainmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2039607131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:PatentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1284426911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:PatentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_936589973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:PatentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_202579806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ListingAndShareRegistryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1689403473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ListingAndShareRegistryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1276853525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ListingAndShareRegistryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_2123680038">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:LegalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_410505567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:LegalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_801610513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:LegalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_112351414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:InvestorRelationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_21539129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:InvestorRelationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_205858665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:InvestorRelationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_718216585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1285545738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_535028712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:InsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1689061437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1620006605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_418515650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:EmployeeBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_605691750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:DepreciationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_181759167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:DepreciationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1897429609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:DepreciationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_854982644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_553826154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1120991972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ConsultingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_885449171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AccountingAndAuditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1508206844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AccountingAndAuditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_160260067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:AccountingAndAuditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_568892551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2102687301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_2014942524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2065535967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_677878867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">radx:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_621183606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">radx:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1680492102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">radx:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1427085780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1651144812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_469194671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1509356073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1040168498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1522337083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1414105029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_818254643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1503779487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1786873216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_558237741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_173458424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_110979779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_2014206622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_125826852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_270557525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_80346681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1932724063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1359131700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1060975826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1689560509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_65170265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_617598281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1320340789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1885746091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_681408275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_1581674724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_937038030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_745832050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_1558766943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_249834797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:NeoIndicateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1186503980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:Pharma15ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1566852509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_691980689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">radx:OtherIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_679673439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:AVb6IntegrinIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_626167827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:PivalateIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_805692997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:Pharma15Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_713553581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">radx:ContingentIssueOfEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1388285171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_752338878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1309018810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_557781320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1258993477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1541665852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:EquitySettledPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1850222835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:ImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1864095034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">radx:UCLAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_665359121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:RadiopharmVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1778566947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">radx:ForfeiturePaymentsExpenseToKeyManagementPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1689105708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1961043526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_352498039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">radx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1185254345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyEightZeroEightTwoThousandAndTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_576659127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1269795725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1063099307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_2009342397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1273330257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_53688547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:AmountsDueToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1042150587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:AmountsDueToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_481200468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:RDAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_824895394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">radx:RDAdvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1016384458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:NeoIndicateContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1781282920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:Pharma15DeferredConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_81216337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:Pharma15DeferredConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1300350713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:Pharma15ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1771943251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:UCLAContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_907008146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:UCLAContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1263862179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:AdvancedPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_911934065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">radx:AdvancedPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1473646678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:AdvancePaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_551840259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">radx:Pharma15DeferredConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_894107997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IntangibleAssetsMaterialToEntityAxis">radx:huPSAAntibodyIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1423495365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="cref_217689316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroSevenZeroOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1475106504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandTwentyFourZeroEightTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_224156013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFoursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_623896292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyFiveElevenTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_825009300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:ZeroNineTwelveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1474773609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_340325290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_845758456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroEightTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_734510058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroEightTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1693899775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyElevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_186786133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwentyElevenTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_504198348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSixTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_884678054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:OneZeroSixTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1015499212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroNineThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_301111933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="radx:GrantDateAxis">radx:TwoThousandAndTwentyOneZeroNineThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">radx:OIPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_293124482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001949257</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">radx:SharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="uref_138071911">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_1453202449">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_1634518116">
        <measure>shares</measure>
    </unit>
    <unit id="uref_880450695">
        <measure>pure</measure>
    </unit>
    <unit id="uref_1001896052">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="uref_1346866186">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="uref_1954685255">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="uref_1642879776">
        <measure>radx:Segments</measure>
    </unit>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_249834797"
      id="fc_249834797"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1186503980"
      id="fc_1186503980"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1835989352"
      id="fc_1116355496"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1118946646"
      id="fc_1768248702"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_260407272"
      id="fc_1788611969"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1778718866"
      id="fc_99218366"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1124718144"
      id="fc_1042536497"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_824292737"
      id="fc_1995917233"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_61988382"
      id="fc_58769135"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_198500851"
      id="fc_1172074595"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1835989352"
      id="fc_764607594"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1118946646"
      id="fc_130946041"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_260407272"
      id="fc_1110236473"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_824292737"
      id="fc_1942389973"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_61988382"
      id="fc_1905324558"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1124718144"
      id="fc_2135865817"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1835989352"
      id="fc_490540358"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_260407272"
      id="fc_1237979453"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1778718866"
      id="fc_2062139543"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1124718144"
      id="fc_1724490241"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_824292737"
      id="fc_998402956"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_61988382"
      id="fc_1796167603"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_198500851"
      id="fc_790647029"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_2011328152"
      id="fc_159022555"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1424152838"
      id="fc_309152123"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_415814143"
      id="fc_839236382"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1008801451"
      id="fc_1737663665"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_415298535"
      id="fc_636457739"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1480035372"
      id="fc_1039270005"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1494054659"
      id="fc_364370527"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughOtherThanGoodwillSaleOfAsset
      contextRef="cref_1085778750"
      id="fc_1152690229"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_2011328152"
      id="fc_397330576"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1424152838"
      id="fc_466550340"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415814143"
      id="fc_716662869"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1480035372"
      id="fc_778327374"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1494054659"
      id="fc_1220478678"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415814143"
      id="fc_1504185799"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1008801451"
      id="fc_1286333568"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415298535"
      id="fc_1270448742"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1480035372"
      id="fc_1620751096"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1085778750"
      id="fc_849140346"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1566852509"
      id="fc_1566852509"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_691980689"
      id="fc_691980689"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1566852509"
      id="fc_165573114"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_691980689"
      id="fc_1793449233"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_540356014"
      id="fc_64281204"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_540356014"
      id="fc_350124766"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_312638053"
      id="fc_1324146248"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments
      contextRef="cref_540356014"
      id="fc_64721603"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstruments
      contextRef="cref_312638053"
      id="fc_15923225"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1863492555"
      id="fc_1138158821"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_308497697"
      id="fc_455076162"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1590527928"
      id="fc_1306199751"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1399891170"
      id="fc_928863346"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_199907254"
      id="fc_1581198739"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1158695048"
      id="fc_1980560945"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1217755389"
      id="fc_2122673013"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1665656946"
      id="fc_1367216253"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:DividendsPaid
      contextRef="cref_1085778750"
      id="fc_1943161247"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:DividendsPaid
      contextRef="cref_198500851"
      id="fc_611255203"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:FrankingAccountBalance
      contextRef="cref_1085778750"
      id="fc_1257405903"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:FrankingAccountBalance
      contextRef="cref_198500851"
      id="fc_1234535655"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OwnershipInterestHeldByNoncontrollingInterests
      contextRef="cref_126621"
      id="fc_1156914257"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:OwnershipInterestHeldByNoncontrollingInterests
      contextRef="cref_346654251"
      id="fc_385587549"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:OwnershipInterestHeldByNoncontrollingInterests
      contextRef="cref_1639151071"
      id="fc_714264368"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:OwnershipInterestHeldByNoncontrollingInterests
      contextRef="cref_766531602"
      id="fc_32722313"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_816128912"
      id="fc_1979540956"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_679673439"
      id="fc_679673439"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_1954685255"
      id="fc_1753504482"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_626167827"
      id="fc_626167827"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_1878796642"
      id="fc_44444051"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_805692997"
      id="fc_805692997"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_1937830845"
      id="fc_1615426202"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_2052780937"
      id="fc_1921979487"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_585009615"
      id="fc_1486771677"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TaxEffectOfTaxAmortisation
      contextRef="cref_879251327"
      id="fc_1884399157"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TaxEffectOfUnrealisedCurrencygainslosses
      contextRef="cref_879251327"
      id="fc_1147713519"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfListedOptionsValue
      contextRef="cref_1672975465"
      id="fc_1423482586"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:NumberOfShareOptionsExpenseForSharebasedPaymentsForOptionsPreviouslyIssuedShares
      contextRef="cref_1121416750"
      id="fc_946830935"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:NumberOfShareOptionsExpenseForSharebasedPaymentsForOptionsPreviouslyIssuedShares
      contextRef="cref_1623135981"
      id="fc_1327990813"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_713553581"
      id="fc_713553581"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_1305557533"
      id="fc_873149817"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TransactionCostsArisingOnShareIssues
      contextRef="cref_404292157"
      id="fc_1202945729"
      unitRef="uref_1634518116"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_1388285171"
      id="fc_1388285171"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_752338878"
      id="fc_752338878"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_1309018810"
      id="fc_1309018810"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_855609256"
      id="fc_1158790242"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_557781320"
      id="fc_557781320"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1309018810"
      id="fc_1480012686"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_557781320"
      id="fc_200249083"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1309018810"
      id="fc_202973915"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_557781320"
      id="fc_1011654367"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_958314475"
      id="fc_1318442436"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1309018810"
      id="fc_2089543271"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_557781320"
      id="fc_873295251"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_958314475"
      id="fc_448116461"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_1309018810"
      id="fc_669088824"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_557781320"
      id="fc_1489628777"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_958314475"
      id="fc_1012565369"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_1258993477"
      id="fc_1258993477"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_1541665852"
      id="fc_1541665852"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1850222835"
      id="fc_1850222835"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1864095034"
      id="fc_1864095034"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TaxEffectOfTaxAmortisation
      contextRef="cref_585009615"
      id="fc_569013496"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:NumberOfShareOptionsExpenseForSharebasedPaymentsForOptionsPreviouslyIssuedShares
      contextRef="cref_1672975465"
      id="fc_800400402"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_987834646"
      id="fc_552518932"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TransactionCostsArisingOnShareIssues
      contextRef="cref_1305557533"
      id="fc_704545704"
      unitRef="uref_1634518116"
      xsi:nil="true"/>
    <radx:PaymentsForMilestones
      contextRef="cref_665359121"
      id="fc_665359121"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="cref_1085778750"
      id="fc_1297016798"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_1778566947"
      id="fc_1778566947"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:KeyManagementPersonnelForfeiturePayments
      contextRef="cref_1085778750"
      id="fc_1500336743"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="cref_1305557533"
      id="fc_687879281"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="cref_682156036"
      id="fc_782403807"
      unitRef="uref_1453202449"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="cref_682156036"
      id="fc_2083204664"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="cref_682156036"
      id="fc_1542713733"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="cref_682156036"
      id="fc_1187745178"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:FairValueAtGrantDate
      contextRef="cref_682156036"
      id="fc_872037522"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="cref_812473718"
      id="fc_2016313472"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:Guarantees
      contextRef="cref_198500851"
      id="fc_2089182294"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="cref_1963669158"
      id="fc_1621405148"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1305557533"
      id="fc_1072134271"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1963669158"
      id="fc_1652632723"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_1305557533"
      id="fc_2134401314"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_617598281"
      id="fc_675358866"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_65170265"
      id="fc_785018398"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_239281928"
      id="fc_437470619"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_617598281"
      id="fc_1221518730"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_65170265"
      id="fc_1236162672"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1885746091"
      id="fc_1385863785"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1320340789"
      id="fc_1001948553"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_617598281"
      id="fc_1637617325"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_65170265"
      id="fc_1041238269"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfEquityGross
      contextRef="cref_65170265"
      id="fc_1119986182"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfEquityGross
      contextRef="cref_239281928"
      id="fc_222488407"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfEquityGross
      contextRef="cref_1885746091"
      id="fc_176495682"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfEquityGross
      contextRef="cref_1320340789"
      id="fc_1739987802"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_617598281"
      id="fc_359935364"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_65170265"
      id="fc_1916364555"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1885746091"
      id="fc_221049018"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1320340789"
      id="fc_280017473"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_65170265"
      id="fc_1493639876"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_1885746091"
      id="fc_1321758055"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_1320340789"
      id="fc_1075372366"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition
      contextRef="cref_239281928"
      id="fc_2126731510"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition
      contextRef="cref_1885746091"
      id="fc_572446653"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition
      contextRef="cref_1320340789"
      id="fc_180484920"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition
      contextRef="cref_812473718"
      id="fc_1839313842"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_617598281"
      id="fc_1436621322"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_65170265"
      id="fc_1925404580"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_1885746091"
      id="fc_196382470"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_1320340789"
      id="fc_459087456"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_80346681"
      id="fc_1018539523"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_1689105708"
      id="fc_1689105708"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_1712076956"
      id="fc_1309227707"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_80346681"
      id="fc_933282117"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1689105708"
      id="fc_479392802"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_270557525"
      id="fc_1871270450"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_125826852"
      id="fc_1346752361"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_80346681"
      id="fc_40964172"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1689105708"
      id="fc_387792199"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_80346681"
      id="fc_3968352"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1689105708"
      id="fc_159363596"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_270557525"
      id="fc_76659898"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_125826852"
      id="fc_2053749044"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_1689105708"
      id="fc_187512234"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_270557525"
      id="fc_1117782280"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_125826852"
      id="fc_568902604"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_1786873216"
      id="fc_250225359"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_1503779487"
      id="fc_122474931"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="cref_1659325166"
      id="fc_610093815"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1786873216"
      id="fc_94027287"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1503779487"
      id="fc_1768441786"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_818254643"
      id="fc_363869"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1414105029"
      id="fc_543863685"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1786873216"
      id="fc_337662974"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1503779487"
      id="fc_10918010"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1503779487"
      id="fc_1176163584"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1659325166"
      id="fc_1124615176"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_818254643"
      id="fc_964864361"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1414105029"
      id="fc_470095097"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1786873216"
      id="fc_522713651"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1503779487"
      id="fc_420113467"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_818254643"
      id="fc_693982173"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1414105029"
      id="fc_930093732"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1786873216"
      id="fc_246818850"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1503779487"
      id="fc_363145339"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1659325166"
      id="fc_409431462"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_818254643"
      id="fc_205211925"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1414105029"
      id="fc_1236307447"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1085778750"
      id="fc_306065306"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1786873216"
      id="fc_147916447"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1503779487"
      id="fc_1473076932"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1414105029"
      id="fc_1797137531"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1085778750"
      id="fc_1490868978"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_1786873216"
      id="fc_883655631"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_1503779487"
      id="fc_1872224087"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_818254643"
      id="fc_78859747"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_1414105029"
      id="fc_409594374"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:CancellationOfSharesToBeIssued
      contextRef="cref_80346681"
      id="fc_12448630"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:CancellationOfSharesToBeIssued
      contextRef="cref_1689105708"
      id="fc_1862807424"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:CancellationOfSharesToBeIssued
      contextRef="cref_270557525"
      id="fc_2067027449"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:CancellationOfSharesToBeIssued
      contextRef="cref_125826852"
      id="fc_598412855"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1786873216"
      id="fc_1729729540"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1503779487"
      id="fc_1539967096"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1659325166"
      id="fc_1131310981"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1085778750"
      id="fc_773670915"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1689105708"
      id="fc_34376451"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="cref_1961043526"
      id="fc_1961043526"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:ResearchAndDevelopmentTaxIncentiveReceived
      contextRef="cref_198500851"
      id="fc_1345645571"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="cref_1085778750"
      id="fc_880167510"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="cref_198500851"
      id="fc_115984388"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForDebtIssueCosts
      contextRef="cref_1085778750"
      id="fc_1111837900"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="cref_1085778750"
      id="fc_1343095385"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SettlementWithLind
      contextRef="cref_1085778750"
      id="fc_185774405"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SettlementWithLind
      contextRef="cref_812473718"
      id="fc_195473295"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:ResearchAndDevelopmentPriorYearsRebate
      contextRef="cref_352498039"
      id="fc_352498039"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="cref_812473718"
      id="fc_851113406"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment
      contextRef="cref_198500851"
      id="fc_920545125"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_815368052"
      id="fc_1114840167"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1818709843"
      id="fc_1943556581"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1185254345"
      id="fc_1185254345"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1269655552"
      id="fc_1772902389"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="cref_812473718"
      id="fc_2112524206"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="cref_198500851"
      id="fc_1409032073"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="cref_198500851"
      id="fc_1464503210"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForIntellectualProperty
      contextRef="cref_1085778750"
      id="fc_1845305462"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentsForIntellectualProperty
      contextRef="cref_812473718"
      id="fc_557226855"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="cref_65170265"
      id="fc_1311781121"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="cref_239281928"
      id="fc_155443331"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="cref_1885746091"
      id="fc_2023138853"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="cref_1320340789"
      id="fc_1552963657"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="cref_65170265"
      id="fc_48322321"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="cref_239281928"
      id="fc_1412901110"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="cref_1885746091"
      id="fc_1829856702"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="cref_1320340789"
      id="fc_1919902673"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesInLieuOfServices
      contextRef="cref_65170265"
      id="fc_1224696408"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesInLieuOfServices
      contextRef="cref_239281928"
      id="fc_301590140"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesInLieuOfServices
      contextRef="cref_1885746091"
      id="fc_871982870"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesInLieuOfServices
      contextRef="cref_1320340789"
      id="fc_1396012027"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1885746091"
      id="fc_646162621"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1320340789"
      id="fc_1891616363"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1689105708"
      id="fc_853383462"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_270557525"
      id="fc_1144784633"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_125826852"
      id="fc_707819370"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1689105708"
      id="fc_1632784439"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_1712076956"
      id="fc_887278420"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_270557525"
      id="fc_704604652"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_125826852"
      id="fc_1839284151"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_80346681"
      id="fc_619995679"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1689105708"
      id="fc_511289097"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_125826852"
      id="fc_1873300390"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_198500851"
      id="fc_1471862857"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_80346681"
      id="fc_1946167464"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_1689105708"
      id="fc_664300016"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_270557525"
      id="fc_400599221"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:OptionsForfeited
      contextRef="cref_125826852"
      id="fc_1956410091"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_80346681"
      id="fc_1783361277"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1689105708"
      id="fc_1209185264"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1712076956"
      id="fc_1429112597"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_198500851"
      id="fc_1231265195"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:ImpairmentOnOtherEquity
      contextRef="cref_1085778750"
      id="fc_2128720553"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_576659127"
      id="fc_576659127"
      unitRef="uref_1001896052"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1269795725"
      id="fc_1269795725"
      unitRef="uref_1001896052"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1063099307"
      id="fc_1063099307"
      unitRef="uref_1001896052"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="cref_1085778750"
      id="fc_1340182865"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_820677847"
      id="fc_421099220"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_2009342397"
      id="fc_2009342397"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_2009342397"
      id="fc_160613664"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1273330257"
      id="fc_1273330257"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1273330257"
      id="fc_906776"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1273330257"
      id="fc_512807925"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1493941943"
      id="fc_223383173"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_290225396"
      id="fc_1512562005"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_71955621"
      id="fc_803299973"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1446399978"
      id="fc_433950526"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1502821912"
      id="fc_1071173234"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1763895519"
      id="fc_1532190310"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1305557533"
      id="fc_1385299093"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_1963669158"
      id="fc_1865366965"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentReceivables
      contextRef="cref_404292157"
      id="fc_1997688841"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_2009342397"
      id="fc_759014810"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_808852886"
      id="fc_1128216398"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1595967763"
      id="fc_2105137680"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1865531277"
      id="fc_1898473069"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_53688547"
      id="fc_53688547"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_53688547"
      id="fc_1356036664"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_53688547"
      id="fc_429185471"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1042150587"
      id="fc_1042150587"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1042150587"
      id="fc_1701923183"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_1042150587"
      id="fc_2113776139"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1986429776"
      id="fc_717037877"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_861240918"
      id="fc_662542452"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_41466566"
      id="fc_281621519"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_705890069"
      id="fc_164102519"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_655907015"
      id="fc_709330579"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_858350249"
      id="fc_1558140744"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_481200468"
      id="fc_481200468"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_481200468"
      id="fc_1840359587"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_481200468"
      id="fc_1870798933"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_824895394"
      id="fc_824895394"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_824895394"
      id="fc_686496107"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_824895394"
      id="fc_1593350607"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_387488510"
      id="fc_791944053"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_387488510"
      id="fc_131209473"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1305557533"
      id="fc_45577752"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_1963669158"
      id="fc_1461129851"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPayables
      contextRef="cref_404292157"
      id="fc_1749938227"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1016384458"
      id="fc_1016384458"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1016384458"
      id="fc_701424536"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1016384458"
      id="fc_1870684131"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1304397351"
      id="fc_1843483613"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1781282920"
      id="fc_1781282920"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1781282920"
      id="fc_1118738496"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1781282920"
      id="fc_371904715"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_81216337"
      id="fc_81216337"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_81216337"
      id="fc_1403551223"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_81216337"
      id="fc_357496978"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1300350713"
      id="fc_1300350713"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1300350713"
      id="fc_1209702173"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1300350713"
      id="fc_1266043904"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_658631945"
      id="fc_1775390985"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1682262865"
      id="fc_1744049292"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_968227831"
      id="fc_2121313631"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1771943251"
      id="fc_1771943251"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1771943251"
      id="fc_1335826267"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1771943251"
      id="fc_774976970"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_907008146"
      id="fc_907008146"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_907008146"
      id="fc_828652398"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_907008146"
      id="fc_1856773610"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_275006410"
      id="fc_320870674"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1263862179"
      id="fc_1263862179"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1263862179"
      id="fc_1205568883"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1263862179"
      id="fc_1277019398"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_911934065"
      id="fc_911934065"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_911934065"
      id="fc_265816370"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_911934065"
      id="fc_1030844899"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1473646678"
      id="fc_1473646678"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_551840259"
      id="fc_551840259"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_2011328152"
      id="fc_317402229"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_1424152838"
      id="fc_1973028825"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_415814143"
      id="fc_253121011"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_1480035372"
      id="fc_1763976589"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_1494054659"
      id="fc_1180279600"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="cref_1305557533"
      id="fc_1701782481"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="cref_1963669158"
      id="fc_2112481639"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="cref_404292157"
      id="fc_358279390"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1502965910"
      id="fc_1418573340"
      unitRef="uref_1954685255"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1502965910"
      id="fc_1231849584"
      unitRef="uref_1346866186"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_259034637"
      id="fc_262315310"
      unitRef="uref_1954685255"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_259034637"
      id="fc_1721108780"
      unitRef="uref_1346866186"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="cref_1502965910"
      id="fc_681948505"
      unitRef="uref_1954685255"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="cref_1502965910"
      id="fc_997356148"
      unitRef="uref_1346866186"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="cref_259034637"
      id="fc_1489093636"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="cref_259034637"
      id="fc_321791850"
      unitRef="uref_1954685255"
      xsi:nil="true"/>
    <ifrs-full:TradeReceivables
      contextRef="cref_259034637"
      id="fc_1653512947"
      unitRef="uref_1346866186"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="cref_1773416733"
      id="fc_1894240016"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssets
      contextRef="cref_1569279335"
      id="fc_252894350"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="cref_1773416733"
      id="fc_1779423083"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CurrentLiabilities
      contextRef="cref_1569279335"
      id="fc_192894733"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="cref_1773416733"
      id="fc_585726619"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CurrentAssetsLiabilities
      contextRef="cref_1569279335"
      id="fc_250676638"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:PaymentForDevelopmentMilestoneToTRIMT
      contextRef="cref_894107997"
      id="fc_894107997"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="cref_1963669158"
      id="fc_864590635"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="cref_1941222514"
      id="fc_158769521"
      unitRef="uref_1453202449"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="cref_1941222514"
      id="fc_847696160"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1781408912"
      id="fc_1418922926"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1130058759"
      id="fc_763163625"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_2112097951"
      id="fc_569864081"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1954644021"
      id="fc_265837238"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <radx:TransactionCostsArisingOnShareIssues
      contextRef="cref_1963669158"
      id="fc_863891120"
      unitRef="uref_1634518116"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_1423495365"
      id="fc_1423495365"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_362669200"
      id="fc_1022874899"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_416724211"
      id="fc_364662766"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_815368052"
      id="fc_2052949950"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_362669200"
      id="fc_1710760730"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_416724211"
      id="fc_148806476"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_815368052"
      id="fc_668324935"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_362669200"
      id="fc_1651375835"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_416724211"
      id="fc_1091844400"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_1818709843"
      id="fc_1492167650"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_362669200"
      id="fc_2056043441"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_416724211"
      id="fc_248034250"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_1818709843"
      id="fc_1417902063"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_362669200"
      id="fc_1225420907"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_217689316"
      id="fc_217689316"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1475106504"
      id="fc_1475106504"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_224156013"
      id="fc_224156013"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_623896292"
      id="fc_623896292"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_825009300"
      id="fc_825009300"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1474773609"
      id="fc_1474773609"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_340325290"
      id="fc_340325290"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_845758456"
      id="fc_845758456"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_734510058"
      id="fc_734510058"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1693899775"
      id="fc_1693899775"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_186786133"
      id="fc_186786133"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_504198348"
      id="fc_504198348"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_884678054"
      id="fc_884678054"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1015499212"
      id="fc_1015499212"
      unitRef="uref_1453202449"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1015499212"
      id="fc_987071452"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_301111933"
      id="fc_301111933"
      unitRef="uref_880450695"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_293124482"
      id="fc_293124482"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_293124482"
      id="fc_1622554041"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_1052646885"
      id="fc_408158136"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_565546587"
      id="fc_440457710"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_1670218366"
      id="fc_1191203498"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1052646885"
      id="fc_1493167621"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_565546587"
      id="fc_317576831"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1670218366"
      id="fc_1875725866"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_1052646885"
      id="fc_592403999"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_495300227"
      id="fc_80560918"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_1712076956"
      id="fc_488678946"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_1052646885"
      id="fc_1136781246"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_565546587"
      id="fc_564845392"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_495300227"
      id="fc_1025368208"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_416724211"
      id="fc_1296959557"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_815368052"
      id="fc_2134010931"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:SharesToBeIssued
      contextRef="cref_1818709843"
      id="fc_110951134"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_1388285171"
      id="fc_1318046048"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="cref_752338878"
      id="fc_1938830686"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TransferFromSharebasedPaymentsToEquitySettledPayments
      contextRef="cref_1052646885"
      id="fc_1329914193"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TransferFromSharebasedPaymentsToEquitySettledPayments
      contextRef="cref_495300227"
      id="fc_1943910193"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:TransferFromSharebasedPaymentsToEquitySettledPayments
      contextRef="cref_1712076956"
      id="fc_524672000"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement
      contextRef="cref_565546587"
      id="fc_566061447"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement
      contextRef="cref_1670218366"
      id="fc_1878136386"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement
      contextRef="cref_495300227"
      id="fc_2036877606"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughLapseOfForfeiturePayment
      contextRef="cref_1052646885"
      id="fc_1461995091"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughLapseOfForfeiturePayment
      contextRef="cref_565546587"
      id="fc_1953787351"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughLapseOfForfeiturePayment
      contextRef="cref_495300227"
      id="fc_852048476"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1052646885"
      id="fc_311659082"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1670218366"
      id="fc_366747874"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="cref_495300227"
      id="fc_1389451734"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CancellationOfTreasuryShares
      contextRef="cref_565546587"
      id="fc_1501844129"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CancellationOfTreasuryShares
      contextRef="cref_1670218366"
      id="fc_1249891472"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:CancellationOfTreasuryShares
      contextRef="cref_495300227"
      id="fc_984566944"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1052646885"
      id="fc_493656812"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1670218366"
      id="fc_1254219294"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_495300227"
      id="fc_1683270865"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_1052646885"
      id="fc_520545991"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_1670218366"
      id="fc_1453955620"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_495300227"
      id="fc_627510160"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_2011328152"
      id="fc_613143594"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1424152838"
      id="fc_375977597"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415298535"
      id="fc_1409111479"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1118946646"
      id="fc_1733803341"
      unitRef="uref_138071911"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="cref_1085778750" id="ixv-28698">0001949257</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="cref_1085778750" id="ixv-28699">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_1085778750" id="ixv-28700">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="cref_1085778750" id="ixv-33693">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="cref_1085778750" id="ixv-33694">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="cref_1085778750" id="ixv-33695">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="cref_1085778750" id="ixv-33696">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="cref_1085778750" id="ixv-33697">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_1085778750" id="ixv-33698">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_1085778750" id="ixv-33699">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="cref_1085778750" id="ixv-33700">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="cref_1085778750" id="ixv-33701">001-41621</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_1085778750" id="ixv-33702">Radiopharm Theranostics Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_1085778750" id="ixv-33703">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="cref_1085778750" id="ixv-33704">Level 3</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_1085778750" id="ixv-33705">62 Lygon Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_1085778750" id="ixv-33706">Carlton VIC</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="cref_1085778750" id="ixv-33707">3053</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="cref_1085778750" id="ixv-33708">AU</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="cref_1558766943" id="ixv-33709">Riccardo Canevari</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="cref_1558766943" id="ixv-33710">Level 3</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_1558766943" id="ixv-33711">62 Lygon Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_1558766943" id="ixv-33712">Carlton VIC</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="cref_1558766943" id="ixv-33713">3053</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="cref_1558766943" id="ixv-33714">AU</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="cref_1558766943" id="ixv-33715">+61</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_1558766943" id="ixv-33716">3 9824 5254</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="cref_1558766943" id="ixv-33717">rc@radiopharmtheranostics.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="cref_1085778750" id="ixv-33718">Ordinary Shares, as represented     by American Depositary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_1085778750" id="ixv-33719">RADX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_1085778750" id="ixv-33720">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1305557533"
      decimals="INF"
      id="ixv-33721"
      unitRef="uref_1634518116">3544216160</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="cref_1085778750" id="ixv-33722">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="cref_1085778750" id="ixv-33723">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="cref_1085778750" id="ixv-33724">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_1085778750" id="ixv-33725">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_1085778750" id="ixv-33726">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="cref_1085778750" id="ixv-33727">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="cref_1085778750" id="ixv-33728">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="cref_1085778750" id="ixv-33729">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="cref_1085778750" id="ixv-33730">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="cref_1085778750" id="ixv-33731">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="cref_1085778750" id="ixv-33732">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="cref_1085778750" id="ixv-33733">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="cref_1085778750" id="ixv-11241">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt; The Company&#x2019;s cybersecurity strategy is designed to provide a comprehensive approach to securing cybersecurity risks across our technology stack, governance framework, and human elements for our operations globally. Cybersecurity risk management is a critical component of our broader risk management strategy. Our cybersecurity program is built on industry best practices and is designed to proactively identify, assess, and mitigate cybersecurity risks, including threats associated with the use of all third-party service providers. Our cybersecurity risk assessment framework categorizes risks based on their potential impact and severity, and the Company implements targeted risk treatment plans to ensure robust protection and resilience. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt; Two of the Company&#x2019;s staff members oversee the prevention, detection, mitigation, and remediation of cybersecurity incidents. Both these employees have extensive experience in risk management and compliance generally, and have been overseeing cybersecurity and IT management at the Company since they joined Radiopharm. They are supported by Continental Resources Inc. The service provider has been engaged by the Company since late 2022 to provide strategic IT advice and manage the Company&#x2019;s IT systems and infrastructure. The service provider, who has over 55 years of experience in securing IT in health and life sciences organizations, manages cybersecurity risks through a number of measures including the development and implementation of cybersecurity policies and procedures, training and penetration testing and systems monitoring. Our executive management team members regularly collaborate and receive reports from our managed IT and cybersecurity service provider, enabling ongoing assessment and monitoring of the Company&#x2019;s cyber risk profile and initiatives. &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="cref_1085778750" id="ixv-33734">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="cref_1085778750" id="ixv-33735">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="cref_1085778750" id="ixv-11247">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;Our Board of Directors entrusts its Audit &amp;amp; Risk Committee with overseeing Radiopharm&#x2019;s cybersecurity risk management, including ensuring that management has established processes to evaluate and manage cybersecurity risks.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="cref_1085778750" id="ixv-11250">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt; In fiscal year 2026, we did not identify any cybersecurity threats that have materially impacted or are likely to materially impact our business strategy, operational results, or financial condition. However, despite our proactive measures, we cannot entirely eliminate cybersecurity risks or guarantee that no undetected incidents have occurred. &lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="cref_1085778750" id="ixv-33736">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="cref_1085778750" id="ixv-33737">2233</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="cref_1085778750" id="ixv-11347">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15pt;"&gt;Opinion on the financial statements&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15pt;"&gt;We have audited the accompanying consolidated statements of financial position of Radiopharm Theranostics Limited and subsidiaries (the &#x201c;Group&#x201d;) as of June 30, 2026 and 2025, the related consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows for each of the three years in the period ended June 30, 2026, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Group as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2026, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="cref_1085778750" id="ixv-33738">GRANT THORNTON AUDIT PTY LTD</dei:AuditorName>
    <dei:AuditorLocation contextRef="cref_1085778750" id="ixv-33739">Melbourne, Australia</dei:AuditorLocation>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33740"
      unitRef="uref_138071911">2767888</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33741"
      unitRef="uref_138071911">3633422</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33742"
      unitRef="uref_138071911">299228</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33743"
      unitRef="uref_138071911">2504499</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33744"
      unitRef="uref_138071911">3594146</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33745"
      unitRef="uref_138071911">263389</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33746"
      unitRef="uref_138071911">39276</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33747"
      unitRef="uref_138071911">299228</ifrs-full:GrossProfit>
    <ifrs-full:OtherIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33748"
      unitRef="uref_138071911">10734382</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33749"
      unitRef="uref_138071911">10256740</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33750"
      unitRef="uref_138071911">1343062</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33751"
      unitRef="uref_138071911">868162</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33752"
      unitRef="uref_138071911">351646</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33753"
      unitRef="uref_138071911">1226108</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33754"
      unitRef="uref_138071911">16215702</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33755"
      unitRef="uref_138071911">14638013</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33756"
      unitRef="uref_138071911">13039246</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33757"
      unitRef="uref_138071911">49962899</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33758"
      unitRef="uref_138071911">27515194</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33759"
      unitRef="uref_138071911">23086267</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33760"
      unitRef="uref_138071911">2405955</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33761"
      unitRef="uref_138071911">1895348</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33762"
      unitRef="uref_138071911">2640178</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33763"
      unitRef="uref_138071911">1671289</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33764"
      unitRef="uref_138071911">-4069680</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33765"
      unitRef="uref_138071911">-8860358</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33766"
      unitRef="uref_138071911">-56783658</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33767"
      unitRef="uref_138071911">-38173865</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33768"
      unitRef="uref_138071911">-47209867</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33769"
      unitRef="uref_138071911">112396</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33770"
      unitRef="uref_138071911">65300</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33771"
      unitRef="uref_138071911">642888</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33772"
      unitRef="uref_138071911">-56896054</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33773"
      unitRef="uref_138071911">-38239165</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33774"
      unitRef="uref_138071911">-47852755</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33775"
      unitRef="uref_138071911">54440</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33776"
      unitRef="uref_138071911">103292</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33777"
      unitRef="uref_138071911">96364</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33778"
      unitRef="uref_138071911">-56950494</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33779"
      unitRef="uref_138071911">-38342457</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33780"
      unitRef="uref_138071911">-47949119</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33781"
      unitRef="uref_138071911">621440</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33782"
      unitRef="uref_138071911">464034</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33783"
      unitRef="uref_138071911">202956</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33784"
      unitRef="uref_138071911">-56329054</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33785"
      unitRef="uref_138071911">-37878423</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33786"
      unitRef="uref_138071911">-47746163</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33787"
      unitRef="uref_138071911">-54527710</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33788"
      unitRef="uref_138071911">-36239055</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33789"
      unitRef="uref_138071911">-45781950</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33790"
      unitRef="uref_138071911">-1801344</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33791"
      unitRef="uref_138071911">-1639368</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33792"
      unitRef="uref_138071911">-1964213</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33793"
      unitRef="uref_138071911">-56329054</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33794"
      unitRef="uref_138071911">-37878423</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33795"
      unitRef="uref_138071911">-47746163</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="cref_1085778750"
      decimals="2"
      id="ixv-33796"
      unitRef="uref_1453202449">-1.79</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="cref_1085778750"
      decimals="2"
      id="ixv-33797"
      unitRef="uref_1453202449">-1.79</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="cref_198500851"
      decimals="2"
      id="ixv-33798"
      unitRef="uref_1453202449">-1.76</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="cref_198500851"
      decimals="2"
      id="ixv-33799"
      unitRef="uref_1453202449">-1.76</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="cref_812473718"
      decimals="2"
      id="ixv-33800"
      unitRef="uref_1453202449">-12.41</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="cref_812473718"
      decimals="2"
      id="ixv-33801"
      unitRef="uref_1453202449">-12.41</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33802"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33803"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33804"
      unitRef="uref_138071911">17447428</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33805"
      unitRef="uref_138071911">10400060</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33806"
      unitRef="uref_138071911">340194</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33807"
      unitRef="uref_138071911">337093</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33808"
      unitRef="uref_138071911">21925696</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33809"
      unitRef="uref_138071911">39853988</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33810"
      unitRef="uref_138071911">46136</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33811"
      unitRef="uref_138071911">53466</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33812"
      unitRef="uref_138071911">38161747</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33813"
      unitRef="uref_138071911">46574422</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33814"
      unitRef="uref_138071911">38207883</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33815"
      unitRef="uref_138071911">46627888</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33816"
      unitRef="uref_138071911">60133579</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33817"
      unitRef="uref_138071911">86481876</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33818"
      unitRef="uref_138071911">10531800</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33819"
      unitRef="uref_138071911">9340993</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33820"
      unitRef="uref_138071911">6860850</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33821"
      unitRef="uref_138071911">3421337</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33822"
      unitRef="uref_138071911">697907</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33823"
      unitRef="uref_138071911">450104</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33824"
      unitRef="uref_138071911">806410</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33825"
      unitRef="uref_138071911">1720551</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33826"
      unitRef="uref_138071911">18896967</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33827"
      unitRef="uref_138071911">14932985</ifrs-full:CurrentLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33828"
      unitRef="uref_138071911">18912929</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33829"
      unitRef="uref_138071911">28676987</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33830"
      unitRef="uref_138071911">18912929</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33831"
      unitRef="uref_138071911">28676987</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33832"
      unitRef="uref_138071911">37809896</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33833"
      unitRef="uref_138071911">43609972</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33834"
      unitRef="uref_138071911">22323683</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33835"
      unitRef="uref_138071911">42871904</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33836"
      unitRef="uref_138071911">209933371</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33837"
      unitRef="uref_138071911">176558493</ifrs-full:IssuedCapital>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33838"
      unitRef="uref_138071911">849544</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherReserves
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33839"
      unitRef="uref_138071911">14414155</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33840"
      unitRef="uref_138071911">13116919</ifrs-full:OtherReserves>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33841"
      unitRef="uref_138071911">-199660317</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33842"
      unitRef="uref_138071911">-145732952</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:NoncontrollingInterests
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33843"
      unitRef="uref_138071911">-2363526</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33844"
      unitRef="uref_138071911">-1920100</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-33845"
      unitRef="uref_138071911">22323683</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33846"
      unitRef="uref_138071911">42871904</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_745832050"
      decimals="0"
      id="ixv-33847"
      unitRef="uref_138071911">97230329</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_937038030"
      decimals="0"
      id="ixv-33848"
      unitRef="uref_138071911">2146566</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_2064533522"
      decimals="0"
      id="ixv-33849"
      unitRef="uref_138071911">10361457</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1581674724"
      decimals="0"
      id="ixv-33850"
      unitRef="uref_138071911">-65353864</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_681408275"
      decimals="0"
      id="ixv-33851"
      unitRef="uref_138071911">1194937</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1259894475"
      decimals="0"
      id="ixv-33852"
      unitRef="uref_138071911">45579425</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="cref_1885746091"
      decimals="0"
      id="ixv-33853"
      unitRef="uref_138071911">-45984906</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_1320340789"
      decimals="0"
      id="ixv-33854"
      unitRef="uref_138071911">-1964213</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_812473718"
      decimals="0"
      id="fc_1321328307"
      unitRef="uref_138071911">-47949119</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-33856"
      unitRef="uref_138071911">202956</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_812473718"
      decimals="0"
      id="fc_1068638903"
      unitRef="uref_138071911">202956</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-33858"
      unitRef="uref_138071911">202956</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1885746091"
      decimals="0"
      id="ixv-33859"
      unitRef="uref_138071911">-45984906</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1320340789"
      decimals="0"
      id="ixv-33860"
      unitRef="uref_138071911">-1964213</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_812473718"
      decimals="0"
      id="fc_560628832"
      unitRef="uref_138071911">-47746163</ifrs-full:ComprehensiveIncome>
    <radx:IssueOfEquityGross
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33862"
      unitRef="uref_138071911">3560298</radx:IssueOfEquityGross>
    <radx:IssueOfEquityGross
      contextRef="cref_812473718"
      decimals="0"
      id="fc_944101969"
      unitRef="uref_138071911">3560298</radx:IssueOfEquityGross>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33864"
      unitRef="uref_138071911">2633140</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33865"
      unitRef="uref_138071911">2633140</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-33866"
      unitRef="uref_138071911">3372264</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33867"
      unitRef="uref_138071911">3372264</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33868"
      unitRef="uref_138071911">223526</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-33869"
      unitRef="uref_138071911">-191834</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33870"
      unitRef="uref_138071911">31692</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33871"
      unitRef="uref_138071911">1297022</radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition>
    <radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition
      contextRef="cref_65170265"
      decimals="0"
      id="ixv-33872"
      unitRef="uref_138071911">-1297022</radx:IncreaseDecreaseInSharesAsPartOfLicenseAcquisition>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33873"
      unitRef="uref_138071911">900000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33874"
      unitRef="uref_138071911">900000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <radx:IssueOfSharesInLieuOfServices
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33875"
      unitRef="uref_138071911">103681</radx:IssueOfSharesInLieuOfServices>
    <radx:IssueOfSharesInLieuOfServices
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33876"
      unitRef="uref_138071911">103681</radx:IssueOfSharesInLieuOfServices>
    <radx:SharesToBeIssued
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-33877"
      unitRef="uref_138071911">24185229</radx:SharesToBeIssued>
    <radx:SharesToBeIssued
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33878"
      unitRef="uref_138071911">24185229</radx:SharesToBeIssued>
    <ifrs-full:ChangesInEquity
      contextRef="cref_617598281"
      decimals="0"
      id="ixv-33879"
      unitRef="uref_138071911">3451387</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_65170265"
      decimals="0"
      id="ixv-33880"
      unitRef="uref_138071911">-1297022</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-33881"
      unitRef="uref_138071911">27365659</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33882"
      unitRef="uref_138071911">29520024</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="cref_1689560509"
      decimals="0"
      id="ixv-33883"
      unitRef="uref_138071911">100681716</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1060975826"
      decimals="0"
      id="ixv-33884"
      unitRef="uref_138071911">849544</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_2011796631"
      decimals="0"
      id="ixv-33885"
      unitRef="uref_138071911">37930072</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1359131700"
      decimals="0"
      id="ixv-33886"
      unitRef="uref_138071911">-111338770</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1932724063"
      decimals="0"
      id="ixv-33887"
      unitRef="uref_138071911">-769276</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-33888"
      unitRef="uref_138071911">27353286</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1689560509"
      decimals="0"
      id="ixv-33889"
      unitRef="uref_138071911">100681716</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1060975826"
      decimals="0"
      id="ixv-33890"
      unitRef="uref_138071911">849544</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_2011796631"
      decimals="0"
      id="ixv-33891"
      unitRef="uref_138071911">37930072</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1359131700"
      decimals="0"
      id="ixv-33892"
      unitRef="uref_138071911">-111338770</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1932724063"
      decimals="0"
      id="ixv-33893"
      unitRef="uref_138071911">-769276</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-33894"
      unitRef="uref_138071911">27353286</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="cref_270557525"
      decimals="0"
      id="ixv-33895"
      unitRef="uref_138071911">-36703089</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_125826852"
      decimals="0"
      id="ixv-33896"
      unitRef="uref_138071911">-1639368</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_198500851"
      decimals="0"
      id="fc_1789851580"
      unitRef="uref_138071911">-38342457</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33898"
      unitRef="uref_138071911">464034</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_198500851"
      decimals="0"
      id="fc_1053917699"
      unitRef="uref_138071911">464034</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33900"
      unitRef="uref_138071911">464034</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_270557525"
      decimals="0"
      id="ixv-33901"
      unitRef="uref_138071911">-36703089</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_125826852"
      decimals="0"
      id="ixv-33902"
      unitRef="uref_138071911">-1639368</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_198500851"
      decimals="0"
      id="fc_1343183130"
      unitRef="uref_138071911">-37878423</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_80346681"
      decimals="0"
      id="ixv-33904"
      unitRef="uref_138071911">74915537</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33905"
      unitRef="uref_138071911">-23885229</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33906"
      unitRef="uref_138071911">51030308</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33907"
      unitRef="uref_138071911">2157778</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33908"
      unitRef="uref_138071911">2157778</ifrs-full:IssueOfConvertibleInstruments>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_80346681"
      decimals="0"
      id="ixv-33909"
      unitRef="uref_138071911">741400</radx:IssueOfSharesForMilestoneCompletion>
    <radx:IssueOfSharesForMilestoneCompletion
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33910"
      unitRef="uref_138071911">741400</radx:IssueOfSharesForMilestoneCompletion>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_80346681"
      decimals="0"
      id="ixv-33911"
      unitRef="uref_138071911">219840</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33912"
      unitRef="uref_138071911">-231115</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33913"
      unitRef="uref_138071911">-11275</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33914"
      unitRef="uref_138071911">-2797451</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_270557525"
      decimals="0"
      id="ixv-33915"
      unitRef="uref_138071911">2797451</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:OptionsForfeited
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33916"
      unitRef="uref_138071911">-221170</radx:OptionsForfeited>
    <radx:OptionsForfeited
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33917"
      unitRef="uref_138071911">-221170</radx:OptionsForfeited>
    <radx:CancellationOfSharesToBeIssued
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33918"
      unitRef="uref_138071911">-300000</radx:CancellationOfSharesToBeIssued>
    <radx:CancellationOfSharesToBeIssued
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33919"
      unitRef="uref_138071911">-300000</radx:CancellationOfSharesToBeIssued>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_270557525"
      decimals="0"
      id="ixv-33920"
      unitRef="uref_138071911">-488544</radx:IncreaseInOwnershipInRADVentures>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_125826852"
      decimals="0"
      id="ixv-33921"
      unitRef="uref_138071911">488544</radx:IncreaseInOwnershipInRADVentures>
    <ifrs-full:ChangesInEquity
      contextRef="cref_80346681"
      decimals="0"
      id="ixv-33922"
      unitRef="uref_138071911">75876777</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-33923"
      unitRef="uref_138071911">-25277187</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_270557525"
      decimals="0"
      id="ixv-33924"
      unitRef="uref_138071911">2308907</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_125826852"
      decimals="0"
      id="ixv-33925"
      unitRef="uref_138071911">488544</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33926"
      unitRef="uref_138071911">53397041</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="cref_2014206622"
      decimals="0"
      id="ixv-33927"
      unitRef="uref_138071911">176558493</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_110979779"
      decimals="0"
      id="ixv-33928"
      unitRef="uref_138071911">849544</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1984381866"
      decimals="0"
      id="ixv-33929"
      unitRef="uref_138071911">13116919</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_173458424"
      decimals="0"
      id="ixv-33930"
      unitRef="uref_138071911">-145732952</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_558237741"
      decimals="0"
      id="ixv-33931"
      unitRef="uref_138071911">-1920100</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-33932"
      unitRef="uref_138071911">42871904</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_2014206622"
      decimals="0"
      id="ixv-33933"
      unitRef="uref_138071911">176558493</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_110979779"
      decimals="0"
      id="ixv-33934"
      unitRef="uref_138071911">849544</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1984381866"
      decimals="0"
      id="ixv-33935"
      unitRef="uref_138071911">13116919</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_173458424"
      decimals="0"
      id="ixv-33936"
      unitRef="uref_138071911">-145732952</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_558237741"
      decimals="0"
      id="ixv-33937"
      unitRef="uref_138071911">-1920100</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1963669158"
      decimals="0"
      id="fc_1428931765"
      unitRef="uref_138071911">42871904</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="cref_818254643"
      decimals="0"
      id="ixv-33939"
      unitRef="uref_138071911">-55149150</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_1414105029"
      decimals="0"
      id="ixv-33940"
      unitRef="uref_138071911">-1801344</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_828730221"
      unitRef="uref_138071911">-56950494</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-33942"
      unitRef="uref_138071911">621440</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_1398903227"
      unitRef="uref_138071911">621440</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-33944"
      unitRef="uref_138071911">621440</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_818254643"
      decimals="0"
      id="ixv-33945"
      unitRef="uref_138071911">-55149150</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1414105029"
      decimals="0"
      id="ixv-33946"
      unitRef="uref_138071911">-1801344</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_1352836370"
      unitRef="uref_138071911">-56329054</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1786873216"
      decimals="0"
      id="ixv-33948"
      unitRef="uref_138071911">33374878</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_1993499913"
      unitRef="uref_138071911">33374878</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-33950"
      unitRef="uref_138071911">2740119</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_307358071"
      unitRef="uref_138071911">2740119</ifrs-full:IssueOfConvertibleInstruments>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-33952"
      unitRef="uref_138071911">-1730159</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_818254643"
      decimals="0"
      id="ixv-33953"
      unitRef="uref_138071911">1730159</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:OptionsForfeited
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-33954"
      unitRef="uref_138071911">-334164</radx:OptionsForfeited>
    <radx:OptionsForfeited
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_336773784"
      unitRef="uref_138071911">-334164</radx:OptionsForfeited>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_818254643"
      decimals="0"
      id="ixv-33956"
      unitRef="uref_138071911">-1357918</radx:IncreaseInOwnershipInRADVentures>
    <radx:IncreaseInOwnershipInRADVentures
      contextRef="cref_1414105029"
      decimals="0"
      id="ixv-33957"
      unitRef="uref_138071911">1357918</radx:IncreaseInOwnershipInRADVentures>
    <radx:ImpairmentOnOtherEquity
      contextRef="cref_1503779487"
      decimals="0"
      id="ixv-33958"
      unitRef="uref_138071911">-849544</radx:ImpairmentOnOtherEquity>
    <radx:ImpairmentOnOtherEquity
      contextRef="cref_818254643"
      decimals="0"
      id="ixv-33959"
      unitRef="uref_138071911">849544</radx:ImpairmentOnOtherEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1786873216"
      decimals="0"
      id="ixv-33960"
      unitRef="uref_138071911">33374878</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1503779487"
      decimals="0"
      id="ixv-33961"
      unitRef="uref_138071911">-849544</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-33962"
      unitRef="uref_138071911">675796</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_818254643"
      decimals="0"
      id="ixv-33963"
      unitRef="uref_138071911">1221785</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1414105029"
      decimals="0"
      id="ixv-33964"
      unitRef="uref_138071911">1357918</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33965"
      unitRef="uref_138071911">35780833</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="cref_1522337083"
      decimals="0"
      id="ixv-33966"
      unitRef="uref_138071911">209933371</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_777909411"
      decimals="0"
      id="ixv-33967"
      unitRef="uref_138071911">14414155</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1040168498"
      decimals="0"
      id="ixv-33968"
      unitRef="uref_138071911">-199660317</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1509356073"
      decimals="0"
      id="ixv-33969"
      unitRef="uref_138071911">-2363526</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_1305557533"
      decimals="0"
      id="fc_199217059"
      unitRef="uref_138071911">22323683</ifrs-full:Equity>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33971"
      unitRef="uref_138071911">536384</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33972"
      unitRef="uref_138071911">5353973</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33973"
      unitRef="uref_138071911">260462</ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33974"
      unitRef="uref_138071911">58353869</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33975"
      unitRef="uref_138071911">42799759</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33976"
      unitRef="uref_138071911">28138720</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33977"
      unitRef="uref_138071911">549213</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33978"
      unitRef="uref_138071911">800309</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33979"
      unitRef="uref_138071911">50484</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <radx:ResearchAndDevelopmentTaxIncentiveReceived
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33980"
      unitRef="uref_138071911">4485434</radx:ResearchAndDevelopmentTaxIncentiveReceived>
    <radx:ResearchAndDevelopmentTaxIncentiveReceived
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33981"
      unitRef="uref_138071911">4851839</radx:ResearchAndDevelopmentTaxIncentiveReceived>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33982"
      unitRef="uref_138071911">-52782838</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33983"
      unitRef="uref_138071911">-36645477</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33984"
      unitRef="uref_138071911">-22975935</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <radx:PaymentsForIntellectualProperty
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33985"
      unitRef="uref_138071911">-2997592</radx:PaymentsForIntellectualProperty>
    <radx:PaymentsForLicenseFeeLiabilities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33986"
      unitRef="uref_138071911">5420869</radx:PaymentsForLicenseFeeLiabilities>
    <radx:PaymentsForLicenseFeeLiabilities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33987"
      unitRef="uref_138071911">1226994</radx:PaymentsForLicenseFeeLiabilities>
    <radx:PaymentsForLicenseFeeLiabilities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33988"
      unitRef="uref_138071911">320000</radx:PaymentsForLicenseFeeLiabilities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33989"
      unitRef="uref_138071911">-5420869</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33990"
      unitRef="uref_138071911">1770598</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33991"
      unitRef="uref_138071911">-320000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33992"
      unitRef="uref_138071911">35378000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33993"
      unitRef="uref_138071911">53977902</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33994"
      unitRef="uref_138071911">29645526</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-33995"
      unitRef="uref_138071911">2003122</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33996"
      unitRef="uref_138071911">4738000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33997"
      unitRef="uref_138071911">1533771</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-33998"
      unitRef="uref_138071911">7369190</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsForDebtIssueCosts
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-33999"
      unitRef="uref_138071911">218633</ifrs-full:PaymentsForDebtIssueCosts>
    <ifrs-full:PaymentsForDebtIssueCosts
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34000"
      unitRef="uref_138071911">117000</ifrs-full:PaymentsForDebtIssueCosts>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34001"
      unitRef="uref_138071911">1900000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34002"
      unitRef="uref_138071911">5167000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <radx:SettlementWithLind
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34003"
      unitRef="uref_138071911">1689721</radx:SettlementWithLind>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34004"
      unitRef="uref_138071911">33374878</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34005"
      unitRef="uref_138071911">45431548</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34006"
      unitRef="uref_138071911">30196945</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34007"
      unitRef="uref_138071911">-24828829</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34008"
      unitRef="uref_138071911">10556669</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34009"
      unitRef="uref_138071911">6901010</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34010"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34011"
      unitRef="uref_138071911">18575040</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1259894475"
      decimals="0"
      id="ixv-34012"
      unitRef="uref_138071911">11699066</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34013"
      unitRef="uref_138071911">-149932</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34014"
      unitRef="uref_138071911">-14874</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34015"
      unitRef="uref_138071911">-25036</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34016"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34017"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34018"
      unitRef="uref_138071911">18575040</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="cref_1085778750" id="ixv-14574">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;1 Segment information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Management has determined, based on the reports reviewed by the chief operating decision maker that are used to make strategic decisions, that the group has one reportable segment being the research, development and commercialization of health technologies. As such, the financial information presented in the body of the financial report represents the results of the Group&#x2019;s sole operating segment. The CODM continues to monitor and review the appropriateness of this segment determination on a regular basis.&#160; &lt;/p&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <radx:NumberOfReportablesSegments
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34019"
      unitRef="uref_1642879776">1</radx:NumberOfReportablesSegments>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="cref_1085778750" id="ixv-14580">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;2 Revenue from contract with customers&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Revenue from contracts with customers&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total revenue from continuing operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="text-decoration:underline"&gt;Information on geographical regions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group derives revenue from their contracts with customers over time in the following geographical regions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Australia&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Contracts with customers&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_576659127;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Australia&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Contracts with customers&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1269795725;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Australia&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;2024&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Contracts with customers&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1063099307;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="text-decoration:underline"&gt;Information on major customers:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; During the years ended June 30, 2026, 2025 and 2024, the Company had the following major customers with revenues amounting to 10 percent or more of total group revenues: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2025&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2024&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Customer A&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Accounting policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the year ended 30 June 2025, the group entered into a strategic development services contract with Lantheus to advance clinical development of innovative radiopharmaceuticals in Australia. For more information in relation to the group&#x2019;s policy for recognizing revenue refer to note 20(n).&lt;/p&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="cref_1085778750" id="ixv-14585">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Revenue from contracts with customers&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total revenue from continuing operations&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_1317385530"
      unitRef="uref_138071911">2767888</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_198500851"
      decimals="0"
      id="fc_879947564"
      unitRef="uref_138071911">3633422</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_812473718"
      decimals="0"
      id="fc_766493339"
      unitRef="uref_138071911">299228</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:Revenue
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_53560875"
      unitRef="uref_138071911">2767888</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="cref_198500851"
      decimals="0"
      id="fc_361356874"
      unitRef="uref_138071911">3633422</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="cref_812473718"
      decimals="0"
      id="fc_368096396"
      unitRef="uref_138071911">299228</ifrs-full:Revenue>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="cref_1085778750" id="ixv-14646">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group derives revenue from their contracts with customers over time in the following geographical regions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Australia&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Contracts with customers&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_576659127;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Australia&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Contracts with customers&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1269795725;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Australia&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;2024&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Contracts with customers&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1063099307;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_469194671"
      decimals="0"
      id="ixv-34026"
      unitRef="uref_1001896052">2767888</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_469194671"
      decimals="0"
      id="ixv-34027"
      unitRef="uref_1001896052">2767888</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1651144812"
      decimals="0"
      id="ixv-34028"
      unitRef="uref_1001896052">3633422</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1651144812"
      decimals="0"
      id="ixv-34029"
      unitRef="uref_1001896052">3633422</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1427085780"
      decimals="0"
      id="ixv-34030"
      unitRef="uref_138071911">299228</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1427085780"
      decimals="0"
      id="ixv-34031"
      unitRef="uref_1001896052">299228</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory contextRef="cref_1085778750" id="ixv-14772">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; During the years ended June 30, 2026, 2025 and 2024, the Company had the following major customers with revenues amounting to 10 percent or more of total group revenues: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2025&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2024&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;A$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Customer A&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,767,888&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,633,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;299,228&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSegmentsMajorCustomersExplanatory>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="cref_1085778750"
      decimals="2"
      id="ixv-34032"
      unitRef="uref_880450695">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="cref_198500851"
      decimals="2"
      id="ixv-34033"
      unitRef="uref_880450695">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="cref_812473718"
      decimals="2"
      id="ixv-34034"
      unitRef="uref_880450695">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1680492102"
      decimals="0"
      id="ixv-34035"
      unitRef="uref_1001896052">2767888</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_621183606"
      decimals="0"
      id="ixv-34036"
      unitRef="uref_1001896052">3633422</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_677878867"
      decimals="0"
      id="ixv-34037"
      unitRef="uref_1001896052">299228</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34038"
      unitRef="uref_1001896052">2767888</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34039"
      unitRef="uref_1001896052">3633422</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34040"
      unitRef="uref_1001896052">299228</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="cref_1085778750" id="ixv-14848">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;3 Other income and expense items&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Other income&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%;"&gt;Interest&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;637,144&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;888,196&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;50,484&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and Development tax incentive&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,097,238&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,368,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,292,578&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,734,382&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,256,740&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,343,062&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;i&gt;R&amp;amp;D tax incentive&lt;/i&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group&#x2019;s research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Where expenditure is incurred outside of Australia, an &#x2018;overseas finding&#x2019; must be obtained from AusIndustry prior to any such expenditure being eligible under the scheme. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2026, the group has included an item in other income of $10,097,238 (2025: $9,368,544, 2024: $1,292,578) to recognize income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate. The assistance received is a direct cash payment from the ATO and is not related to any tax liability or income tax calculation. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The $10,097,238 recognized at 30 June 2026 includes &lt;span style="-sec-ix-hidden:fc_352498039;"&gt;nil&lt;/span&gt; relating to prior years rebate. The $9,368,544 recognized at 30 June 2025 includes $3,587,887 relating to the prior year&#x2019;s rebate. The funds were only received in the prior year and eligibility to receive the rebate for this expenditure was less than certain prior to this as the overseas findings for program was not received until the prior year. The funds were only received in the current year and eligibility to receive the rebate for this expenditure was less than certain prior to this as the overseas findings for program was not received until the current year. For the year ended 30 June 2024, the group has included an item in other income of $1,292,578 to recognize income over the period necessary to match the grant on a systematic basis. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Other losses&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2024     &lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Fair value adjustment on financing agreements&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1340182865;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(489,787&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_851113406;"&gt;366,719&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Net foreign exchange (Losses)/Gains&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(655,393&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;138,141&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;94,964&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Loss on sale of available-for-sale assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;6(a)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(212,769&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_920545125;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,687,791&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(868,162&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(351,646&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,226,108&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Breakdown of expenses by nature&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;General and administrative expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Accounting and audit&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;949,683&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;957,895&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;845,818&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Consulting&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;406,564&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;286,138&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;95,179&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Depreciation&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,331&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,331&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,534&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Employee benefits&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;11,186,055&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,120,149&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,448,779&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Insurance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;341,658&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;105,762&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;359,209&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Investor relations&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;472,262&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;313,671&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;323,588&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Legal&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;631,909&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;656,036&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;164,754&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Listing and share registry&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;188,341&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;190,795&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;193,797&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Patent costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;244,529&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;205,017&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;204,163&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Travel and entertainment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;864,801&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;808,546&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;427,676&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;922,569&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;986,673&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;968,749&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;16,215,702&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;14,638,013&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,039,246&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Research and development&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Amortization&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,698,702&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,588,306&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,118,752&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;AVb6 Integrin (TRIMT)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;918,221&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,876,983&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;993,645&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Consulting Fees R&amp;amp;D&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,324,355&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;930,292&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;929,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;hu PSA Anti-body (Diaprost)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,011,056&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,925,445&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;298,312&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Impairment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;6(b)(viii)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,266,823&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1850222835;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,478,892&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;R&amp;amp;D Ventures&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;11,040,742&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,989,964&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,931,541&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;NanoMab&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;15,070,282&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,185,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,501,174&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Neoindicate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;351,529&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;437,400&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;529,424&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Pivalate - Imperial&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;6,153,044&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,184,136&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,962,355&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;UCLA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1864095034;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;226,063&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,253,493&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;128,145&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;171,605&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;89,450&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;49,962,899&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;27,515,194&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;23,086,267&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The categories shown here align with the intellectual property held by the group as disclosed in note 6 and represents the amount of R&amp;amp;D expended on progressing the respective intellectual property.&lt;/p&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <radx:DisclosureOfOtherIncomeTableTextBlock contextRef="cref_1085778750" id="ixv-14852">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Other income&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%;"&gt;Interest&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;637,144&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;888,196&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;50,484&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and Development tax incentive&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,097,238&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,368,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,292,578&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,734,382&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,256,740&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,343,062&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfOtherIncomeTableTextBlock>
    <radx:InterestIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_630698584"
      unitRef="uref_138071911">637144</radx:InterestIncome>
    <radx:InterestIncome
      contextRef="cref_198500851"
      decimals="0"
      id="fc_1440174674"
      unitRef="uref_138071911">888196</radx:InterestIncome>
    <radx:InterestIncome
      contextRef="cref_812473718"
      decimals="0"
      id="fc_563857141"
      unitRef="uref_138071911">50484</radx:InterestIncome>
    <radx:ResearchAndDevelopmentsTaxIncentive
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34044"
      unitRef="uref_138071911">10097238</radx:ResearchAndDevelopmentsTaxIncentive>
    <radx:ResearchAndDevelopmentsTaxIncentive
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34045"
      unitRef="uref_138071911">9368544</radx:ResearchAndDevelopmentsTaxIncentive>
    <radx:ResearchAndDevelopmentsTaxIncentive
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34046"
      unitRef="uref_138071911">1292578</radx:ResearchAndDevelopmentsTaxIncentive>
    <ifrs-full:OtherIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34047"
      unitRef="uref_138071911">10734382</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34048"
      unitRef="uref_138071911">10256740</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34049"
      unitRef="uref_138071911">1343062</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_2065535967"
      decimals="0"
      id="ixv-34050"
      unitRef="uref_138071911">10097238</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_2014942524"
      decimals="0"
      id="ixv-34051"
      unitRef="uref_138071911">9368544</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="cref_2102687301"
      decimals="0"
      id="ixv-34052"
      unitRef="uref_138071911">1292578</ifrs-full:OtherIncome>
    <radx:ResearchAndDevelopmentPriorYearsRebate
      contextRef="cref_686324981"
      decimals="0"
      id="ixv-34053"
      unitRef="uref_138071911">10097238</radx:ResearchAndDevelopmentPriorYearsRebate>
    <radx:ResearchAndDevelopmentPriorYearsRebate
      contextRef="cref_568892551"
      decimals="0"
      id="ixv-34054"
      unitRef="uref_138071911">9368544</radx:ResearchAndDevelopmentPriorYearsRebate>
    <radx:ResearchAndDevelopmentPriorYearsRebate
      contextRef="cref_711082873"
      decimals="0"
      id="ixv-34055"
      unitRef="uref_138071911">3587887</radx:ResearchAndDevelopmentPriorYearsRebate>
    <radx:TaxEffectOfResearchAndDevelopmentTaxIncentive
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34056"
      unitRef="uref_138071911">1292578</radx:TaxEffectOfResearchAndDevelopmentTaxIncentive>
    <radx:DisclosureOfOtherLossesTableTextBlock contextRef="cref_1085778750" id="ixv-14935">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Other losses&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2024     &lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Fair value adjustment on financing agreements&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1340182865;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(489,787&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_851113406;"&gt;366,719&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Net foreign exchange (Losses)/Gains&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(655,393&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;138,141&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;94,964&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Loss on sale of available-for-sale assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;6(a)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(212,769&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_920545125;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,687,791&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(868,162&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(351,646&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,226,108&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfOtherLossesTableTextBlock>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34057"
      unitRef="uref_138071911">-489787</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34058"
      unitRef="uref_138071911">655393</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34059"
      unitRef="uref_138071911">-138141</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="cref_812473718"
      decimals="0"
      id="fc_1314735791"
      unitRef="uref_138071911">-94964</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34061"
      unitRef="uref_138071911">212769</ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34062"
      unitRef="uref_138071911">1687791</ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:OtherExpenseByFunction
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34063"
      unitRef="uref_138071911">868162</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34064"
      unitRef="uref_138071911">351646</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34065"
      unitRef="uref_138071911">1226108</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="cref_1085778750" id="ixv-15065">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Breakdown of expenses by nature&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;General and administrative expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Accounting and audit&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;949,683&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;957,895&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;845,818&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Consulting&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;406,564&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;286,138&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;95,179&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Depreciation&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,331&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,331&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,534&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Employee benefits&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;11,186,055&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,120,149&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,448,779&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Insurance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;341,658&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;105,762&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;359,209&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Investor relations&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;472,262&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;313,671&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;323,588&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Legal&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;631,909&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;656,036&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;164,754&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Listing and share registry&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;188,341&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;190,795&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;193,797&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Patent costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;244,529&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;205,017&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;204,163&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Travel and entertainment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;864,801&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;808,546&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;427,676&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;922,569&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;986,673&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;968,749&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;16,215,702&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;14,638,013&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,039,246&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left;"&gt;Research and development&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Amortization&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,698,702&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,588,306&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,118,752&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;AVb6 Integrin (TRIMT)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;918,221&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,876,983&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;993,645&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Consulting Fees R&amp;amp;D&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,324,355&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;930,292&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;929,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;hu PSA Anti-body (Diaprost)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,011,056&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,925,445&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;298,312&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Impairment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;6(b)(viii)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,266,823&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1850222835;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,478,892&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;R&amp;amp;D Ventures&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;11,040,742&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,989,964&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,931,541&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;NanoMab&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;15,070,282&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,185,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,501,174&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Neoindicate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;351,529&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;437,400&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;529,424&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Pivalate - Imperial&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;6,153,044&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,184,136&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,962,355&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;UCLA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1864095034;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;226,063&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,253,493&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;128,145&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;171,605&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;89,450&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;49,962,899&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;27,515,194&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;23,086,267&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_160260067"
      decimals="0"
      id="fc_160260067"
      unitRef="uref_138071911">949683</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1508206844"
      decimals="0"
      id="fc_1508206844"
      unitRef="uref_138071911">957895</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_885449171"
      decimals="0"
      id="fc_885449171"
      unitRef="uref_138071911">845818</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1120991972"
      decimals="0"
      id="fc_1120991972"
      unitRef="uref_138071911">406564</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_553826154"
      decimals="0"
      id="fc_553826154"
      unitRef="uref_138071911">286138</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_854982644"
      decimals="0"
      id="fc_854982644"
      unitRef="uref_138071911">95179</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1897429609"
      decimals="0"
      id="fc_1897429609"
      unitRef="uref_138071911">7331</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_181759167"
      decimals="0"
      id="fc_181759167"
      unitRef="uref_138071911">7331</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_605691750"
      decimals="0"
      id="fc_605691750"
      unitRef="uref_138071911">7534</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_418515650"
      decimals="0"
      id="fc_418515650"
      unitRef="uref_138071911">11186055</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1620006605"
      decimals="0"
      id="fc_1620006605"
      unitRef="uref_138071911">10120149</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1689061437"
      decimals="0"
      id="fc_1689061437"
      unitRef="uref_138071911">9448779</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_535028712"
      decimals="0"
      id="fc_535028712"
      unitRef="uref_138071911">341658</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1285545738"
      decimals="0"
      id="fc_1285545738"
      unitRef="uref_138071911">105762</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_718216585"
      decimals="0"
      id="fc_718216585"
      unitRef="uref_138071911">359209</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_205858665"
      decimals="0"
      id="fc_205858665"
      unitRef="uref_138071911">472262</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_21539129"
      decimals="0"
      id="fc_21539129"
      unitRef="uref_138071911">313671</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_112351414"
      decimals="0"
      id="fc_112351414"
      unitRef="uref_138071911">323588</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_801610513"
      decimals="0"
      id="fc_801610513"
      unitRef="uref_138071911">631909</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_410505567"
      decimals="0"
      id="fc_410505567"
      unitRef="uref_138071911">656036</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_2123680038"
      decimals="0"
      id="fc_2123680038"
      unitRef="uref_138071911">164754</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1276853525"
      decimals="0"
      id="fc_1276853525"
      unitRef="uref_138071911">188341</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1689403473"
      decimals="0"
      id="fc_1689403473"
      unitRef="uref_138071911">190795</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_202579806"
      decimals="0"
      id="fc_202579806"
      unitRef="uref_138071911">193797</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_936589973"
      decimals="0"
      id="fc_936589973"
      unitRef="uref_138071911">244529</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1284426911"
      decimals="0"
      id="fc_1284426911"
      unitRef="uref_138071911">205017</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_2039607131"
      decimals="0"
      id="fc_2039607131"
      unitRef="uref_138071911">204163</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_630773908"
      decimals="0"
      id="fc_630773908"
      unitRef="uref_138071911">864801</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_192897766"
      decimals="0"
      id="fc_192897766"
      unitRef="uref_138071911">808546</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1451871145"
      decimals="0"
      id="fc_1451871145"
      unitRef="uref_138071911">427676</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1346579919"
      decimals="0"
      id="fc_315951882"
      unitRef="uref_138071911">922569</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_993985842"
      decimals="0"
      id="fc_1227265290"
      unitRef="uref_138071911">986673</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_892721806"
      decimals="0"
      id="fc_856415268"
      unitRef="uref_138071911">968749</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_1378724436"
      unitRef="uref_138071911">16215702</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_198500851"
      decimals="0"
      id="fc_1135927662"
      unitRef="uref_138071911">14638013</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="cref_812473718"
      decimals="0"
      id="fc_2024395390"
      unitRef="uref_138071911">13039246</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_58801058"
      decimals="0"
      id="fc_58801058"
      unitRef="uref_138071911">2698702</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1504167164"
      decimals="0"
      id="fc_1504167164"
      unitRef="uref_138071911">2588306</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_292626312"
      decimals="0"
      id="fc_292626312"
      unitRef="uref_138071911">3118752</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_2021512896"
      decimals="0"
      id="fc_2021512896"
      unitRef="uref_138071911">918221</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_897947490"
      decimals="0"
      id="fc_897947490"
      unitRef="uref_138071911">1876983</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_745646697"
      decimals="0"
      id="fc_745646697"
      unitRef="uref_138071911">993645</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1074339372"
      decimals="0"
      id="fc_1074339372"
      unitRef="uref_138071911">1324355</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_891507282"
      decimals="0"
      id="fc_891507282"
      unitRef="uref_138071911">930292</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_874894537"
      decimals="0"
      id="fc_874894537"
      unitRef="uref_138071911">929229</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_2074446413"
      decimals="0"
      id="fc_2074446413"
      unitRef="uref_138071911">7011056</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1267373319"
      decimals="0"
      id="fc_1267373319"
      unitRef="uref_138071911">2925445</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1828563044"
      decimals="0"
      id="fc_1828563044"
      unitRef="uref_138071911">298312</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1715402857"
      decimals="0"
      id="fc_1715402857"
      unitRef="uref_138071911">5266823</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_293179339"
      decimals="0"
      id="fc_293179339"
      unitRef="uref_138071911">1478892</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_680055745"
      decimals="0"
      id="fc_680055745"
      unitRef="uref_138071911">11040742</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_270941582"
      decimals="0"
      id="fc_270941582"
      unitRef="uref_138071911">5989964</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_662260166"
      decimals="0"
      id="fc_662260166"
      unitRef="uref_138071911">3931541</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1668330041"
      decimals="0"
      id="fc_1668330041"
      unitRef="uref_138071911">15070282</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1650050184"
      decimals="0"
      id="fc_1650050184"
      unitRef="uref_138071911">7185000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_484307968"
      decimals="0"
      id="fc_484307968"
      unitRef="uref_138071911">6501174</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_577038710"
      decimals="0"
      id="fc_577038710"
      unitRef="uref_138071911">351529</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_2040435642"
      decimals="0"
      id="fc_2040435642"
      unitRef="uref_138071911">437400</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1521170066"
      decimals="0"
      id="fc_1521170066"
      unitRef="uref_138071911">529424</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_2088230386"
      decimals="0"
      id="fc_2088230386"
      unitRef="uref_138071911">6153044</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1664407651"
      decimals="0"
      id="fc_1664407651"
      unitRef="uref_138071911">5184136</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_467084138"
      decimals="0"
      id="fc_467084138"
      unitRef="uref_138071911">3962355</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_133146093"
      decimals="0"
      id="fc_133146093"
      unitRef="uref_138071911">226063</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_109617195"
      decimals="0"
      id="fc_109617195"
      unitRef="uref_138071911">1253493</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1346579919"
      decimals="0"
      id="fc_1346579919"
      unitRef="uref_138071911">128145</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_993985842"
      decimals="0"
      id="fc_993985842"
      unitRef="uref_138071911">171605</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_892721806"
      decimals="0"
      id="ixv-34132"
      unitRef="uref_138071911">89450</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_1085778750"
      decimals="0"
      id="fc_107825965"
      unitRef="uref_138071911">49962899</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_198500851"
      decimals="0"
      id="fc_1850735203"
      unitRef="uref_138071911">27515194</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34135"
      unitRef="uref_138071911">23086267</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="cref_1085778750" id="ixv-15539">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;4 Income tax expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Australian tax expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;i&gt;Numerical reconciliation of income tax                                             expense to prima facie tax payable&lt;/i&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt;     $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt;     $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt;     $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left;"&gt;Loss from continuing operations before income     tax expense&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(39,945,437&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(32,188,619&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(42,740,210&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax at the Australian tax rate of 25% (2025: 25%, 2024:     25%)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(9,986,359&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(8,047,155&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(10,685,053&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax effect of amounts which are not deductible/(taxable)     in calculating taxable income:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Research and Development tax incentive&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(2,524,310&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,342,136&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(323,145&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Accounting expenditure subject to R&amp;amp;D tax incentive&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,803,010&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,384,221&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;742,862&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Accrued expenses&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;319,935&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;242,082&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;44,172&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Amortization&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(658,079&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(629,735&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_569013496;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Employee leave obligations&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(43,146&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;917&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,639&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Patent costs&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;61,132&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;51,254&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;51,041&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;601,489&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;473,837&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;660,045&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt;"&gt;Unrealized currency movements&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;3,011&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;43,430&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(27,266&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Subtotal&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;3,563,043&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,223,870&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,151,348&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Tax losses and other timing differences     for which no deferred tax asset is recognized&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,423,316&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,827,533&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,533,705&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1615426202;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1921979487;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1486771677;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(ii) Tax losses&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Unused tax losses for which no deferred tax asset has been recognized&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;128,380,671&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;102,687,407&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;83,377,275&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Potential tax benefit at 25% (2025: 25%, 2024: 25%)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;32,095,168&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;25,671,852&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;20,844,319&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The above potential tax benefit for tax losses has not been recognized in the statement of financial position as of 30 June 2026 as it is not probable that they will be utilized. These tax losses can only be utilized in the future if the continuity of ownership test is passed, or failing that, the same business test is passed. The taxation benefits of tax losses and temporary difference not brought to account will only be obtained if: (i) the entity derives future assessable income of a nature and of an amount sufficient to enable the benefit from the deductions for the losses to be realized; (ii) the entity continues to comply with the conditions for deductibility imposed by law; and (iii) no change in tax legislation adversely affects the entity in realizing the benefits from deducting the losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group operates in different tax jurisdictions and continues to meet its statutory requirements in these jurisdictions. The tax losses in each jurisdiction are subject to testing to make sure they meet all relevant statutory tests for them to be offset against future income&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(b) US tax expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Income tax expense&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: italic;"&gt;Current tax&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Current tax on profits for the year&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total current tax expense&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(ii) Numerical reconciliation of income tax expense to prima facie tax payable&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left;"&gt;Loss from continuing operations before income     tax expense&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(16,896,177&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(5,930,262&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(5,112,545&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax at the US tax rate of 27.5% (2025: 27.5%, 2024: 27.5%)*&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(4,646,449&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,630,822&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,405,950&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax effect of amounts which are not deductible/(taxable)     in calculating taxable income:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Accrued expenses&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;221,775&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;28,021&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(17,719&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Amortization&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(18,257&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(19,075&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1884399157;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Employee leave obligations&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;347,200&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(13,835&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;26,576&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt;"&gt;Unrealized currency (gains)/losses&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(183,545&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(9,784&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1147713519;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Subtotal&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;367,173&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(14,673&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,857&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Tax losses and other timing differences     for which no deferred tax asset is recognized&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,333,716&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,748,787&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,493,457&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;*&lt;/td&gt; &lt;td style="text-align: justify;"&gt;the tax rate is driven                                             by 21.1% for the federal rate and 6.5% for the new York sate rate&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Tax losses&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Unused tax losses for which no deferred tax asset has been recognized&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;29,689,955&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,930,988&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;7,571,756&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Potential tax benefit at 27.5% (2025: 27.5%, 2024: 27.5%)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;8,164,738&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,831,022&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,082,233&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The above potential tax benefit for tax losses has not been recognized in the statement of financial position as of 30 June 2026 as it is not probable that they will be utilized. These tax losses can only be utilized in the future if the continuity of ownership test is passed, or failing that, the same business test is passed. The taxation benefits of tax losses and temporary difference not brought to account will only be obtained if: (i) the entity derives future assessable income of a nature and of an amount sufficient to enable the benefit from the deductions for the losses to be realized; (ii) the entity continues to comply with the conditions for deductibility imposed by law; and (iii) no change in tax legislation adversely affects the entity in realizing the benefits from deducting the losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group operates in different tax jurisdictions and continues to meet its statutory requirements in these jurisdictions. The tax losses in each jurisdiction are subject to testing to make sure they meet all relevant statutory tests for them to be offset against future income&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <radx:DisclosureOfNumericalReconciliationOfIncomeTaxExpenseToPrimaFacieTaxPayableExplanatory contextRef="cref_1085778750" id="ixv-15554">&lt;i&gt;Numerical reconciliation of income tax                                             expense to prima facie tax payable&lt;/i&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt;     $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt;     $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt;     $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left;"&gt;Loss from continuing operations before income     tax expense&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(39,945,437&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(32,188,619&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(42,740,210&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax at the Australian tax rate of 25% (2025: 25%, 2024:     25%)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(9,986,359&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(8,047,155&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(10,685,053&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax effect of amounts which are not deductible/(taxable)     in calculating taxable income:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Research and Development tax incentive&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(2,524,310&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,342,136&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(323,145&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Accounting expenditure subject to R&amp;amp;D tax incentive&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,803,010&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,384,221&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;742,862&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Accrued expenses&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;319,935&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;242,082&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;44,172&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Amortization&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(658,079&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(629,735&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_569013496;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Employee leave obligations&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(43,146&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;917&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,639&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Patent costs&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;61,132&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;51,254&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;51,041&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;601,489&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;473,837&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;660,045&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt;"&gt;Unrealized currency movements&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;3,011&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;43,430&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(27,266&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Subtotal&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;3,563,043&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,223,870&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,151,348&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Tax losses and other timing differences     for which no deferred tax asset is recognized&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,423,316&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,827,533&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,533,705&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1615426202;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1921979487;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1486771677;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Numerical reconciliation of income tax expense to prima facie tax payable&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left;"&gt;Loss from continuing operations before income     tax expense&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(16,896,177&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(5,930,262&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(5,112,545&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax at the US tax rate of 27.5% (2025: 27.5%, 2024: 27.5%)*&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(4,646,449&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,630,822&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,405,950&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Tax effect of amounts which are not deductible/(taxable)     in calculating taxable income:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Accrued expenses&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;221,775&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;28,021&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(17,719&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Amortization&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(18,257&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(19,075&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1884399157;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left;"&gt;Employee leave obligations&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;347,200&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(13,835&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;26,576&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt;"&gt;Unrealized currency (gains)/losses&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(183,545&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(9,784&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1147713519;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.25in;"&gt;Subtotal&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;367,173&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(14,673&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,857&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Tax losses and other timing differences     for which no deferred tax asset is recognized&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,333,716&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,748,787&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,493,457&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;*&lt;/td&gt; &lt;td style="text-align: justify;"&gt;the tax rate is driven                                             by 21.1% for the federal rate and 6.5% for the new York sate rate&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</radx:DisclosureOfNumericalReconciliationOfIncomeTaxExpenseToPrimaFacieTaxPayableExplanatory>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_858361064"
      unitRef="uref_138071911">-39945437</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_1232063515"
      unitRef="uref_138071911">-32188619</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_585009615"
      decimals="0"
      id="fc_369836500"
      unitRef="uref_138071911">-42740210</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ApplicableTaxRate
      contextRef="cref_1937830845"
      decimals="2"
      id="ixv-34139"
      unitRef="uref_880450695">0.25</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="cref_2052780937"
      decimals="2"
      id="ixv-34140"
      unitRef="uref_880450695">0.25</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="cref_585009615"
      decimals="2"
      id="ixv-34141"
      unitRef="uref_880450695">0.25</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1080073657"
      unitRef="uref_138071911">-9986359</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_1572169743"
      unitRef="uref_138071911">-8047155</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="cref_585009615"
      decimals="0"
      id="fc_498051268"
      unitRef="uref_138071911">-10685053</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <radx:TaxEffectOfResearchAndDevelopmentTaxIncentive
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1893422406"
      unitRef="uref_138071911">2524310</radx:TaxEffectOfResearchAndDevelopmentTaxIncentive>
    <radx:TaxEffectOfResearchAndDevelopmentTaxIncentive
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_772539294"
      unitRef="uref_138071911">2342136</radx:TaxEffectOfResearchAndDevelopmentTaxIncentive>
    <radx:TaxEffectOfResearchAndDevelopmentTaxIncentive
      contextRef="cref_585009615"
      decimals="0"
      id="fc_981877603"
      unitRef="uref_138071911">323145</radx:TaxEffectOfResearchAndDevelopmentTaxIncentive>
    <radx:TaxEffectOfAccountingExpenditureSubjectToResearchandDevelopmentTaxIncentive
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_74671620"
      unitRef="uref_138071911">5803010</radx:TaxEffectOfAccountingExpenditureSubjectToResearchandDevelopmentTaxIncentive>
    <radx:TaxEffectOfAccountingExpenditureSubjectToResearchandDevelopmentTaxIncentive
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_1061797154"
      unitRef="uref_138071911">5384221</radx:TaxEffectOfAccountingExpenditureSubjectToResearchandDevelopmentTaxIncentive>
    <radx:TaxEffectOfAccountingExpenditureSubjectToResearchandDevelopmentTaxIncentive
      contextRef="cref_585009615"
      decimals="0"
      id="fc_415095756"
      unitRef="uref_138071911">742862</radx:TaxEffectOfAccountingExpenditureSubjectToResearchandDevelopmentTaxIncentive>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1202376321"
      unitRef="uref_138071911">319935</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_138456697"
      unitRef="uref_138071911">242082</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="cref_585009615"
      decimals="0"
      id="fc_2000616942"
      unitRef="uref_138071911">44172</ifrs-full:TaxEffectOfTaxLosses>
    <radx:TaxEffectOfTaxAmortisation
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1240376559"
      unitRef="uref_138071911">658079</radx:TaxEffectOfTaxAmortisation>
    <radx:TaxEffectOfTaxAmortisation
      contextRef="cref_2052780937"
      decimals="0"
      id="ixv-34155"
      unitRef="uref_138071911">629735</radx:TaxEffectOfTaxAmortisation>
    <radx:TaxEffectOfEmployeeLeaveObligations
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1222911440"
      unitRef="uref_138071911">-43146</radx:TaxEffectOfEmployeeLeaveObligations>
    <radx:TaxEffectOfEmployeeLeaveObligations
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_2102249598"
      unitRef="uref_138071911">917</radx:TaxEffectOfEmployeeLeaveObligations>
    <radx:TaxEffectOfEmployeeLeaveObligations
      contextRef="cref_585009615"
      decimals="0"
      id="fc_1862940773"
      unitRef="uref_138071911">3639</radx:TaxEffectOfEmployeeLeaveObligations>
    <radx:TaxEffectOfPatentCosts
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1352939465"
      unitRef="uref_138071911">61132</radx:TaxEffectOfPatentCosts>
    <radx:TaxEffectOfPatentCosts
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_32755749"
      unitRef="uref_138071911">51254</radx:TaxEffectOfPatentCosts>
    <radx:TaxEffectOfPatentCosts
      contextRef="cref_585009615"
      decimals="0"
      id="fc_2055521320"
      unitRef="uref_138071911">51041</radx:TaxEffectOfPatentCosts>
    <radx:TaxEffectOfSharebasedPayments
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1637516416"
      unitRef="uref_138071911">601489</radx:TaxEffectOfSharebasedPayments>
    <radx:TaxEffectOfSharebasedPayments
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_2037194603"
      unitRef="uref_138071911">473837</radx:TaxEffectOfSharebasedPayments>
    <radx:TaxEffectOfSharebasedPayments
      contextRef="cref_585009615"
      decimals="0"
      id="fc_2020292996"
      unitRef="uref_138071911">660045</radx:TaxEffectOfSharebasedPayments>
    <radx:TaxEffectOfUnrealizedCurrencyMovements
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1553281857"
      unitRef="uref_138071911">3011</radx:TaxEffectOfUnrealizedCurrencyMovements>
    <radx:TaxEffectOfUnrealizedCurrencyMovements
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_848950677"
      unitRef="uref_138071911">43430</radx:TaxEffectOfUnrealizedCurrencyMovements>
    <radx:TaxEffectOfUnrealizedCurrencyMovements
      contextRef="cref_585009615"
      decimals="0"
      id="fc_442460664"
      unitRef="uref_138071911">-27266</radx:TaxEffectOfUnrealizedCurrencyMovements>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1770901872"
      unitRef="uref_138071911">3563043</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_2088030539"
      unitRef="uref_138071911">3223870</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="cref_585009615"
      decimals="0"
      id="fc_450968407"
      unitRef="uref_138071911">1151348</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="cref_1937830845"
      decimals="0"
      id="fc_1937830845"
      unitRef="uref_138071911">6423316</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="cref_2052780937"
      decimals="0"
      id="fc_2052780937"
      unitRef="uref_138071911">4827533</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="cref_585009615"
      decimals="0"
      id="fc_585009615"
      unitRef="uref_138071911">9533705</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="cref_1085778750" id="ixv-34174">Tax losses&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Unused tax losses for which no deferred tax asset has been recognized&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;128,380,671&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;102,687,407&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;83,377,275&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Potential tax benefit at 25% (2025: 25%, 2024: 25%)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;32,095,168&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;25,671,852&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;20,844,319&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;Tax losses&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Unused tax losses for which no deferred tax asset has been recognized&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;29,689,955&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,930,988&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;7,571,756&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Potential tax benefit at 27.5% (2025: 27.5%, 2024: 27.5%)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;8,164,738&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,831,022&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,082,233&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="cref_1699112522"
      decimals="0"
      id="ixv-34175"
      unitRef="uref_138071911">128380671</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="cref_1315326579"
      decimals="0"
      id="ixv-34176"
      unitRef="uref_138071911">102687407</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="cref_1130774008"
      decimals="0"
      id="ixv-34177"
      unitRef="uref_138071911">83377275</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <radx:PotentialTaxBenefitRate
      contextRef="cref_1699112522"
      decimals="2"
      id="ixv-34178"
      unitRef="uref_880450695">0.25</radx:PotentialTaxBenefitRate>
    <radx:PotentialTaxBenefitRate
      contextRef="cref_1315326579"
      decimals="2"
      id="ixv-34179"
      unitRef="uref_880450695">0.25</radx:PotentialTaxBenefitRate>
    <radx:PotentialTaxBenefitRate
      contextRef="cref_1130774008"
      decimals="2"
      id="ixv-34180"
      unitRef="uref_880450695">0.25</radx:PotentialTaxBenefitRate>
    <radx:PotentialTaxBenefit
      contextRef="cref_1699112522"
      decimals="0"
      id="ixv-34181"
      unitRef="uref_138071911">32095168</radx:PotentialTaxBenefit>
    <radx:PotentialTaxBenefit
      contextRef="cref_1315326579"
      decimals="0"
      id="ixv-34182"
      unitRef="uref_138071911">25671852</radx:PotentialTaxBenefit>
    <radx:PotentialTaxBenefit
      contextRef="cref_1130774008"
      decimals="0"
      id="ixv-34183"
      unitRef="uref_138071911">20844319</radx:PotentialTaxBenefit>
    <radx:DisclosureOfIncomeTaxExpenseExplanatory contextRef="cref_1085778750" id="ixv-34184">Income tax expense&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: italic;"&gt;Current tax&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Current tax on profits for the year&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total current tax expense&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Income tax expense&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;54,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;103,292&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;96,364&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfIncomeTaxExpenseExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34185"
      unitRef="uref_138071911">54440</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34186"
      unitRef="uref_138071911">103292</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34187"
      unitRef="uref_138071911">96364</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34188"
      unitRef="uref_138071911">54440</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34189"
      unitRef="uref_138071911">103292</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34190"
      unitRef="uref_138071911">96364</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34191"
      unitRef="uref_138071911">54440</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34192"
      unitRef="uref_138071911">103292</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34193"
      unitRef="uref_138071911">96364</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34195"
      unitRef="uref_138071911">-16896177</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34196"
      unitRef="uref_138071911">-5930262</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="cref_879251327"
      decimals="0"
      id="fc_910447092"
      unitRef="uref_138071911">-5112545</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ApplicableTaxRate
      contextRef="cref_898783114"
      decimals="3"
      id="fc_1397869314"
      unitRef="uref_880450695">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="cref_1662401931"
      decimals="3"
      id="fc_104051111"
      unitRef="uref_880450695">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="cref_879251327"
      decimals="3"
      id="fc_2014217810"
      unitRef="uref_880450695">0.275</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="cref_898783114"
      decimals="0"
      id="fc_1906481532"
      unitRef="uref_138071911">-4646449</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="cref_1662401931"
      decimals="0"
      id="fc_496556634"
      unitRef="uref_138071911">-1630822</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="cref_879251327"
      decimals="0"
      id="fc_508051551"
      unitRef="uref_138071911">-1405950</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34204"
      unitRef="uref_138071911">221775</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34205"
      unitRef="uref_138071911">28021</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="cref_879251327"
      decimals="0"
      id="fc_2089910947"
      unitRef="uref_138071911">-17719</ifrs-full:TaxEffectOfTaxLosses>
    <radx:TaxEffectOfTaxAmortisation
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34207"
      unitRef="uref_138071911">18257</radx:TaxEffectOfTaxAmortisation>
    <radx:TaxEffectOfTaxAmortisation
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34208"
      unitRef="uref_138071911">19075</radx:TaxEffectOfTaxAmortisation>
    <radx:TaxEffectOfEmployeeLeaveObligations
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34209"
      unitRef="uref_138071911">347200</radx:TaxEffectOfEmployeeLeaveObligations>
    <radx:TaxEffectOfEmployeeLeaveObligations
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34210"
      unitRef="uref_138071911">-13835</radx:TaxEffectOfEmployeeLeaveObligations>
    <radx:TaxEffectOfEmployeeLeaveObligations
      contextRef="cref_879251327"
      decimals="0"
      id="fc_1275288322"
      unitRef="uref_138071911">26576</radx:TaxEffectOfEmployeeLeaveObligations>
    <radx:TaxEffectOfUnrealisedCurrencygainslosses
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34212"
      unitRef="uref_138071911">183545</radx:TaxEffectOfUnrealisedCurrencygainslosses>
    <radx:TaxEffectOfUnrealisedCurrencygainslosses
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34213"
      unitRef="uref_138071911">9784</radx:TaxEffectOfUnrealisedCurrencygainslosses>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34214"
      unitRef="uref_138071911">367173</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34215"
      unitRef="uref_138071911">-14673</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="cref_879251327"
      decimals="0"
      id="fc_1222765362"
      unitRef="uref_138071911">8857</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34217"
      unitRef="uref_138071911">4333716</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34218"
      unitRef="uref_138071911">1748787</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="cref_879251327"
      decimals="0"
      id="fc_538026398"
      unitRef="uref_138071911">1493457</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_898783114"
      decimals="0"
      id="ixv-34220"
      unitRef="uref_138071911">54440</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_1662401931"
      decimals="0"
      id="ixv-34221"
      unitRef="uref_138071911">103292</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="cref_879251327"
      decimals="0"
      id="fc_879251327"
      unitRef="uref_138071911">96364</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <radx:PecentageOfFederalTaxRate
      contextRef="cref_1085778750"
      decimals="3"
      id="ixv-34224"
      unitRef="uref_880450695">0.211</radx:PecentageOfFederalTaxRate>
    <radx:PercentageOfNewYorkStateRate
      contextRef="cref_1085778750"
      decimals="3"
      id="ixv-34225"
      unitRef="uref_880450695">0.065</radx:PercentageOfNewYorkStateRate>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="cref_1834664750"
      decimals="0"
      id="ixv-34227"
      unitRef="uref_138071911">29689955</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="cref_2051121825"
      decimals="0"
      id="ixv-34228"
      unitRef="uref_138071911">13930988</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="cref_560997269"
      decimals="0"
      id="ixv-34229"
      unitRef="uref_138071911">7571756</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <radx:PotentialTaxBenefitRate
      contextRef="cref_1834664750"
      decimals="3"
      id="ixv-34230"
      unitRef="uref_880450695">0.275</radx:PotentialTaxBenefitRate>
    <radx:PotentialTaxBenefitRate
      contextRef="cref_2051121825"
      decimals="3"
      id="ixv-34231"
      unitRef="uref_880450695">0.275</radx:PotentialTaxBenefitRate>
    <radx:PotentialTaxBenefitRate
      contextRef="cref_560997269"
      decimals="3"
      id="ixv-34232"
      unitRef="uref_880450695">0.275</radx:PotentialTaxBenefitRate>
    <radx:PotentialTaxBenefit
      contextRef="cref_1834664750"
      decimals="0"
      id="ixv-34233"
      unitRef="uref_138071911">8164738</radx:PotentialTaxBenefit>
    <radx:PotentialTaxBenefit
      contextRef="cref_2051121825"
      decimals="0"
      id="ixv-34234"
      unitRef="uref_138071911">3831022</radx:PotentialTaxBenefit>
    <radx:PotentialTaxBenefit
      contextRef="cref_560997269"
      decimals="0"
      id="ixv-34235"
      unitRef="uref_138071911">2082233</radx:PotentialTaxBenefit>
    <ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory contextRef="cref_1085778750" id="ixv-16260">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;5 Financial assets and financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Current assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Cash at bank and on hand&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Reconciliation to cash flow statement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The above figures reconcile to the amount of cash shown in the consolidated statement of cash flows at the end of the financial year and period, respectively, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Balances as above&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Balances per statement of cash flows&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Classification as cash equivalents&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition and are repayable with 24-hour notice with no loss of interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Risk exposure&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to interest rate risk is discussed in note 10. The maximum exposure to credit risk at the end of the reporting year is the carrying amount of each class of cash and cash equivalents mentioned above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Trade and other receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-26&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-25&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-24&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Non-&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left;"&gt;Trade receivables&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;1,227,040&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_421099220;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;1,227,040&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_759014810;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_2009342397;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_160613664;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1273330257;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&#160;&lt;span style="-sec-ix-hidden:fc_906776;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_512807925;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Accrued receivables (i)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;15,877,895&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_223383173;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;15,877,895&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,171,532&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1512562005;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,171,532&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;802,988&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_803299973;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;802,988&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other receivables&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;342,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_433950526;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;342,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;228,528&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1071173234;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;228,528&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;184,425&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1532190310;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;184,425&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;17,447,428&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1385299093;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;17,447,428&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,400,060&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1865366965;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,400,060&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;987,413&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1997688841;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;987,413&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Accrued receivables&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Accrued receivables comprise $15,877,895 from the Australian Taxation Office in relation to the R&amp;amp;D tax incentive (30 June 2025: $10,171,532). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-25&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-25&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-24&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Non-&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left;"&gt;Trade payables&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;5,466,476&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1128216398;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;5,466,476&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,347,397&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2105137680;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,347,397&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,434,524&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1898473069;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,434,524&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Amounts due to employees&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;15(b)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_53688547;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1356036664;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_429185471;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1042150587;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1701923183;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2113776139;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;490,335&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_717037877;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;490,335&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Accrued expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;4,836,856&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_662542452;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;4,836,856&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,750,662&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_281621519;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,750,662&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,680,442&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_164102519;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,680,442&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Other payables&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;228,468&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_709330579;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;228,468&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;242,934&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;242,934&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;248,302&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1558140744;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;248,302&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;R&amp;amp;D advance&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_481200468;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1840359587;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1870798933;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_824895394;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_686496107;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1593350607;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,003,190&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_791944053;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_131209473;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_45577752;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1461129851;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,856,793&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1749938227;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,853,603&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(d) Other financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Non- current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non- current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left;"&gt;Diaprost contingent consideration&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;1,979,902&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;6,916,482&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;8,896,384&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,328,087&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;8,841,829&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;10,169,916&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;NanoMab     contingent consideration&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;4,502,764&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,050,443&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,553,207&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,832,833&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,899,858&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,732,691&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;NeoIndicate     contingent consideration&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1016384458;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_701424536;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1870684131;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1843483613;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,870,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,870,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Pivalate contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;378,184&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,646,950&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,025,134&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;225,245&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,933,981&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,159,226&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Pharma15     deferred consideration&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1781282920;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1118738496;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_371904715;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_81216337;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1403551223;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_357496978;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Pharma15 contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1300350713;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1209702173;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1266043904;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1775390985;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,134,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,134,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;TRIMT contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1744049292;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,758,256&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,758,256&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2121313631;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,423,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,423,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;UCLA contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1771943251;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1335826267;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_774976970;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_907008146;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_828652398;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1856773610;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;MD Anderson contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_320870674;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,540,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,540,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;35,172&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,573,034&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,608,206&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Advanced payment liability&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1263862179;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1205568883;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1277019398;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_911934065;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_265816370;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1030844899;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,860,850&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;18,912,929&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,421,337&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;28,676,987&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Payment to be made in the     form of ordinary shares in the company, based on the price of the 7-day volume weighted average price (VWAP) prior to the announcement     of the milestone on the ASX.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The NeoIndicate asset was     handed back to the university during the financial year, resulting in the unwinding of contingent consideration for its milestone     payments.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Pharma15 asset was     fully impaired during the year and as a result the likelihood of milestones being met for the progression of the asset has been also     reduced to nil.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The contingent consideration includes amounts related to the provision of milestone payments. For more information, please refer to note 13.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Advance payment liability relates to the share placement agreement with Lind Global Fund II, LP. The amount represents the fair value of the advance payment liability under the agreement and was repaid in fiscal 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(e) Financial liabilities with significant estimation uncertainty&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;At 30 June 2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Financial Liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;NanoMab contingent consideration&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;5,553,207&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Diaprost contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;8,896,384&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;TRIMT contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,758,256&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pivalate contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,025,134&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;NeoIndicate contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_249834797;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pharma15 contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1186503980;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;MD Anderson contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,540,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Advance payment liability&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1473646678;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total financial liabilities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;At 30 June 2025&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Financial Liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;NanoMab contingent consideration&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;6,732,691&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Diaprost contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,169,916&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;TRIMT contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,423,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pivalate contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,159,226&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;NeoIndicate contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,870,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pharma15 contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,134,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Pharma15 deferred consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_551840259;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;MD Anderson contingent consideration&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,608,206&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Contingent consideration&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The amortized cost of contingent consideration relating to the acquisition of licenses is estimated using a present value technique which discounts the management&#x2019;s estimate of the probability that the milestone will be achieved. For more information refer to note 13 and note 9.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The weighted average effective interest rate used at 30 June 2026 for all assets except for NanoMab was 8.46% (2025: 8.46%). For the NanoMab asset it was 9.21% (2025: 8.46%). The rate for NanoMab was different as an amendment to the agreement was entered into during the year and the effective interest rate was recalculated at the date of amendment. The effective interest rate for each instrument was based on the expected rate of return for the instrument, which has been determined using the pricing model. Contingent consideration is carried on the statement of financial position sheet at amortized cost using the effective interest method. &lt;/p&gt;</ifrs-full:DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="cref_1085778750" id="ixv-16265">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Current assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Cash at bank and on hand&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:Cash
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34236"
      unitRef="uref_138071911">4138074</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34237"
      unitRef="uref_138071911">29116835</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34238"
      unitRef="uref_138071911">18575040</ifrs-full:Cash>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34239"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34240"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34241"
      unitRef="uref_138071911">18575040</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="cref_1085778750" id="ixv-16332">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The above figures reconcile to the amount of cash shown in the consolidated statement of cash flows at the end of the financial year and period, respectively, as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Balances as above&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Balances per statement of cash flows&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;18,575,040&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34242"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34243"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34244"
      unitRef="uref_138071911">18575040</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1305557533"
      decimals="0"
      id="fc_63642200"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1963669158"
      decimals="0"
      id="fc_939301211"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_404292157"
      decimals="0"
      id="fc_2096889429"
      unitRef="uref_138071911">18575040</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="cref_1085778750" id="ixv-16426">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Trade and other receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-26&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-25&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-24&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Non-&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left;"&gt;Trade receivables&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;1,227,040&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_421099220;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;1,227,040&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_759014810;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_2009342397;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_160613664;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1273330257;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&#160;&lt;span style="-sec-ix-hidden:fc_906776;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_512807925;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Accrued receivables (i)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;15,877,895&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_223383173;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;15,877,895&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,171,532&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1512562005;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,171,532&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;802,988&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_803299973;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;802,988&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other receivables&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;342,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_433950526;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;342,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;228,528&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1071173234;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;228,528&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;184,425&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1532190310;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;184,425&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;17,447,428&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1385299093;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;17,447,428&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,400,060&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1865366965;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,400,060&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;987,413&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1997688841;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;987,413&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Accrued receivables&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Accrued receivables comprise $15,877,895 from the Australian Taxation Office in relation to the R&amp;amp;D tax incentive (30 June 2025: $10,171,532). &lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_820677847"
      decimals="0"
      id="ixv-34248"
      unitRef="uref_138071911">1227040</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_820677847"
      decimals="0"
      id="ixv-34249"
      unitRef="uref_138071911">1227040</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1493941943"
      decimals="0"
      id="fc_367163782"
      unitRef="uref_138071911">15877895</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1493941943"
      decimals="0"
      id="fc_1493941943"
      unitRef="uref_138071911">15877895</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_290225396"
      decimals="0"
      id="fc_838689820"
      unitRef="uref_138071911">10171532</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_290225396"
      decimals="0"
      id="fc_290225396"
      unitRef="uref_138071911">10171532</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_71955621"
      decimals="0"
      id="fc_1679625513"
      unitRef="uref_138071911">802988</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_71955621"
      decimals="0"
      id="fc_71955621"
      unitRef="uref_138071911">802988</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1446399978"
      decimals="0"
      id="ixv-34256"
      unitRef="uref_138071911">342493</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1446399978"
      decimals="0"
      id="ixv-34257"
      unitRef="uref_138071911">342493</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1502821912"
      decimals="0"
      id="ixv-34258"
      unitRef="uref_138071911">228528</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1502821912"
      decimals="0"
      id="ixv-34259"
      unitRef="uref_138071911">228528</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1763895519"
      decimals="0"
      id="ixv-34260"
      unitRef="uref_138071911">184425</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1763895519"
      decimals="0"
      id="ixv-34261"
      unitRef="uref_138071911">184425</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34262"
      unitRef="uref_138071911">17447428</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34263"
      unitRef="uref_138071911">17447428</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34264"
      unitRef="uref_138071911">10400060</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34265"
      unitRef="uref_138071911">10400060</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34266"
      unitRef="uref_138071911">987413</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34267"
      unitRef="uref_138071911">987413</ifrs-full:TradeAndOtherReceivables>
    <radx:AccruedReceivablesCurrent
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34268"
      unitRef="uref_138071911">15877895</radx:AccruedReceivablesCurrent>
    <radx:AccruedReceivablesCurrent
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34269"
      unitRef="uref_138071911">10171532</radx:AccruedReceivablesCurrent>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="cref_1085778750" id="ixv-16707">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-25&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-25&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30-Jun-24&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Non-&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left;"&gt;Trade payables&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;5,466,476&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1128216398;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; font-weight: bold; text-align: right;"&gt;5,466,476&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,347,397&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2105137680;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,347,397&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,434,524&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1898473069;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; text-align: right;"&gt;6,434,524&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Amounts due to employees&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;15(b)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_53688547;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1356036664;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_429185471;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1042150587;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1701923183;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2113776139;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;490,335&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_717037877;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;490,335&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Accrued expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;4,836,856&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_662542452;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;4,836,856&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,750,662&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_281621519;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,750,662&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,680,442&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_164102519;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,680,442&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Other payables&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;228,468&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_709330579;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;228,468&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;242,934&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;242,934&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;248,302&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1558140744;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;248,302&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;R&amp;amp;D advance&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_481200468;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1840359587;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1870798933;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_824895394;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_686496107;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1593350607;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,003,190&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_791944053;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_131209473;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_45577752;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1461129851;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,856,793&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1749938227;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,853,603&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_808852886"
      decimals="0"
      id="ixv-34270"
      unitRef="uref_138071911">5466476</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_808852886"
      decimals="0"
      id="ixv-34271"
      unitRef="uref_138071911">5466476</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1595967763"
      decimals="0"
      id="ixv-34272"
      unitRef="uref_138071911">6347397</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_1595967763"
      decimals="0"
      id="ixv-34273"
      unitRef="uref_138071911">6347397</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1865531277"
      decimals="0"
      id="ixv-34274"
      unitRef="uref_138071911">6434524</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_1865531277"
      decimals="0"
      id="ixv-34275"
      unitRef="uref_138071911">6434524</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1986429776"
      decimals="0"
      id="ixv-34276"
      unitRef="uref_138071911">490335</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_1986429776"
      decimals="0"
      id="ixv-34277"
      unitRef="uref_138071911">490335</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_861240918"
      decimals="0"
      id="ixv-34278"
      unitRef="uref_138071911">4836856</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_861240918"
      decimals="0"
      id="ixv-34279"
      unitRef="uref_138071911">4836856</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_41466566"
      decimals="0"
      id="ixv-34280"
      unitRef="uref_138071911">2750662</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_41466566"
      decimals="0"
      id="ixv-34281"
      unitRef="uref_138071911">2750662</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_705890069"
      decimals="0"
      id="ixv-34282"
      unitRef="uref_138071911">1680442</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_705890069"
      decimals="0"
      id="ixv-34283"
      unitRef="uref_138071911">1680442</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_655907015"
      decimals="0"
      id="ixv-34284"
      unitRef="uref_138071911">228468</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_655907015"
      decimals="0"
      id="ixv-34285"
      unitRef="uref_138071911">228468</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_2027155156"
      decimals="0"
      id="ixv-34286"
      unitRef="uref_138071911">242934</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_2027155156"
      decimals="0"
      id="ixv-34287"
      unitRef="uref_138071911">242934</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_858350249"
      decimals="0"
      id="ixv-34288"
      unitRef="uref_138071911">248302</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_858350249"
      decimals="0"
      id="ixv-34289"
      unitRef="uref_138071911">248302</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_387488510"
      decimals="0"
      id="ixv-34290"
      unitRef="uref_138071911">2003190</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34291"
      unitRef="uref_138071911">10531800</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34292"
      unitRef="uref_138071911">10531800</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34293"
      unitRef="uref_138071911">9340993</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34294"
      unitRef="uref_138071911">9340993</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34295"
      unitRef="uref_138071911">10856793</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34296"
      unitRef="uref_138071911">8853603</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="cref_1085778750" id="ixv-17086">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(d) Other financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Non- current&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non- current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left;"&gt;Diaprost contingent consideration&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;1,979,902&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;6,916,482&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;8,896,384&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,328,087&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;8,841,829&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;10,169,916&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;NanoMab     contingent consideration&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;4,502,764&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,050,443&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,553,207&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,832,833&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,899,858&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,732,691&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;NeoIndicate     contingent consideration&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1016384458;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_701424536;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1870684131;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1843483613;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,870,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,870,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Pivalate contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;378,184&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,646,950&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,025,134&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;225,245&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,933,981&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,159,226&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Pharma15     deferred consideration&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1781282920;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1118738496;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_371904715;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_81216337;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1403551223;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_357496978;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Pharma15 contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1300350713;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1209702173;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1266043904;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1775390985;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,134,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,134,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;TRIMT contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1744049292;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,758,256&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,758,256&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2121313631;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,423,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,423,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;UCLA contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1771943251;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1335826267;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_774976970;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_907008146;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_828652398;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1856773610;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;MD Anderson contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_320870674;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,540,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,540,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;35,172&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,573,034&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,608,206&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Advanced payment liability&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1263862179;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1205568883;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1277019398;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_911934065;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_265816370;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1030844899;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,860,850&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;18,912,929&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,421,337&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;28,676,987&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Payment to be made in the     form of ordinary shares in the company, based on the price of the 7-day volume weighted average price (VWAP) prior to the announcement     of the milestone on the ASX.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The NeoIndicate asset was     handed back to the university during the financial year, resulting in the unwinding of contingent consideration for its milestone     payments.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Pharma15 asset was     fully impaired during the year and as a result the likelihood of milestones being met for the progression of the asset has been also     reduced to nil.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_158447489"
      decimals="0"
      id="ixv-34297"
      unitRef="uref_138071911">1979902</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_158447489"
      decimals="0"
      id="ixv-34298"
      unitRef="uref_138071911">6916482</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_158447489"
      decimals="0"
      id="ixv-34299"
      unitRef="uref_138071911">8896384</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_58409172"
      decimals="0"
      id="ixv-34300"
      unitRef="uref_138071911">1328087</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_58409172"
      decimals="0"
      id="ixv-34301"
      unitRef="uref_138071911">8841829</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_58409172"
      decimals="0"
      id="ixv-34302"
      unitRef="uref_138071911">10169916</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1477221416"
      decimals="0"
      id="fc_1351611906"
      unitRef="uref_138071911">4502764</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1477221416"
      decimals="0"
      id="fc_1458693029"
      unitRef="uref_138071911">1050443</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1477221416"
      decimals="0"
      id="fc_1477221416"
      unitRef="uref_138071911">5553207</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1430126581"
      decimals="0"
      id="fc_569852528"
      unitRef="uref_138071911">1832833</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1430126581"
      decimals="0"
      id="fc_1503119618"
      unitRef="uref_138071911">4899858</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1430126581"
      decimals="0"
      id="fc_1430126581"
      unitRef="uref_138071911">6732691</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1304397351"
      decimals="0"
      id="fc_612133084"
      unitRef="uref_138071911">1870454</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1304397351"
      decimals="0"
      id="fc_1304397351"
      unitRef="uref_138071911">1870454</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1214084812"
      decimals="0"
      id="ixv-34311"
      unitRef="uref_138071911">378184</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1214084812"
      decimals="0"
      id="ixv-34312"
      unitRef="uref_138071911">1646950</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1214084812"
      decimals="0"
      id="ixv-34313"
      unitRef="uref_138071911">2025134</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_476095383"
      decimals="0"
      id="ixv-34314"
      unitRef="uref_138071911">225245</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_476095383"
      decimals="0"
      id="ixv-34315"
      unitRef="uref_138071911">1933981</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_476095383"
      decimals="0"
      id="ixv-34316"
      unitRef="uref_138071911">2159226</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_658631945"
      decimals="0"
      id="ixv-34317"
      unitRef="uref_138071911">1134164</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_658631945"
      decimals="0"
      id="ixv-34318"
      unitRef="uref_138071911">1134164</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1682262865"
      decimals="0"
      id="ixv-34319"
      unitRef="uref_138071911">7758256</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1682262865"
      decimals="0"
      id="ixv-34320"
      unitRef="uref_138071911">7758256</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_968227831"
      decimals="0"
      id="ixv-34321"
      unitRef="uref_138071911">8423667</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_968227831"
      decimals="0"
      id="ixv-34322"
      unitRef="uref_138071911">8423667</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_275006410"
      decimals="0"
      id="ixv-34323"
      unitRef="uref_138071911">1540798</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_275006410"
      decimals="0"
      id="ixv-34324"
      unitRef="uref_138071911">1540798</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1546356962"
      decimals="0"
      id="ixv-34325"
      unitRef="uref_138071911">35172</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1546356962"
      decimals="0"
      id="ixv-34326"
      unitRef="uref_138071911">1573034</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1546356962"
      decimals="0"
      id="ixv-34327"
      unitRef="uref_138071911">1608206</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34328"
      unitRef="uref_138071911">6860850</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34329"
      unitRef="uref_138071911">18912929</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34330"
      unitRef="uref_138071911">25773779</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34331"
      unitRef="uref_138071911">3421337</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34332"
      unitRef="uref_138071911">28676987</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34333"
      unitRef="uref_138071911">32098324</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="cref_1085778750" id="ixv-17504">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(e) Financial liabilities with significant estimation uncertainty&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;At 30 June 2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Financial Liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;NanoMab contingent consideration&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;5,553,207&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Diaprost contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;8,896,384&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;TRIMT contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;7,758,256&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pivalate contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,025,134&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;NeoIndicate contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_249834797;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pharma15 contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1186503980;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;MD Anderson contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,540,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Advance payment liability&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1473646678;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total financial liabilities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;At 30 June 2025&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Financial Liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;NanoMab contingent consideration&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;6,732,691&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Diaprost contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,169,916&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;TRIMT contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,423,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pivalate contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,159,226&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;NeoIndicate contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,870,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Pharma15 contingent consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,134,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Pharma15 deferred consideration&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_551840259;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;MD Anderson contingent consideration&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,608,206&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_36056968"
      decimals="0"
      id="ixv-34337"
      unitRef="uref_138071911">5553207</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_950767289"
      decimals="0"
      id="ixv-34338"
      unitRef="uref_138071911">8896384</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_865489246"
      decimals="0"
      id="ixv-34339"
      unitRef="uref_138071911">7758256</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_422981330"
      decimals="0"
      id="ixv-34340"
      unitRef="uref_138071911">2025134</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_916272453"
      decimals="0"
      id="ixv-34341"
      unitRef="uref_138071911">1540798</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34342"
      unitRef="uref_138071911">25773779</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_298583932"
      decimals="0"
      id="ixv-34343"
      unitRef="uref_138071911">6732691</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1546656074"
      decimals="0"
      id="ixv-34344"
      unitRef="uref_138071911">10169916</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1424935193"
      decimals="0"
      id="ixv-34345"
      unitRef="uref_138071911">8423667</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1173656975"
      decimals="0"
      id="ixv-34346"
      unitRef="uref_138071911">2159226</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_119581305"
      decimals="0"
      id="ixv-34347"
      unitRef="uref_138071911">1870454</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1841843539"
      decimals="0"
      id="ixv-34348"
      unitRef="uref_138071911">1134164</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_2028021515"
      decimals="0"
      id="ixv-34349"
      unitRef="uref_138071911">1608206</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34350"
      unitRef="uref_138071911">32098324</ifrs-full:FinancialLiabilities>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="cref_825383145"
      decimals="4"
      id="ixv-34351"
      unitRef="uref_880450695">0.0846</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="cref_2113010095"
      decimals="4"
      id="ixv-34352"
      unitRef="uref_880450695">0.0846</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="cref_1305557533"
      decimals="4"
      id="ixv-34353"
      unitRef="uref_880450695">0.0921</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="cref_1963669158"
      decimals="4"
      id="ixv-34354"
      unitRef="uref_880450695">0.0846</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory contextRef="cref_1085778750" id="ixv-17683">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;6 Non-financial assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;AVb6&lt;br/&gt; Integrin&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;hu PSA&lt;br/&gt; Anti-body&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;NanoMab&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;MAb&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pharma&#160;15&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pivalate&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Other&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Year ended 30 June 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left;"&gt;Opening net book amount&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;14,179,639&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;9,654,514&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;15,596,071&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;5,445,016&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;246,614&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;222,807&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;46,574,422&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Sale of asset(note 6(a)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_159022555;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_309152123;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_839236382;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1737663665;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_636457739;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1039270005;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_364370527;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1152690229;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Exchange difference&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_397330576;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_466550340;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_716662869;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(56,188&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(178,193&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_778327374;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1220478678;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(234,381&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Amortization charge&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(884,592&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(741,732&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(973,548&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(66,388&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1409111479;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(22,404&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(10,038&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,698,702&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Impairment charge&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_613143594;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_375977597;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1504185799;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1286333568;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1270448742;"&gt;(5,266,823&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1620751096;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(212,769&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_849140346;"&gt;(5,479,592&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Closing net book amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,295,047&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,912,782&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;14,622,523&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1566852509;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;224,210&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_691980689;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;38,161,747&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 30 June 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;17,691,796&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,212,081&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;19,470,972&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,374,030&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,940,599&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;336,055&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;275,415&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;62,300,948&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Exchange difference&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_317402229;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1973028825;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_253121011;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(63,810&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(320,127&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1763976589;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1180279600;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(383                                             937)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Accumulation amortization and impairment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,396,749&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(7,299,299&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,848,449&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(203,035&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,620,472&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(111,845&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(275,415&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(23,755,264&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Net book amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,295,047&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,912,782&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;14,622,523&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_165573114;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;224,210&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1793449233;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;38,161                                             747&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;AVb6&lt;br/&gt; Integrin&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;hu PSA&lt;br/&gt; Anti-body&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;NanoMab&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;MAb&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pharma&#160;15&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pivalate&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Other&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Year ended 30 June 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left;"&gt;Opening net book amount&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;15,064,229&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;10,275,699&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;16,569,620&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;1,283,925&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;5,384,777&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;269,018&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;240,020&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;49,087,288&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Sale of asset (note 6(a))&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1116355496;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1768248702;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1788611969;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_99218366;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1042536497;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1995917233;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_58769135;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1172074595;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Exchange differences&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_764607594;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_130946041;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1110236473;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;15,201&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,239&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1942389973;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1905324558;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;75,440&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Amortization charge&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(884,590&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(621,185&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(973,549&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(69,365&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2135865817;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(22,404&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(17,213&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,588,306&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Impairment charge&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_490540358;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1733803341;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1237979453;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2062139543;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1724490241;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_998402956;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1796167603;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_790647029;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;losing net book amount&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,179,639&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;9,654,514&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;15,596,071&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,445,016&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;246,614&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;222,807&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;46,574,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 30 June 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;17,691,796&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,212,081&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;19,470,972&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,374,030&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,940,599&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;336,055&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;275,415&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;62,300,948&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Accumulated amortization and impairment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,512,157&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,557,567&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,874,901&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(144,269&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,495,583&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(89,441&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(52,608&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(15,726,526&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Net book amount&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,179,639&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;9,654,514&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;15,596,071&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,445,016&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;246,614&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;222,807&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;46,574,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s intellectual property is measured at initial cost, less any accumulated amortization and impairment losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) AVb6 Integrin&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has recognized the Intellectual Property &#x201c;AVb6 Integrin&#x201d; through the acquisition of a license developed at TRIMT GmbH (TRIMT), a world-renowned independent research and treatment centre specializing in cancer, based in Radeberg, Germany.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; It is the board&#x2019;s expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognized as intangible assets relate to the upfront licenses fee paid in respect of the license agreement, value of equity issued to the licensor and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements. The carrying value of the contingent considerations was probability-adjusted based on the directors&#x2019; assumptions, 70% probability of completing the first therapeutic milestone (milestone 3). Other milestones were deemed uncertain as per management&#x2019;s assessment. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; AVb6 Integrin is amortized over a period of 20 years, being management&#x2019;s assessed useful life of the intangible asset. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) hu PSA Anti-body&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has recognized the Intellectual Property &#x201c;hu PSA Anti-body&#x201d; through the acquisition exclusive license developed at Diaprost AB (Diaprost), a world-renowned independent research and treatment centre specializing in prostate cancer, based in Lund, Sweden.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; It is the board&#x2019;s expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognized as intangible assets relate to the upfront licenses fee paid in respect of the license agreement and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements. The carrying value of the contingent considerations was probability-adjusted based on the directors&#x2019; assumptions, 70% probability of completing milestones 1 and 2. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; hu PSA Anti-body is amortized over a period of 15 years, being management&#x2019;s assessed useful life of the intangible asset. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) NanoMab&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The board has recognized the Intellectual Property &#x201c;NanoMab&#x201d; through the acquisition of a license developed at NanoMab Technology Limited, a world-renowned independent biopharmaceutical company focusing on cancer precision therapies through radiopharmaceuticals, based in Hong Kong.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; It is the board&#x2019;s expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognized as intangible assets relate to the upfront licenses fee paid in respect of the license agreement, value of equity issued to the licensor and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements. The carrying value of the contingent consideration on license acquisition was probability-adjusted based on the directors&#x2019; assumptions, 70% probability of completing milestone 1. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; NanoMab is amortized over a period of 20 years, being management&#x2019;s assessed useful life of the intangible asset. &lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iv) MAb&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has recognized the Intellectual Property &#x201c;MAb&#x201d; through Radiopharm Ventures, LLC, a joint venture between Radiopharm Theranostics (USA), Inc and The Board of Regents of the University of Texas System and the MD Anderson Cancer Center.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;It is the board&#x2019;s expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognized as intangible assets relate to MD Anderson&#x2019;s investment in Radiopharm Ventures, LLC. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; MAb is amortized over a period of 20 years, being management&#x2019;s assessed useful life of the intangible asset. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(v) Pharma15&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has recognized the Intellectual Property &#x201c;Pharma15&#x201d; through the acquisition of Pharma15 Corporation. It is the board&#x2019;s expectation that it will generate future economic benefits for the group. The amounts currently recognized are the upfront consideration paid to shareholders, deferred consideration to be paid one year after acquisition and contingent consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group identified impairment indicators at 30 June 2026 and Company assessed that due to the no funding committed to the program for the foreseeable future and the Pharma15 asset was to be fully impaired at 30 June 2026.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(vi) Pivalate&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has recognized the Intellectual Property &#x201c;Pivalate&#x201d; through the acquisition of a license developed at Cancer Research Technologies Limited (CRT), a world-renowned independent research and treatment centre for cancer, based in London, United Kingdom.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;It is the board&#x2019;s expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognized as intangible assets relate to the upfront licenses fee paid in respect of the license agreement and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Pivalate is amortized over a period of 15 years, being management&#x2019;s assessed useful life of the intangible asset. &lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(vii) Other intellectual property&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Other intellectual property includes the following IP acquired by the group.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;NeoIndicate&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has recognized the Intellectual Property &#x201c;NeoIndicate&#x201d; through the acquisition of a sublicence developed at NeoIndicate LLC, a private research university based in Ohio.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In January 2026, the Company returned the asset back to the university and as a result the asset was derecognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(viii) Impairment test for intellectual property&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Radiopharm holds specific intangible assets which are not yet available for use, or which while available for use, have not yet obtained regulatory and licensing approval for commercialization and marketing of the products. As the assets are not capable of generating independent cash inflows, they are required to be allocated to a cash-generating unit, being the smallest identifiable group of assets which generates cash inflows that are largely independent of the cash inflows from others in the group. However, as the business does not generate cash inflows, and there is no &#x2018;cost&#x2019; for the cash-generating unit, assets are tested for impairment at the asset level, to ensure that individual assets are not impaired below their fair value less costs of disposal. Consequently, management consider it appropriate to consider the fair value less cost of disposal of each asset individually when assessing whether impairment is measured. As a result, the recoverable value of each individual asset is to be determined.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group identified impairment indicators at 30 June 2026 and Company assessed that due to the no funding committed to the program for the foreseeable future and the Pharma15 asset was to be fully impaired at 30 June 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;See note 20(j) for the other accounting policies relevant to intangible assets and note 20(d) for the group&#x2019;s policy regarding impairments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Employee benefit obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;30 June 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Current&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Non- &lt;br/&gt;     current&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;br/&gt; current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non- &lt;br/&gt;     current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left; padding-bottom: 1.5pt;"&gt;Leave obligations (i)&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;697,907&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1701782481;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;697,907&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;450,104&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 5%; padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_2112481639;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;450,104&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;399,788&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_358279390;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;399,788&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; &lt;i&gt;(i) Leave obligations&lt;/i&gt; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The leave obligations cover the group&#x2019;s liabilities for annual leave which are classified as either other long-term benefits or short-term benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The current portion of this liability includes all of the accrued annual leave and pro-rata payments employees are entitled to in certain circumstances. The entire amount of the provision of $697,907 (2025: $450,104) is presented as current, since the group does not have an unconditional right to defer settlement for any of these obligations. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; However, based on past experience, the group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months. &lt;/p&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="cref_1085778750" id="ixv-17687">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;AVb6&lt;br/&gt; Integrin&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;hu PSA&lt;br/&gt; Anti-body&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;NanoMab&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;MAb&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pharma&#160;15&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pivalate&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Other&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Year ended 30 June 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left;"&gt;Opening net book amount&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;14,179,639&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;9,654,514&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;15,596,071&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;5,445,016&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;246,614&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;222,807&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;46,574,422&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Sale of asset(note 6(a)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_159022555;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_309152123;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_839236382;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1737663665;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_636457739;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1039270005;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_364370527;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1152690229;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Exchange difference&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_397330576;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_466550340;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_716662869;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(56,188&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(178,193&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_778327374;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1220478678;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(234,381&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Amortization charge&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(884,592&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(741,732&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(973,548&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(66,388&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1409111479;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(22,404&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(10,038&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,698,702&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Impairment charge&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_613143594;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_375977597;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1504185799;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1286333568;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1270448742;"&gt;(5,266,823&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1620751096;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(212,769&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_849140346;"&gt;(5,479,592&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Closing net book amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,295,047&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,912,782&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;14,622,523&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1566852509;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;224,210&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_691980689;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;38,161,747&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 30 June 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;17,691,796&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,212,081&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;19,470,972&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,374,030&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,940,599&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;336,055&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;275,415&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;62,300,948&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Exchange difference&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_317402229;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1973028825;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_253121011;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(63,810&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(320,127&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1763976589;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1180279600;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(383                                             937)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Accumulation amortization and impairment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,396,749&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(7,299,299&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,848,449&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(203,035&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,620,472&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(111,845&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(275,415&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(23,755,264&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Net book amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;13,295,047&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,912,782&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;14,622,523&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_165573114;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;224,210&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1793449233;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;38,161                                             747&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;AVb6&lt;br/&gt; Integrin&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;hu PSA&lt;br/&gt; Anti-body&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;NanoMab&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;MAb&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pharma&#160;15&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Pivalate&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Other&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Year ended 30 June 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left;"&gt;Opening net book amount&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;15,064,229&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;10,275,699&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;16,569,620&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;1,283,925&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;5,384,777&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;269,018&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;240,020&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; text-align: right;"&gt;49,087,288&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Sale of asset (note 6(a))&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1116355496;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1768248702;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1788611969;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_99218366;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1042536497;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1995917233;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_58769135;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1172074595;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Exchange differences&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_764607594;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_130946041;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1110236473;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;15,201&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,239&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1942389973;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1905324558;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;75,440&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Amortization charge&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(884,590&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(621,185&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(973,549&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(69,365&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2135865817;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(22,404&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(17,213&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,588,306&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Impairment charge&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_490540358;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1733803341;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1237979453;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2062139543;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1724490241;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_998402956;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1796167603;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_790647029;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;losing net book amount&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,179,639&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;9,654,514&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;15,596,071&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,445,016&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;246,614&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;222,807&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;46,574,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 30 June 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;17,691,796&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,212,081&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;19,470,972&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,374,030&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,940,599&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;336,055&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;275,415&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;62,300,948&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Accumulated amortization and impairment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,512,157&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,557,567&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,874,901&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(144,269&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,495,583&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(89,441&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(52,608&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(15,726,526&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Net book amount&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,179,639&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;9,654,514&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;15,596,071&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,445,016&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;246,614&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;222,807&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;46,574,422&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_489116657"
      decimals="0"
      id="ixv-34355"
      unitRef="uref_138071911">14179639</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1617380781"
      decimals="0"
      id="ixv-34356"
      unitRef="uref_138071911">9654514</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_2010781659"
      decimals="0"
      id="ixv-34357"
      unitRef="uref_138071911">15596071</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1886757926"
      decimals="0"
      id="ixv-34358"
      unitRef="uref_138071911">1229761</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_538344337"
      decimals="0"
      id="ixv-34359"
      unitRef="uref_138071911">5445016</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_481931119"
      decimals="0"
      id="ixv-34360"
      unitRef="uref_138071911">246614</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_584156497"
      decimals="0"
      id="ixv-34361"
      unitRef="uref_138071911">222807</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34362"
      unitRef="uref_138071911">46574422</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1008801451"
      decimals="0"
      id="ixv-34363"
      unitRef="uref_138071911">-56188</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415298535"
      decimals="0"
      id="ixv-34364"
      unitRef="uref_138071911">-178193</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34365"
      unitRef="uref_138071911">-234381</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_2011328152"
      decimals="0"
      id="ixv-34366"
      unitRef="uref_138071911">-884592</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1424152838"
      decimals="0"
      id="ixv-34367"
      unitRef="uref_138071911">-741732</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415814143"
      decimals="0"
      id="ixv-34368"
      unitRef="uref_138071911">-973548</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1008801451"
      decimals="0"
      id="ixv-34369"
      unitRef="uref_138071911">-66388</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1480035372"
      decimals="0"
      id="ixv-34370"
      unitRef="uref_138071911">-22404</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1494054659"
      decimals="0"
      id="ixv-34371"
      unitRef="uref_138071911">-10038</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34372"
      unitRef="uref_138071911">-2698702</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1494054659"
      decimals="0"
      id="ixv-34373"
      unitRef="uref_138071911">-212769</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_515724922"
      decimals="0"
      id="ixv-34374"
      unitRef="uref_138071911">13295047</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1238301015"
      decimals="0"
      id="ixv-34375"
      unitRef="uref_138071911">8912782</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1111408546"
      decimals="0"
      id="ixv-34376"
      unitRef="uref_138071911">14622523</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_654635920"
      decimals="0"
      id="ixv-34377"
      unitRef="uref_138071911">1107185</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1665330828"
      decimals="0"
      id="ixv-34378"
      unitRef="uref_138071911">224210</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34379"
      unitRef="uref_138071911">38161747</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_2011328152"
      decimals="0"
      id="ixv-34380"
      unitRef="uref_138071911">17691796</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1424152838"
      decimals="0"
      id="ixv-34381"
      unitRef="uref_138071911">16212081</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_415814143"
      decimals="0"
      id="ixv-34382"
      unitRef="uref_138071911">19470972</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1008801451"
      decimals="0"
      id="ixv-34383"
      unitRef="uref_138071911">1374030</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_415298535"
      decimals="0"
      id="ixv-34384"
      unitRef="uref_138071911">6940599</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1480035372"
      decimals="0"
      id="ixv-34385"
      unitRef="uref_138071911">336055</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1494054659"
      decimals="0"
      id="ixv-34386"
      unitRef="uref_138071911">275415</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34387"
      unitRef="uref_138071911">62300948</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_1008801451"
      decimals="0"
      id="ixv-34388"
      unitRef="uref_138071911">-63810</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_415298535"
      decimals="0"
      id="ixv-34389"
      unitRef="uref_138071911">-320127</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34390"
      unitRef="uref_138071911">-383937</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentProperty>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_2011328152"
      decimals="0"
      id="ixv-34391"
      unitRef="uref_138071911">4396749</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1424152838"
      decimals="0"
      id="ixv-34392"
      unitRef="uref_138071911">7299299</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415814143"
      decimals="0"
      id="ixv-34393"
      unitRef="uref_138071911">4848449</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1008801451"
      decimals="0"
      id="ixv-34394"
      unitRef="uref_138071911">203035</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_415298535"
      decimals="0"
      id="ixv-34395"
      unitRef="uref_138071911">6620472</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1480035372"
      decimals="0"
      id="ixv-34396"
      unitRef="uref_138071911">111845</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1494054659"
      decimals="0"
      id="ixv-34397"
      unitRef="uref_138071911">275415</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34398"
      unitRef="uref_138071911">23755264</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_515724922"
      decimals="0"
      id="ixv-34399"
      unitRef="uref_138071911">13295047</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1238301015"
      decimals="0"
      id="ixv-34400"
      unitRef="uref_138071911">8912782</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1111408546"
      decimals="0"
      id="ixv-34401"
      unitRef="uref_138071911">14622523</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_654635920"
      decimals="0"
      id="ixv-34402"
      unitRef="uref_138071911">1107185</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1665330828"
      decimals="0"
      id="ixv-34403"
      unitRef="uref_138071911">224210</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34404"
      unitRef="uref_138071911">38161747</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_7718076"
      decimals="0"
      id="ixv-34405"
      unitRef="uref_138071911">15064229</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1328464632"
      decimals="0"
      id="ixv-34406"
      unitRef="uref_138071911">10275699</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_625013276"
      decimals="0"
      id="ixv-34407"
      unitRef="uref_138071911">16569620</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_2111569484"
      decimals="0"
      id="ixv-34408"
      unitRef="uref_138071911">1283925</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_675422079"
      decimals="0"
      id="ixv-34409"
      unitRef="uref_138071911">5384777</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_236469634"
      decimals="0"
      id="ixv-34410"
      unitRef="uref_138071911">269018</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_2147404629"
      decimals="0"
      id="ixv-34411"
      unitRef="uref_138071911">240020</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34412"
      unitRef="uref_138071911">49087288</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1778718866"
      decimals="0"
      id="ixv-34413"
      unitRef="uref_138071911">15201</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1124718144"
      decimals="0"
      id="ixv-34414"
      unitRef="uref_138071911">60239</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34415"
      unitRef="uref_138071911">75440</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1835989352"
      decimals="0"
      id="ixv-34416"
      unitRef="uref_138071911">-884590</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1118946646"
      decimals="0"
      id="ixv-34417"
      unitRef="uref_138071911">-621185</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_260407272"
      decimals="0"
      id="ixv-34418"
      unitRef="uref_138071911">-973549</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1778718866"
      decimals="0"
      id="ixv-34419"
      unitRef="uref_138071911">-69365</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_824292737"
      decimals="0"
      id="ixv-34420"
      unitRef="uref_138071911">-22404</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_61988382"
      decimals="0"
      id="ixv-34421"
      unitRef="uref_138071911">-17213</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34422"
      unitRef="uref_138071911">-2588306</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_489116657"
      decimals="0"
      id="ixv-34423"
      unitRef="uref_138071911">14179639</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1617380781"
      decimals="0"
      id="ixv-34424"
      unitRef="uref_138071911">9654514</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_2010781659"
      decimals="0"
      id="ixv-34425"
      unitRef="uref_138071911">15596071</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1886757926"
      decimals="0"
      id="ixv-34426"
      unitRef="uref_138071911">1229761</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_538344337"
      decimals="0"
      id="ixv-34427"
      unitRef="uref_138071911">5445016</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_481931119"
      decimals="0"
      id="ixv-34428"
      unitRef="uref_138071911">246614</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_584156497"
      decimals="0"
      id="ixv-34429"
      unitRef="uref_138071911">222807</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34430"
      unitRef="uref_138071911">46574422</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1835989352"
      decimals="0"
      id="ixv-34431"
      unitRef="uref_138071911">17691796</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1118946646"
      decimals="0"
      id="ixv-34432"
      unitRef="uref_138071911">16212081</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_260407272"
      decimals="0"
      id="ixv-34433"
      unitRef="uref_138071911">19470972</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1778718866"
      decimals="0"
      id="ixv-34434"
      unitRef="uref_138071911">1374030</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_1124718144"
      decimals="0"
      id="ixv-34435"
      unitRef="uref_138071911">6940599</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_824292737"
      decimals="0"
      id="ixv-34436"
      unitRef="uref_138071911">336055</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_61988382"
      decimals="0"
      id="ixv-34437"
      unitRef="uref_138071911">275415</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:ChangesInInvestmentProperty
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34438"
      unitRef="uref_138071911">62300948</ifrs-full:ChangesInInvestmentProperty>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1835989352"
      decimals="0"
      id="ixv-34439"
      unitRef="uref_138071911">3512157</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1118946646"
      decimals="0"
      id="ixv-34440"
      unitRef="uref_138071911">6557567</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_260407272"
      decimals="0"
      id="ixv-34441"
      unitRef="uref_138071911">3874901</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1778718866"
      decimals="0"
      id="ixv-34442"
      unitRef="uref_138071911">144269</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_1124718144"
      decimals="0"
      id="ixv-34443"
      unitRef="uref_138071911">1495583</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_824292737"
      decimals="0"
      id="ixv-34444"
      unitRef="uref_138071911">89441</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_61988382"
      decimals="0"
      id="ixv-34445"
      unitRef="uref_138071911">52608</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34446"
      unitRef="uref_138071911">15726526</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_489116657"
      decimals="0"
      id="ixv-34447"
      unitRef="uref_138071911">14179639</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1617380781"
      decimals="0"
      id="ixv-34448"
      unitRef="uref_138071911">9654514</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_2010781659"
      decimals="0"
      id="ixv-34449"
      unitRef="uref_138071911">15596071</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1886757926"
      decimals="0"
      id="ixv-34450"
      unitRef="uref_138071911">1229761</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_538344337"
      decimals="0"
      id="ixv-34451"
      unitRef="uref_138071911">5445016</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_481931119"
      decimals="0"
      id="ixv-34452"
      unitRef="uref_138071911">246614</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_584156497"
      decimals="0"
      id="ixv-34453"
      unitRef="uref_138071911">222807</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34454"
      unitRef="uref_138071911">46574422</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <radx:PercentageOnProbabilityOnDirectorsAssumption
      contextRef="cref_1698932143"
      decimals="2"
      id="ixv-34455"
      unitRef="uref_880450695">0.70</radx:PercentageOnProbabilityOnDirectorsAssumption>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="cref_1698932143" id="ixv-34456">P20Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <radx:PercentageOnProbabilityOnDirectorsAssumption
      contextRef="cref_1497733908"
      decimals="2"
      id="ixv-34457"
      unitRef="uref_880450695">0.70</radx:PercentageOnProbabilityOnDirectorsAssumption>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="cref_1497733908" id="ixv-34458">P15Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <radx:PercentageOnProbabilityOnDirectorsAssumption
      contextRef="cref_1940931547"
      decimals="2"
      id="ixv-34459"
      unitRef="uref_880450695">0.70</radx:PercentageOnProbabilityOnDirectorsAssumption>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="cref_1940931547" id="ixv-34460">P20Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="cref_194685560" id="ixv-34461">P20Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="cref_233224037" id="ixv-34462">P15Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory contextRef="cref_1085778750" id="ixv-18855">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Employee benefit obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;30 June 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Current&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Non- &lt;br/&gt;     current&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non-&lt;br/&gt; current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Non- &lt;br/&gt;     current&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Total&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right; font-weight: bold;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left; padding-bottom: 1.5pt;"&gt;Leave obligations (i)&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;697,907&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1701782481;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;697,907&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;450,104&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 5%; padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_2112481639;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;450,104&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;399,788&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_358279390;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 5%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;399,788&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; &lt;i&gt;(i) Leave obligations&lt;/i&gt; &lt;/p&gt;</ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34463"
      unitRef="uref_138071911">697907</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="cref_1305557533"
      decimals="0"
      id="fc_422900191"
      unitRef="uref_138071911">697907</ifrs-full:ProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34465"
      unitRef="uref_138071911">450104</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="cref_1963669158"
      decimals="0"
      id="fc_1912404370"
      unitRef="uref_138071911">450104</ifrs-full:ProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34467"
      unitRef="uref_138071911">399788</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:ProvisionsForEmployeeBenefits
      contextRef="cref_404292157"
      decimals="0"
      id="fc_2094687344"
      unitRef="uref_138071911">399788</ifrs-full:ProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34470"
      unitRef="uref_138071911">697907</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34471"
      unitRef="uref_138071911">450104</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <radx:FullAmountOfAccruedLeaveOrRequirePayment contextRef="cref_1085778750" id="ixv-34472">P12M</radx:FullAmountOfAccruedLeaveOrRequirePayment>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="cref_1085778750" id="ixv-18996">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;7 Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Share capital&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;br/&gt; 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;br/&gt; 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;br/&gt; 2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;br/&gt; 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30 June&lt;br/&gt; 2024&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Shares&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Ordinary shares&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt;"&gt;Ordinary Shares Fully paid&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;3,544,216,160&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;7(a)(i)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;3,544,216,160,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Movements in ordinary shares:&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Details&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Number of &lt;br/&gt;     shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Total &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-weight: bold;"&gt;Balance at 1 July 2023&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;339,313,037&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;97,230,329&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.070 pursuant to rights issue (2023-12-08)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,197,244&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,113,808&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue at $0.105 of forfeiture shares as per employment contract (2023-12-14)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,128,815&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;223,526&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.0864 in lieu of cash for     services rendered&#160;(2024-01-05)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,200,013&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;103,681&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.07 pursuant to rights issue shortfall (2024-01-31)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,714,145&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,309,990&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.07 pursuant to rights issue shortfall (2024-02-09)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,950,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;136,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.059 pursuant to Lind agreement (2024-02-14)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;20,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_552518932;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.059 as part of Pharma15 acquisition (2024-03-04)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;25,856,470&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,297,022&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.052 pursuant to Lind agreement (2024-03-12)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,769,231&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.045 pursuant to Lind agreement (2024-04-15)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,666,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.035 pursuant to Lind agreement (2024-05-16)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,571,429&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Less: Transaction costs arising     on share issues&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1202945729;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,633,140&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Balance at 1 July 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to issue of     securities(2024-07-01)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;597,130,727&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,885,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to Tranche     2 placement shares&#160;(2024-08-21)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;858,056,603&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;34,322,264&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to Tranche     2 placement shares (2024-08-21)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;14,031,195&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;561,248&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.050 pursuant to Lantheus     investment (2024-08-23)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;149,625,180&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,481,259&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to issue of     placement shares&#160;(2024-09-13)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;93,750,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,750,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.036 pursuant to the achievement     of a milestone (2024-12-13)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;20,594,438&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;741,400&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.036 pursuant to forfeiture     shares (2024-12-16)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,091,615&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;219,840&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.060 pursuant to issue of     placement shares to Lantheus (2025-01-20)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;133,333,333&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.025 pursuant to a milestone     payment (2025-06-12)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,969,360&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;774,234&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Less: Transaction costs arising     on share issues&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_863891120;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,858,697&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Balance at 1 July 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.030 pursuant to rights issue (2025-10-24)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;415,706,190&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,471,186&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.030 pursuant to rights issue (2025-12-05)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,599,991&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;378,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.030 pursuant to rights issue (2025-12-09)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;750,960,477&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,528,814&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Less: Transaction costs arising     on share issues&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_704545704;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,003,122&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;3,544,216,160&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Other reserves&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following table shows a breakdown of the statement of financial position line item &#x2018;other reserves and the movements in these reserves during the year and period, respectively. A description of the nature and purpose of each reserve is provided below the table.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Shares to &lt;br/&gt; be issued&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Share-based&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Equity&lt;br/&gt; settled&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Total &lt;br/&gt; other &lt;br/&gt; reserves&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;Notes&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-weight: bold;"&gt;At 1 July 2023&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1423495365;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;10,778,749&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;330,001&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(747,293&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;10,361,457&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Currency translation differences&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1022874899;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_364662766;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2052949950;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Other comprehensive loss&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1710760730;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_148806476;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_668324935;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Transactions with owners in their capacity     as owners&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of options as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1651375835;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1091844400;"&gt;44,796&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(44,796&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1492167650;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;-&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of shares as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2056043441;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_248034250;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(147,038&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1417902063;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(147,038&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;7(b)(ii)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1225420907;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,327,468&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1114840167;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1943556581;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,327,468&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Shares to be issued&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;24,185,229&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1296959557;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2134010931;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_110951134;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;24,185,229&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;At 30 June 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_293124482;"&gt;24,185,229&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,151,013&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;138,167&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(544,337&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;37,930,072&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 1 July 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1622554041;"&gt;24,185,229&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;14,151,013&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;138,167&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(544,337&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;37,930,072&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Currency translation differences&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_408158136;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_440457710;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1191203498;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;464,034&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;464,034&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Other comprehensive loss&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1493167621;"&gt;24,185,229&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_317576831;"&gt;14,151,013&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1875725866;"&gt;138,167&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(80,303&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;38,394,106&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Transactions with owners in their capacity as owners&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Transfer from Share-based payments to equity settled payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1329914193;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(136,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;136,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1943910193;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_524672000;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of options as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_592403999;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;43,506&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(43,506&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_80560918;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_488678946;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of shares as part of placement&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(23,885,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_566061447;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1878136386;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2036877606;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(23,885,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of shares as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1136781246;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_564845392;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(200,394&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1025368208;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(200,394&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Lapse of forfeiture payment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1461995091;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1953787351;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(30,721&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_852048476;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(30,721&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_311659082;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,157,778&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_366747874;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1389451734;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,157,778&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Cancellation of shares to be issued relating to Lind&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1501844129;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1249891472;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_984566944;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_493656812;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,797,451&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1254219294;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1683270865;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,797,451&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Forfeiture of options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_520545991;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(221,170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1453955620;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_627510160;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(221,170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;At 30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1318046048;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1938830686;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(80,303&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,116,919&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Shares to &lt;br/&gt; be issued&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Share-based&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Equity&lt;br/&gt; settled&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Total &lt;br/&gt; other &lt;br/&gt; reserves&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;Notes&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-weight: bold;"&gt;At 1 July 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1388285171;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_752338878;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(80,303&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;13,116,919&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Currency translation differences&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1309018810;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1158790242;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_557781320;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;621,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;621,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Other comprehensive loss&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1480012686;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_200249083;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;541,137&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,738,359&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Transactions with owners in their capacity     as owners&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;7(b)(ii)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_202973915;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,740,119&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1011654367;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1318442436;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,740,119&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2089543271;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,730,159&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_873295251;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_448116461;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,730,159&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Forfeiture of options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_669088824;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(334,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1489628777;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1012565369;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(334,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;At 30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1258993477;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,873,018&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1541665852;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;541,137&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,414,155&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Nature and purpose of other reserves&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Shares to be issued&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Share coded as shares to be issued were issued on 1 July 2024 as part of the capital raise announced in June 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Share-based payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The share-based payment reserve records items recognized as expenses on valuation of share options issued to key management personnel, other employees and eligible contractors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Foreign currency translations&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Exchange differences arising on translation of foreign controlled entities are recognized in other comprehensive income or loss as described in note 20(c) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Equity settled payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Equity settled payments reserve records items recognized as expenses on valuation of shares to be issued to key management personnel and other employees for forfeiture of long term incentives at previous employers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Movements in options:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Details&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of&lt;br/&gt; options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June     2023&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;151,710,315&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,642,295&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,455,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;763,778&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ESOP unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,795,456&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;742,379&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Expense for share-based payments for options previously     issued&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_946830935;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,866,107&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2024&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;186,960,995&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,014,559&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;968,815,574&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;29,985&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ESOP unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;164,472,155&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,396,110&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Forfeiture of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(4,351,176&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(221,170&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(163,605,052&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,797,451&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Expense for share-based payments     for options previously issued&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1327990813;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;775,189&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2025&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,152,292,496&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;214,480,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,939,747&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of listed options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,179,266,658&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1423482586;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(6,605,604&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,730,159&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Forfeiture of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(37,224,710&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(334,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Expense for share-based payments     for options previously issued&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_800400402;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;800,372&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,502,209,506&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,873,018&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Other equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; width: 64%; text-align: left;"&gt;Contingent issue of equity&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_713553581;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_873149817;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Contingent issue of equity includes amounts related to the value of consideration shares to be issued to the Pharma15 shareholders once certain milestones are met as per their agreement. Due to the impairment of the Pharma15 asset, the contingent consideration was reversed out at 30 June 2026. For more information, please refer to note 13(g).&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="cref_1085778750" id="ixv-19000">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Share capital&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June &lt;br/&gt; 2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;br/&gt; 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;br/&gt; 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;br/&gt; 2026&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;br/&gt; 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30 June&lt;br/&gt; 2024&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Shares&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Ordinary shares&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt;"&gt;Ordinary Shares Fully paid&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;3,544,216,160&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;7(a)(i)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;3,544,216,160,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34473"
      unitRef="uref_1634518116">3544216160</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34474"
      unitRef="uref_1634518116">2364949502</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34475"
      unitRef="uref_1634518116">460367051</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <radx:OrdinarySharesFullyPaid
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34476"
      unitRef="uref_138071911">209933371</radx:OrdinarySharesFullyPaid>
    <radx:OrdinarySharesFullyPaid
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34477"
      unitRef="uref_138071911">176558493</radx:OrdinarySharesFullyPaid>
    <radx:OrdinarySharesFullyPaid
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34478"
      unitRef="uref_138071911">100681716</radx:OrdinarySharesFullyPaid>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34479"
      unitRef="uref_1634518116">3544216160</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34480"
      unitRef="uref_1634518116">2364949502</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34481"
      unitRef="uref_1634518116">460367051</ifrs-full:NumberOfSharesIssued>
    <radx:OrdinarySharesValue
      contextRef="cref_1305557533"
      decimals="0"
      id="fc_1016650430"
      unitRef="uref_138071911">209933371</radx:OrdinarySharesValue>
    <radx:OrdinarySharesValue
      contextRef="cref_1963669158"
      decimals="0"
      id="fc_1340877163"
      unitRef="uref_138071911">176558493</radx:OrdinarySharesValue>
    <radx:OrdinarySharesValue
      contextRef="cref_404292157"
      decimals="0"
      id="fc_1639613574"
      unitRef="uref_138071911">100681716</radx:OrdinarySharesValue>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory contextRef="cref_1085778750" id="ixv-19129">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Movements in ordinary shares:&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Details&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Number of &lt;br/&gt;     shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Total &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; font-weight: bold;"&gt;Balance at 1 July 2023&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;339,313,037&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;97,230,329&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.070 pursuant to rights issue (2023-12-08)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,197,244&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,113,808&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue at $0.105 of forfeiture shares as per employment contract (2023-12-14)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,128,815&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;223,526&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.0864 in lieu of cash for     services rendered&#160;(2024-01-05)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,200,013&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;103,681&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.07 pursuant to rights issue shortfall (2024-01-31)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,714,145&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,309,990&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.07 pursuant to rights issue shortfall (2024-02-09)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,950,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;136,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.059 pursuant to Lind agreement (2024-02-14)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;20,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_552518932;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.059 as part of Pharma15 acquisition (2024-03-04)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;25,856,470&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,297,022&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.052 pursuant to Lind agreement (2024-03-12)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,769,231&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.045 pursuant to Lind agreement (2024-04-15)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,666,667&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.035 pursuant to Lind agreement (2024-05-16)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,571,429&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Less: Transaction costs arising     on share issues&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1202945729;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,633,140&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Balance at 1 July 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;460,367,051&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;100,681,716&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to issue of     securities(2024-07-01)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;597,130,727&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,885,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to Tranche     2 placement shares&#160;(2024-08-21)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;858,056,603&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;34,322,264&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to Tranche     2 placement shares (2024-08-21)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;14,031,195&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;561,248&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.050 pursuant to Lantheus     investment (2024-08-23)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;149,625,180&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,481,259&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.040 pursuant to issue of     placement shares&#160;(2024-09-13)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;93,750,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,750,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.036 pursuant to the achievement     of a milestone (2024-12-13)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;20,594,438&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;741,400&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.036 pursuant to forfeiture     shares (2024-12-16)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,091,615&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;219,840&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.060 pursuant to issue of     placement shares to Lantheus (2025-01-20)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;133,333,333&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ordinary shares at $0.025 pursuant to a milestone     payment (2025-06-12)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,969,360&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;774,234&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Less: Transaction costs arising     on share issues&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_863891120;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,858,697&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;Balance at 1 July 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,364,949,502&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.030 pursuant to rights issue (2025-10-24)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;415,706,190&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,471,186&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.030 pursuant to rights issue (2025-12-05)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,599,991&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;378,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue at $0.030 pursuant to rights issue (2025-12-09)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;750,960,477&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,528,814&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Less: Transaction costs arising     on share issues&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_704545704;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,003,122&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;3,544,216,160&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_442824516"
      decimals="INF"
      id="ixv-34485"
      unitRef="uref_1634518116">339313037</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_442824516"
      decimals="0"
      id="ixv-34486"
      unitRef="uref_138071911">97230329</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="cref_276989555"
      decimals="3"
      id="ixv-34487"
      unitRef="uref_1453202449">0.07</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1354820612"
      decimals="INF"
      id="ixv-34488"
      unitRef="uref_1634518116">30197244</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1354820612"
      decimals="0"
      id="ixv-34489"
      unitRef="uref_138071911">2113808</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_987019731"
      decimals="3"
      id="ixv-34490"
      unitRef="uref_1453202449">0.105</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_2062279520"
      decimals="INF"
      id="ixv-34491"
      unitRef="uref_1634518116">2128815</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_2062279520"
      decimals="0"
      id="ixv-34492"
      unitRef="uref_138071911">223526</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_79226475"
      decimals="4"
      id="ixv-34493"
      unitRef="uref_1453202449">0.0864</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_235866821"
      decimals="INF"
      id="ixv-34494"
      unitRef="uref_1634518116">1200013</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_235866821"
      decimals="0"
      id="ixv-34495"
      unitRef="uref_138071911">103681</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_522101770"
      decimals="2"
      id="ixv-34496"
      unitRef="uref_1453202449">0.07</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1316836734"
      decimals="INF"
      id="ixv-34497"
      unitRef="uref_1634518116">18714145</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1316836734"
      decimals="0"
      id="ixv-34498"
      unitRef="uref_138071911">1309990</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_713120193"
      decimals="2"
      id="ixv-34499"
      unitRef="uref_1453202449">0.07</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1083727377"
      decimals="INF"
      id="ixv-34500"
      unitRef="uref_1634518116">1950000</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1083727377"
      decimals="0"
      id="ixv-34501"
      unitRef="uref_138071911">136500</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1801638694"
      decimals="3"
      id="ixv-34502"
      unitRef="uref_1453202449">0.059</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_987834646"
      decimals="INF"
      id="ixv-34503"
      unitRef="uref_1634518116">20000000</radx:IssueOfOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1115980466"
      decimals="3"
      id="ixv-34504"
      unitRef="uref_1453202449">0.059</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_272871356"
      decimals="INF"
      id="ixv-34505"
      unitRef="uref_1634518116">25856470</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_272871356"
      decimals="0"
      id="ixv-34506"
      unitRef="uref_138071911">1297022</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1446556830"
      decimals="3"
      id="ixv-34507"
      unitRef="uref_1453202449">0.052</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_971503140"
      decimals="INF"
      id="ixv-34508"
      unitRef="uref_1634518116">5769231</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_971503140"
      decimals="0"
      id="ixv-34509"
      unitRef="uref_138071911">300000</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1104773571"
      decimals="3"
      id="ixv-34510"
      unitRef="uref_1453202449">0.045</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_394609396"
      decimals="INF"
      id="ixv-34511"
      unitRef="uref_1634518116">6666667</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_394609396"
      decimals="0"
      id="ixv-34512"
      unitRef="uref_138071911">300000</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1621380337"
      decimals="3"
      id="ixv-34513"
      unitRef="uref_1453202449">0.035</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1742620739"
      decimals="INF"
      id="ixv-34514"
      unitRef="uref_1634518116">8571429</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1742620739"
      decimals="0"
      id="ixv-34515"
      unitRef="uref_138071911">300000</radx:IssueOfOrdinarySharesValue>
    <radx:TransactionCostsArisingOnShareIssuesValue
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34516"
      unitRef="uref_138071911">-2633140</radx:TransactionCostsArisingOnShareIssuesValue>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_404292157"
      decimals="INF"
      id="ixv-34517"
      unitRef="uref_1634518116">460367051</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34518"
      unitRef="uref_138071911">100681716</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_1259894475"
      decimals="INF"
      id="ixv-34519"
      unitRef="uref_1634518116">460367051</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_1259894475"
      decimals="0"
      id="ixv-34520"
      unitRef="uref_138071911">100681716</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="cref_276303662"
      decimals="3"
      id="ixv-34521"
      unitRef="uref_1453202449">0.04</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_2122001255"
      decimals="INF"
      id="ixv-34522"
      unitRef="uref_1634518116">597130727</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_2122001255"
      decimals="0"
      id="ixv-34523"
      unitRef="uref_138071911">23885229</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_692413006"
      decimals="3"
      id="ixv-34524"
      unitRef="uref_1453202449">0.04</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1960491201"
      decimals="INF"
      id="ixv-34525"
      unitRef="uref_1634518116">858056603</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1960491201"
      decimals="0"
      id="ixv-34526"
      unitRef="uref_138071911">34322264</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1529876341"
      decimals="3"
      id="ixv-34527"
      unitRef="uref_1453202449">0.04</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1103562920"
      decimals="INF"
      id="ixv-34528"
      unitRef="uref_1634518116">14031195</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1103562920"
      decimals="0"
      id="ixv-34529"
      unitRef="uref_138071911">561248</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_366909380"
      decimals="3"
      id="ixv-34530"
      unitRef="uref_1453202449">0.05</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_346236073"
      decimals="INF"
      id="ixv-34531"
      unitRef="uref_1634518116">149625180</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_346236073"
      decimals="0"
      id="ixv-34532"
      unitRef="uref_138071911">7481259</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_786742383"
      decimals="3"
      id="ixv-34533"
      unitRef="uref_1453202449">0.04</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1673541035"
      decimals="INF"
      id="ixv-34534"
      unitRef="uref_1634518116">93750000</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1673541035"
      decimals="0"
      id="ixv-34535"
      unitRef="uref_138071911">3750000</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_123290324"
      decimals="3"
      id="ixv-34536"
      unitRef="uref_1453202449">0.036</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1540898789"
      decimals="INF"
      id="ixv-34537"
      unitRef="uref_1634518116">20594438</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1540898789"
      decimals="0"
      id="ixv-34538"
      unitRef="uref_138071911">741400</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_872043276"
      decimals="3"
      id="ixv-34539"
      unitRef="uref_1453202449">0.036</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_962250976"
      decimals="INF"
      id="ixv-34540"
      unitRef="uref_1634518116">7091615</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_962250976"
      decimals="0"
      id="ixv-34541"
      unitRef="uref_138071911">219840</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1113578005"
      decimals="3"
      id="ixv-34542"
      unitRef="uref_1453202449">0.06</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_974563778"
      decimals="INF"
      id="ixv-34543"
      unitRef="uref_1634518116">133333333</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_974563778"
      decimals="0"
      id="ixv-34544"
      unitRef="uref_138071911">8000000</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1135754045"
      decimals="3"
      id="ixv-34545"
      unitRef="uref_1453202449">0.025</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1610866922"
      decimals="INF"
      id="ixv-34546"
      unitRef="uref_1634518116">30969360</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1610866922"
      decimals="0"
      id="ixv-34547"
      unitRef="uref_138071911">774234</radx:IssueOfOrdinarySharesValue>
    <radx:TransactionCostsArisingOnShareIssuesValue
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34548"
      unitRef="uref_138071911">-3858697</radx:TransactionCostsArisingOnShareIssuesValue>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_1963669158"
      decimals="INF"
      id="ixv-34549"
      unitRef="uref_1634518116">2364949502</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34550"
      unitRef="uref_138071911">176558493</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_1963669158"
      decimals="INF"
      id="ixv-34551"
      unitRef="uref_1634518116">2364949502</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34552"
      unitRef="uref_138071911">176558493</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="cref_883977399"
      decimals="3"
      id="ixv-34553"
      unitRef="uref_1453202449">0.03</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1920512828"
      decimals="INF"
      id="ixv-34554"
      unitRef="uref_1634518116">415706190</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_1920512828"
      decimals="0"
      id="ixv-34555"
      unitRef="uref_138071911">12471186</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1457716369"
      decimals="3"
      id="ixv-34556"
      unitRef="uref_1453202449">0.03</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_823319036"
      decimals="INF"
      id="ixv-34557"
      unitRef="uref_1634518116">12599991</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_823319036"
      decimals="0"
      id="ixv-34558"
      unitRef="uref_138071911">378000</radx:IssueOfOrdinarySharesValue>
    <ifrs-full:ParValuePerShare
      contextRef="cref_1307110558"
      decimals="3"
      id="ixv-34559"
      unitRef="uref_1453202449">0.03</ifrs-full:ParValuePerShare>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_308524805"
      decimals="INF"
      id="ixv-34560"
      unitRef="uref_1634518116">750960477</radx:IssueOfOrdinaryShares>
    <radx:IssueOfOrdinarySharesValue
      contextRef="cref_308524805"
      decimals="0"
      id="ixv-34561"
      unitRef="uref_138071911">22528814</radx:IssueOfOrdinarySharesValue>
    <radx:TransactionCostsArisingOnShareIssuesValue
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34562"
      unitRef="uref_138071911">-2003122</radx:TransactionCostsArisingOnShareIssuesValue>
    <ifrs-full:NumberOfSharesIssued
      contextRef="cref_1305557533"
      decimals="INF"
      id="ixv-34563"
      unitRef="uref_1634518116">3544216160</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapitalOrdinaryShares
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34564"
      unitRef="uref_138071911">209933371</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory contextRef="cref_1085778750" id="ixv-34565">A description of the nature and purpose of each reserve is provided below the table.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Shares to &lt;br/&gt; be issued&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Share-based&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Equity&lt;br/&gt; settled&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Total &lt;br/&gt; other &lt;br/&gt; reserves&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;Notes&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-weight: bold;"&gt;At 1 July 2023&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1423495365;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;10,778,749&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;330,001&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(747,293&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;10,361,457&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Currency translation differences&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1022874899;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_364662766;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2052949950;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Other comprehensive loss&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1710760730;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_148806476;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_668324935;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;202,956&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Transactions with owners in their capacity     as owners&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of options as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1651375835;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1091844400;"&gt;44,796&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(44,796&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1492167650;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;-&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of shares as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2056043441;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_248034250;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(147,038&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1417902063;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(147,038&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;7(b)(ii)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1225420907;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,327,468&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1114840167;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1943556581;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,327,468&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Shares to be issued&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;24,185,229&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1296959557;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2134010931;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_110951134;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;24,185,229&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;At 30 June 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_293124482;"&gt;24,185,229&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,151,013&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;138,167&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(544,337&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;37,930,072&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 1 July 2024&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1622554041;"&gt;24,185,229&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;14,151,013&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;138,167&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(544,337&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;37,930,072&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Currency translation differences&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_408158136;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_440457710;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1191203498;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;464,034&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;464,034&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Other comprehensive loss&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1493167621;"&gt;24,185,229&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_317576831;"&gt;14,151,013&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1875725866;"&gt;138,167&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(80,303&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;38,394,106&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Transactions with owners in their capacity as owners&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Transfer from Share-based payments to equity settled payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1329914193;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(136,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;136,454&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1943910193;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_524672000;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of options as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_592403999;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;43,506&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(43,506&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_80560918;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_488678946;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of shares as part of placement&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(23,885,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_566061447;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1878136386;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2036877606;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(23,885,229&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of shares as part of forfeiture payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1136781246;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_564845392;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(200,394&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1025368208;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(200,394&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Lapse of forfeiture payment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1461995091;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1953787351;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(30,721&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_852048476;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(30,721&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_311659082;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,157,778&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_366747874;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1389451734;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,157,778&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Cancellation of shares to be issued relating to Lind&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1501844129;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1249891472;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_984566944;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(300,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_493656812;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,797,451&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1254219294;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1683270865;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,797,451&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Forfeiture of options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_520545991;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(221,170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1453955620;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_627510160;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(221,170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;At 30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1318046048;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1938830686;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(80,303&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,116,919&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Shares to &lt;br/&gt; be issued&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Share-based&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Equity&lt;br/&gt; settled&lt;br/&gt; payments&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;Total &lt;br/&gt; other &lt;br/&gt; reserves&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0.125in; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center;"&gt;Notes&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;$&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-weight: bold;"&gt;At 1 July 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1388285171;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_752338878;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(80,303&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;13,116,919&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Currency translation differences&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1309018810;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1158790242;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_557781320;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;621,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;621,440&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Other comprehensive loss&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1480012686;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_200249083;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;541,137&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,738,359&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left;"&gt;Transactions with owners in their capacity     as owners&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Issue of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;7(b)(ii)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_202973915;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,740,119&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1011654367;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1318442436;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,740,119&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2089543271;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,730,159&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_873295251;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_448116461;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,730,159&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt;"&gt;Forfeiture of options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_669088824;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(334,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1489628777;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1012565369;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(334,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;At 30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1258993477;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,873,018&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1541665852;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;541,137&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,414,155&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;/span&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:OtherReserves
      contextRef="cref_418281911"
      decimals="0"
      id="ixv-34566"
      unitRef="uref_138071911">10778749</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_97917737"
      decimals="0"
      id="ixv-34567"
      unitRef="uref_138071911">330001</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_124540725"
      decimals="0"
      id="ixv-34568"
      unitRef="uref_138071911">-747293</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_2064533522"
      decimals="0"
      id="ixv-34569"
      unitRef="uref_138071911">10361457</ifrs-full:OtherReserves>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_1818709843"
      decimals="0"
      id="ixv-34570"
      unitRef="uref_138071911">202956</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-34571"
      unitRef="uref_138071911">202956</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1818709843"
      decimals="0"
      id="ixv-34572"
      unitRef="uref_138071911">202956</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-34573"
      unitRef="uref_138071911">202956</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_815368052"
      decimals="0"
      id="ixv-34574"
      unitRef="uref_138071911">-44796</radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-34575"
      unitRef="uref_138071911">0</radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_815368052"
      decimals="0"
      id="ixv-34576"
      unitRef="uref_138071911">-147038</radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-34577"
      unitRef="uref_138071911">-147038</radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments>
    <ifrs-full:IssueOfEquity
      contextRef="cref_416724211"
      decimals="0"
      id="ixv-34578"
      unitRef="uref_138071911">3327468</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-34579"
      unitRef="uref_138071911">3327468</ifrs-full:IssueOfEquity>
    <radx:SharesToBeIssued
      contextRef="cref_362669200"
      decimals="0"
      id="ixv-34580"
      unitRef="uref_138071911">24185229</radx:SharesToBeIssued>
    <radx:SharesToBeIssued
      contextRef="cref_239281928"
      decimals="0"
      id="ixv-34581"
      unitRef="uref_138071911">24185229</radx:SharesToBeIssued>
    <ifrs-full:OtherReserves
      contextRef="cref_301496185"
      decimals="0"
      id="ixv-34582"
      unitRef="uref_138071911">14151013</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_531204171"
      decimals="0"
      id="ixv-34583"
      unitRef="uref_138071911">138167</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_723492209"
      decimals="0"
      id="ixv-34584"
      unitRef="uref_138071911">-544337</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_2011796631"
      decimals="0"
      id="ixv-34585"
      unitRef="uref_138071911">37930072</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_301496185"
      decimals="0"
      id="ixv-34586"
      unitRef="uref_138071911">14151013</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_531204171"
      decimals="0"
      id="ixv-34587"
      unitRef="uref_138071911">138167</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_723492209"
      decimals="0"
      id="ixv-34588"
      unitRef="uref_138071911">-544337</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_2011796631"
      decimals="0"
      id="ixv-34589"
      unitRef="uref_138071911">37930072</ifrs-full:OtherReserves>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_495300227"
      decimals="0"
      id="ixv-34590"
      unitRef="uref_138071911">464034</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34591"
      unitRef="uref_138071911">464034</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_495300227"
      decimals="0"
      id="ixv-34592"
      unitRef="uref_138071911">-80303</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34593"
      unitRef="uref_138071911">38394106</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <radx:TransferFromSharebasedPaymentsToEquitySettledPayments
      contextRef="cref_565546587"
      decimals="0"
      id="ixv-34594"
      unitRef="uref_138071911">-136454</radx:TransferFromSharebasedPaymentsToEquitySettledPayments>
    <radx:TransferFromSharebasedPaymentsToEquitySettledPayments
      contextRef="cref_1670218366"
      decimals="0"
      id="ixv-34595"
      unitRef="uref_138071911">136454</radx:TransferFromSharebasedPaymentsToEquitySettledPayments>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_565546587"
      decimals="0"
      id="ixv-34596"
      unitRef="uref_138071911">43506</radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments
      contextRef="cref_1670218366"
      decimals="0"
      id="ixv-34597"
      unitRef="uref_138071911">-43506</radx:IncreaseDecreaseThroughIssueOfOptionsAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement
      contextRef="cref_1052646885"
      decimals="0"
      id="ixv-34598"
      unitRef="uref_138071911">-23885229</radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34599"
      unitRef="uref_138071911">-23885229</radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfPlacement>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_1670218366"
      decimals="0"
      id="ixv-34600"
      unitRef="uref_138071911">-200394</radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34601"
      unitRef="uref_138071911">-200394</radx:IncreaseDecreaseThroughIssueOfSharesAsPartOfForfeiturePayments>
    <radx:IncreaseDecreaseThroughLapseOfForfeiturePayment
      contextRef="cref_1670218366"
      decimals="0"
      id="ixv-34602"
      unitRef="uref_138071911">-30721</radx:IncreaseDecreaseThroughLapseOfForfeiturePayment>
    <radx:IncreaseDecreaseThroughLapseOfForfeiturePayment
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34603"
      unitRef="uref_138071911">-30721</radx:IncreaseDecreaseThroughLapseOfForfeiturePayment>
    <ifrs-full:IssueOfEquity
      contextRef="cref_565546587"
      decimals="0"
      id="ixv-34604"
      unitRef="uref_138071911">2157778</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34605"
      unitRef="uref_138071911">2157778</ifrs-full:IssueOfEquity>
    <ifrs-full:CancellationOfTreasuryShares
      contextRef="cref_1052646885"
      decimals="0"
      id="ixv-34606"
      unitRef="uref_138071911">-300000</ifrs-full:CancellationOfTreasuryShares>
    <ifrs-full:CancellationOfTreasuryShares
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34607"
      unitRef="uref_138071911">-300000</ifrs-full:CancellationOfTreasuryShares>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_565546587"
      decimals="0"
      id="ixv-34608"
      unitRef="uref_138071911">-2797451</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34609"
      unitRef="uref_138071911">-2797451</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_565546587"
      decimals="0"
      id="ixv-34610"
      unitRef="uref_138071911">221170</radx:IncreaseDecreaseThroughForfeitureOfOptions>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_1712076956"
      decimals="0"
      id="ixv-34611"
      unitRef="uref_138071911">221170</radx:IncreaseDecreaseThroughForfeitureOfOptions>
    <ifrs-full:OtherReserves
      contextRef="cref_1972543109"
      decimals="0"
      id="ixv-34612"
      unitRef="uref_138071911">13197222</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_1342992216"
      decimals="0"
      id="ixv-34613"
      unitRef="uref_138071911">-80303</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_1984381866"
      decimals="0"
      id="ixv-34614"
      unitRef="uref_138071911">13116919</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_1972543109"
      decimals="0"
      id="ixv-34615"
      unitRef="uref_138071911">13197222</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_1342992216"
      decimals="0"
      id="ixv-34616"
      unitRef="uref_138071911">-80303</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_1984381866"
      decimals="0"
      id="ixv-34617"
      unitRef="uref_138071911">13116919</ifrs-full:OtherReserves>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_958314475"
      decimals="0"
      id="ixv-34618"
      unitRef="uref_138071911">621440</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-34619"
      unitRef="uref_138071911">621440</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_855609256"
      decimals="0"
      id="ixv-34620"
      unitRef="uref_138071911">13197222</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_958314475"
      decimals="0"
      id="ixv-34621"
      unitRef="uref_138071911">541137</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-34622"
      unitRef="uref_138071911">13738359</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:IssueOfEquity
      contextRef="cref_855609256"
      decimals="0"
      id="ixv-34623"
      unitRef="uref_138071911">2740119</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-34624"
      unitRef="uref_138071911">2740119</ifrs-full:IssueOfEquity>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_855609256"
      decimals="0"
      id="ixv-34625"
      unitRef="uref_138071911">-1730159</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:IncreaseDecreaseThroughExpirationOfOptions
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-34626"
      unitRef="uref_138071911">-1730159</radx:IncreaseDecreaseThroughExpirationOfOptions>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_855609256"
      decimals="0"
      id="ixv-34627"
      unitRef="uref_138071911">334164</radx:IncreaseDecreaseThroughForfeitureOfOptions>
    <radx:IncreaseDecreaseThroughForfeitureOfOptions
      contextRef="cref_1659325166"
      decimals="0"
      id="ixv-34628"
      unitRef="uref_138071911">334164</radx:IncreaseDecreaseThroughForfeitureOfOptions>
    <ifrs-full:OtherReserves
      contextRef="cref_402616417"
      decimals="0"
      id="ixv-34629"
      unitRef="uref_138071911">13873018</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_208910529"
      decimals="0"
      id="ixv-34630"
      unitRef="uref_138071911">541137</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="cref_777909411"
      decimals="0"
      id="ixv-34631"
      unitRef="uref_138071911">14414155</ifrs-full:OtherReserves>
    <radx:DisclosureOfMovementsInOptionsExplanatory contextRef="cref_1085778750" id="ixv-20605">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Movements in options:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Details&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of&lt;br/&gt; options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;br/&gt; &#160;&#160;&#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June     2023&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;151,710,315&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,642,295&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,455,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;763,778&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ESOP unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,795,456&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;742,379&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Expense for share-based payments for options previously     issued&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_946830935;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,866,107&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2024&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;186,960,995&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;14,014,559&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;968,815,574&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;29,985&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of ESOP unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;164,472,155&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,396,110&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Forfeiture of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(4,351,176&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(221,170&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(163,605,052&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,797,451&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Expense for share-based payments     for options previously issued&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1327990813;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;775,189&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2025&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,152,292,496&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of unlisted options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;214,480,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,939,747&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Issue of listed options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,179,266,658&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1423482586;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Expiration of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(6,605,604&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(1,730,159&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Forfeiture of options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(37,224,710&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(334,164&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Expense for share-based payments     for options previously issued&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_800400402;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;800,372&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Balance at 30 June 2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,502,209,506&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;13,873,018&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfMovementsInOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_435790906"
      decimals="0"
      id="ixv-34632"
      unitRef="uref_880450695">151710315</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:NumberOfOutstandingShareOptionsValue
      contextRef="cref_435790906"
      decimals="0"
      id="ixv-34633"
      unitRef="uref_138071911">10642295</radx:NumberOfOutstandingShareOptionsValue>
    <radx:NumberOfShareOptionsIssueOfUnlistedOptionsShares
      contextRef="cref_1121416750"
      decimals="0"
      id="ixv-34634"
      unitRef="uref_880450695">16455224</radx:NumberOfShareOptionsIssueOfUnlistedOptionsShares>
    <radx:NumberOfIssueOfUnlistedOptionsValue
      contextRef="cref_1121416750"
      decimals="0"
      id="ixv-34635"
      unitRef="uref_138071911">763778</radx:NumberOfIssueOfUnlistedOptionsValue>
    <radx:NumberOfShareOptionsIssueOfESOPUnlistedOptionsShares
      contextRef="cref_1121416750"
      decimals="0"
      id="ixv-34636"
      unitRef="uref_880450695">18795456</radx:NumberOfShareOptionsIssueOfESOPUnlistedOptionsShares>
    <radx:NumberOfIssueOfESOPUnlistedOptionsValue
      contextRef="cref_1121416750"
      decimals="0"
      id="ixv-34637"
      unitRef="uref_138071911">742379</radx:NumberOfIssueOfESOPUnlistedOptionsValue>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="cref_1121416750"
      decimals="0"
      id="ixv-34638"
      unitRef="uref_138071911">1866107</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_996975840"
      decimals="0"
      id="ixv-34639"
      unitRef="uref_880450695">186960995</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:NumberOfOutstandingShareOptionsValue
      contextRef="cref_996975840"
      decimals="0"
      id="ixv-34640"
      unitRef="uref_138071911">14014559</radx:NumberOfOutstandingShareOptionsValue>
    <radx:NumberOfShareOptionsIssueOfUnlistedOptionsShares
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34641"
      unitRef="uref_880450695">968815574</radx:NumberOfShareOptionsIssueOfUnlistedOptionsShares>
    <radx:NumberOfIssueOfUnlistedOptionsValue
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34642"
      unitRef="uref_138071911">29985</radx:NumberOfIssueOfUnlistedOptionsValue>
    <radx:NumberOfShareOptionsIssueOfESOPUnlistedOptionsShares
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34643"
      unitRef="uref_880450695">164472155</radx:NumberOfShareOptionsIssueOfESOPUnlistedOptionsShares>
    <radx:NumberOfIssueOfESOPUnlistedOptionsValue
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34644"
      unitRef="uref_138071911">1396110</radx:NumberOfIssueOfESOPUnlistedOptionsValue>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34645"
      unitRef="uref_880450695">4351176</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <radx:NumberOfForfeitureOfOptionsValue
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34646"
      unitRef="uref_138071911">221170</radx:NumberOfForfeitureOfOptionsValue>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34647"
      unitRef="uref_880450695">163605052</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <radx:NumberOfExpirationOfOptionsValue
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34648"
      unitRef="uref_138071911">2797451</radx:NumberOfExpirationOfOptionsValue>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="cref_1623135981"
      decimals="0"
      id="ixv-34649"
      unitRef="uref_138071911">775189</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_327595348"
      decimals="0"
      id="ixv-34650"
      unitRef="uref_880450695">1152292496</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:NumberOfOutstandingShareOptionsValue
      contextRef="cref_327595348"
      decimals="0"
      id="ixv-34651"
      unitRef="uref_138071911">13197222</radx:NumberOfOutstandingShareOptionsValue>
    <radx:NumberOfShareOptionsIssueOfESOPUnlistedOptionsShares
      contextRef="cref_1672975465"
      decimals="0"
      id="ixv-34652"
      unitRef="uref_880450695">214480666</radx:NumberOfShareOptionsIssueOfESOPUnlistedOptionsShares>
    <radx:NumberOfIssueOfESOPUnlistedOptionsValue
      contextRef="cref_1672975465"
      decimals="0"
      id="ixv-34653"
      unitRef="uref_138071911">1939747</radx:NumberOfIssueOfESOPUnlistedOptionsValue>
    <radx:NumberOfShareOptionsIssueOflistedOptionsShares
      contextRef="cref_1672975465"
      decimals="INF"
      id="ixv-34654"
      unitRef="uref_1634518116">1179266658</radx:NumberOfShareOptionsIssueOflistedOptionsShares>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="cref_1672975465"
      decimals="0"
      id="ixv-34655"
      unitRef="uref_880450695">6605604</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <radx:NumberOfExpirationOfOptionsValue
      contextRef="cref_1672975465"
      decimals="0"
      id="ixv-34656"
      unitRef="uref_138071911">1730159</radx:NumberOfExpirationOfOptionsValue>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="cref_1672975465"
      decimals="INF"
      id="ixv-34657"
      unitRef="uref_880450695">37224710</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <radx:NumberOfForfeitureOfOptionsValue
      contextRef="cref_1672975465"
      decimals="0"
      id="ixv-34658"
      unitRef="uref_138071911">334164</radx:NumberOfForfeitureOfOptionsValue>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="cref_1672975465"
      decimals="0"
      id="ixv-34659"
      unitRef="uref_138071911">800372</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1794279675"
      decimals="0"
      id="ixv-34660"
      unitRef="uref_880450695">2502209506</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:NumberOfOutstandingShareOptionsValue
      contextRef="cref_1794279675"
      decimals="0"
      id="ixv-34661"
      unitRef="uref_138071911">13873018</radx:NumberOfOutstandingShareOptionsValue>
    <radx:DisclosureOfOtherEquityExplanatory contextRef="cref_1085778750" id="ixv-20824">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Other equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;30 June&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;30 June&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2024&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; width: 64%; text-align: left;"&gt;Contingent issue of equity&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right;"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_713553581;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_873149817;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfOtherEquityExplanatory>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_1445455089"
      decimals="0"
      id="ixv-34662"
      unitRef="uref_138071911">849544</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_1897982295"
      decimals="0"
      id="ixv-34663"
      unitRef="uref_138071911">849544</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_1963669158"
      decimals="0"
      id="fc_1297905700"
      unitRef="uref_138071911">849544</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_404292157"
      decimals="0"
      id="ixv-34665"
      unitRef="uref_138071911">849544</ifrs-full:OtherEquityInterest>
    <radx:DisclosureOfCashFlowInformationExplanatory contextRef="cref_1085778750" id="ixv-20888">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;8 Cash flow information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Reconciliation of profit after income tax to net cash inflow from operating activities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026&lt;br/&gt; &#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025&lt;br/&gt; &#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024&lt;br/&gt; &#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; font-weight: bold; text-align: left;"&gt;Loss for the year&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(56,950,494&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(38,342,457&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(47,949,119&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Adjustments for&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Depreciation and amortization&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,706,033&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,595,637&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,126,286&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(1,671,289&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,069,680&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,860,358&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Finance costs&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;112,396&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(285&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;109,207&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Finance income&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(637,144&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(888,196&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2112524206;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Leave provision&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;270,995&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;46,640&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;111,196&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,405,955&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,895,348&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,640,178&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Disposal of intellectual property&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;212,769&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1409032073;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,687,791&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Impairment&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,266,823&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1464503210;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,478,892&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Net foreign currency (gains)/losses&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;655,393&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(138,141&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(94,964&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Change in operating assets and liabilities:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Movement in trade receivables&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(7,047,369&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(9,412,647&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,480,495&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Movement in other current assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(3,101&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,948,714&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;73,871&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Movement in trade payables&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,896,195&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;514,645&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,499,874&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Net cash outflow from operating activities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(52,782,838&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(36,645,477&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(22,975,935&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Non-cash investing and financing activities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Non-cash investing and financing activities disclosed in other notes are:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;options                                             issued for no cash consideration - note 16.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfCashFlowInformationExplanatory>
    <ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory contextRef="cref_1085778750" id="ixv-20893">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Reconciliation of profit after income tax to net cash inflow from operating activities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2026&lt;br/&gt; &#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2025&lt;br/&gt; &#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June &lt;br/&gt; 2024&lt;br/&gt; &#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; font-weight: bold; text-align: left;"&gt;Loss for the year&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;(56,950,494&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(38,342,457&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;(47,949,119&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Adjustments for&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Depreciation and amortization&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,706,033&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,595,637&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,126,286&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Contingent consideration&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(1,671,289&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,069,680&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,860,358&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Finance costs&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;112,396&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(285&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;109,207&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Finance income&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(637,144&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(888,196&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2112524206;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Leave provision&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;270,995&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;46,640&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;111,196&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,405,955&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,895,348&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,640,178&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Disposal of intellectual property&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;212,769&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1409032073;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,687,791&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Impairment&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;5,266,823&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1464503210;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,478,892&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Net foreign currency (gains)/losses&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;655,393&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(138,141&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(94,964&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Change in operating assets and liabilities:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Movement in trade receivables&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(7,047,369&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(9,412,647&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,480,495&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Movement in other current assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;(3,101&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,948,714&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;73,871&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Movement in trade payables&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,896,195&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;514,645&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,499,874&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Net cash outflow from operating activities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(52,782,838&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(36,645,477&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(22,975,935&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34666"
      unitRef="uref_138071911">-56950494</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34667"
      unitRef="uref_138071911">-38342457</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34668"
      unitRef="uref_138071911">-47949119</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34669"
      unitRef="uref_138071911">2706033</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34670"
      unitRef="uref_138071911">2595637</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34671"
      unitRef="uref_138071911">3126286</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34672"
      unitRef="uref_138071911">-1671289</ifrs-full:AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34673"
      unitRef="uref_138071911">4069680</ifrs-full:AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34674"
      unitRef="uref_138071911">8860358</ifrs-full:AdjustmentsForDecreaseIncreaseInFinancialAssetsHeldForTrading>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34675"
      unitRef="uref_138071911">112396</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34676"
      unitRef="uref_138071911">-285</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34677"
      unitRef="uref_138071911">109207</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34678"
      unitRef="uref_138071911">-637144</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34679"
      unitRef="uref_138071911">-888196</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34680"
      unitRef="uref_138071911">270995</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34681"
      unitRef="uref_138071911">46640</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34682"
      unitRef="uref_138071911">111196</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34683"
      unitRef="uref_138071911">2405955</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34684"
      unitRef="uref_138071911">1895348</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34685"
      unitRef="uref_138071911">2640178</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34686"
      unitRef="uref_138071911">212769</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34687"
      unitRef="uref_138071911">1687791</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34688"
      unitRef="uref_138071911">5266823</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34689"
      unitRef="uref_138071911">1478892</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34690"
      unitRef="uref_138071911">655393</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34691"
      unitRef="uref_138071911">-138141</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34692"
      unitRef="uref_138071911">-94964</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34693"
      unitRef="uref_138071911">-7047369</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34694"
      unitRef="uref_138071911">-9412647</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34695"
      unitRef="uref_138071911">3480495</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34696"
      unitRef="uref_138071911">-3101</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34697"
      unitRef="uref_138071911">2948714</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34698"
      unitRef="uref_138071911">73871</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34699"
      unitRef="uref_138071911">1896195</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34700"
      unitRef="uref_138071911">514645</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34701"
      unitRef="uref_138071911">3499874</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34702"
      unitRef="uref_138071911">-52782838</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34703"
      unitRef="uref_138071911">-36645477</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34704"
      unitRef="uref_138071911">-22975935</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="cref_1085778750" id="ixv-21174">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;9 Material estimates and judgements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the group&#x2019;s accounting policies.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be wrong due to changes in estimates and judgements. Detailed information about each of these estimates and judgements is included in other notes together with information about the basis of calculation for each affected line item in the financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The areas involving judgement or estimation are detailed below.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Judgements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Impairment&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group&#x2019;s intangible assets are assessed for impairment at each reporting period.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Management has considered the following potential indicators:&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The                                             market capitalization of Radiopharm Theranostics Limited on the Australian Securities Exchange                                             on the impairment testing date of 30 June 2026 in excess of the net book value of assets;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The                                             scientific results and progress of the trials;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Comparisons                                             with companies in a similar field of development and similar stage; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Changes                                             in growth of the biotech sector.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Management has identified an indicator of impairment in the year ended 30 June 2026 and has completed further testing as detailed in note 6(b)(viii). As at 30 June 2026 an indicator of impairment were identified and the Pharma15 asset was impaired. In addition, the NeoIndicate asset was handed back to the university during the year and the carrying amount of the asset was also fully impaired.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.9pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Joint venture&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; As set out in note 12(b), Radiopharm established a joint venture in the year ended 30 June 2023, Radiopharm Ventures LLC, with MD Anderson. Radiopharm has increased ownership of the joint venture from 75% at 30 June 2025 to 87.5% at 30 June 2026. Under the agreement, based on the structure and substance of the agreement, management have assessed there to be &#x2018;control&#x2019; by Radiopharm in the joint venture, based on the governance structure of the joint venture, the split of voting rights, and the assessment of the rights (substantive or protective) held by Radiopharm and MD Anderson. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;On the basis that management have assessed there to be control, the joint venture has been consolidated in these financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Based on the structure and substance of the Joint Venture, management has assessed Radiopharm to have control at the year ended 30 June 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) R&amp;amp;D tax incentive income accrual&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s research and development (R&amp;amp;D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Judgement is applied to each transaction the group incurs each financial year, by determining a percentage of each transaction that relates to R&amp;amp;D.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;R&amp;amp;D income is determined using eligibility criteria and percentages of eligibility estimated by management. These estimated eligibility percentages determine the base for which the R&amp;amp;D tax rebate is calculation and therefore is subject to a degree of uncertainty.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.9pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Useful life of intangible assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Management have assessed that &#x201c;ready for use&#x201d; for the group is not the commercialization of an intangible asset but rather the goal to develop intangible assets to a point that a trade sale of a license is more likely. They have concluded that all intangible assets, excluding Pharma 15, are &#x201c;ready for use&#x201d; and have applied judgement over the period which each asset is expected to be available for use by the entity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The life of the asset is indeterminate at this stage of development. The maximum life in which the group has control of the intangible asset can be determined by the length of legal protection of the intellectual property (IP) covered by the patent life over the IP. The life of an asset is determined by reference to that IP protection, subject to reassessment each year, taking into consideration changing expectations about possible timing of trade sale of a license.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The useful life is determined using the expiry date of the last patent to expire. These dates determine the life of the IP and therefore is subject to a degree of uncertainty.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.85pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Share-based payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;This model requires the following inputs which involve judgements to be made:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Volatility                                             rate is calculated by analyzing the movement of the closing share price each day for the                                             term of the option preceding grant date; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Risk-free rate is obtained by referencing     the Capital Market Yields for Government Bonds supplied by the RBA.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The rate is selected by determining what     the rate is at the date the options are granted to the holder.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Additionally, there are different rates supplied     by the RBA each day dependent on the terms of the bond (2, 3, 5, 10 years). The term of the option will determine which rate is used     (i.e. a 5-year term will use the 5-year bond rate). If an options term is between two terms, for example 4 years, the rate that is     used is that of the lower term i.e. the 3-year bond rate.&lt;/p&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;These inputs determine the value of each share-based payment and therefore it is subject to a degree of uncertainty.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.85pt; text-indent: 0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iv) Contingent consideration&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The amortized cost of the group&#x2019;s contingent consideration relating to the acquisition of licenses is estimated using a present value technique which discounts the management&#x2019;s estimate of the probability that the milestone will be achieved and when it is expected to be achieved. Management&#x2019;s assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;At the end of the reporting year, the group has applied judgement to multiple milestones detailed in note 13. Refer to Note 5(e) where the interest rate has been disclosed.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The probability of achieving each milestone is a significant input in determining the amortized cost of the consideration and therefore is subject to uncertainty.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The amortized cost of contingent consideration is sensitive to changes in the probability of clinical trial success and the timeframe for completion of those clinical trials. These sensitivities are interdependent. A 1% change in the probability of clinical trial success or a 1-year reduction in the timeframe for completion of clinical trials would have a material impact on the carrying value of contingent consideration. &lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(v) Lantheus strategic development services contract&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the year ended 30 June 2025, the group entered into a strategic development services contract with Lantheus to advance clinical development of innovative radiopharmaceuticals in Australia. Under the contract, Radiopharm will lead the clinical development efforts in Australia while Lantheus covers all the clinical development costs associated with the program.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Radiopharm will also receive up to US$2 million as one-off milestone payments upon achieving key clinical development objectives. Each payment will be made after each milestone is completed. At 30 June 2026 no milestones had been met. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Under the Lantheus contract, the Group has promised to deliver and manage the clinical development program. This has been assessed as a single performance obligation as it is a significant service of integrating the interrelated clinical trial activities into one combined output.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The Group incurs internal and external costs, which are recouped over time, once certain criteria are met. These costs and recoupments are forecast at reporting date, over the expected development period of 3 years, to determine the expected percentage of completion at different stages of the overall contract. Management apply judgement in the use of assumptions in the forecast, including the probability of the costs being determined with reasonable accuracy, their timing, and their eligibility to be recouped, to develop a pattern of expected percentage completion at each stage of the project. In doing so, management make judgments on the likelihood of overall project success, including meeting strict&#160;criteria for progress payments and&#160;for milestone payments. Future revenue is only included in the model to the extent it is highly probable. The probability assigned to each milestone determines the value of the consideration and therefore is subject to a degree of uncertainty, and at this time those amounts are considered not sufficiently probable to recognize. The discount rate used at 30 June 2026 was 10.27%. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The Company is acting as a principal in the arrangement as it has control of the services provided before they are transferred to the Customer and is the primary contracting party for any third-party contractors appointed. This includes contracting third parties under the scope of the work orders and utilizing their employee&#x2019;s skillset&#x2019;s to complete the project. There are no fixed fees payable under the arrangement. Accordingly, the Company will recognize revenue from the arrangement on a gross basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has determined that certain variable consideration is constrained and has not been considered in the transaction price for revenue recognition. This was assessed based on management&#x2019;s estimate of the probability of the milestone&#x2019;s achievement. Management&#x2019;s assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters. These amounts will be reassessed in future periods.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Revenue is recognized over time based on the Group&#x2019;s measure of progress towards completion of the performance obligation. A cost input method has been used as there is no clear output that can easily be tracked, however the Group is able to forecast the expenditure required to complete the project and track the completion on a monthly basis based on invoices and the time put into the over the expected development period of 3 years. The transaction price includes an upfront payment which has been assessed to meet the definition of a significant financing component. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; At 30 June 2026, the Group recognized A$2,767,888 as revenue, A$2,504,499 as cost of sales and A$806,410 as deferred revenue. Please refer to note 20 for additional details on the accounting policy. &lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="cref_711082873"
      decimals="2"
      id="ixv-34705"
      unitRef="uref_880450695">0.75</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="cref_686324981"
      decimals="3"
      id="ixv-34706"
      unitRef="uref_880450695">0.875</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="cref_1085778750" id="ixv-34707">Additionally, there are different rates supplied     by the RBA each day dependent on the terms of the bond (2, 3, 5, 10 years). The term of the option will determine which rate is used     (i.e. a 5-year term will use the 5-year bond rate). If an options term is between two terms, for example 4 years, the rate that is     used is that of the lower term i.e. the 3-year bond rate.</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <radx:PercentageOfProbabilityOnClinicalTrialSuccess
      contextRef="cref_1085778750"
      decimals="2"
      id="ixv-34708"
      unitRef="uref_880450695">0.01</radx:PercentageOfProbabilityOnClinicalTrialSuccess>
    <radx:ReductionInTimeframeForCompletionOfClinicalTrials contextRef="cref_1085778750" id="ixv-34709">P1Y</radx:ReductionInTimeframeForCompletionOfClinicalTrials>
    <radx:MileStonePayments
      contextRef="cref_1085778750"
      decimals="-6"
      id="ixv-34710"
      unitRef="uref_138071911">2000000</radx:MileStonePayments>
    <radx:ServicesAndDevelopmentPeriod contextRef="cref_1085778750" id="ixv-34711">P3Y</radx:ServicesAndDevelopmentPeriod>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="cref_1305557533"
      decimals="4"
      id="ixv-34712"
      unitRef="uref_880450695">0.1027</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <radx:ServicesAndDevelopmentPeriod contextRef="cref_1085778750" id="ixv-34713">P3Y</radx:ServicesAndDevelopmentPeriod>
    <ifrs-full:Revenue
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34714"
      unitRef="uref_1001896052">2767888</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34715"
      unitRef="uref_1001896052">2504499</ifrs-full:CostOfSales>
    <ifrs-full:Prepayments
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34716"
      unitRef="uref_1001896052">806410</ifrs-full:Prepayments>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="cref_1085778750" id="ixv-21414">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;10 Financial risk management&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;This note explains the group&#x2019;s exposure to financial risks and how these risks could affect the group&#x2019;s future financial performance.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s risk management is predominantly controlled by the board. The board monitors the group&#x2019;s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Market risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Foreign exchange risk&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign exchange rate risk arises from financial assets and financial liabilities denominated in a currency that is not the group&#x2019;s functional currency. Exposure to foreign currency risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency of the group. This risk is measured using sensitivity analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Exposure&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to foreign currency risk at the end of the reporting year and period, respectively, expressed in Australian dollar, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;USD &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;EUR &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;GBP &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;USD &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;EUR &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;GBP &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;89,600&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1418573340;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1231849584;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,994,099&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_262315310;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1721108780;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Trade receivables&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,211,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_681948505;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_997356148;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1489093636;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_321791850;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1653512947;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Trade payables&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,300,500&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;277,820&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;35,315&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;5,482,682&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;57,897&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;231,930&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total exposure&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,601,898&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;277,820&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;35,315&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,476,781&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;57,897&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;231,930&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Sensitivity&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;As shown in the table above, the group is primarily exposed to changes in (United States dollar) USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD denominated financial instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has conducted a sensitivity analysis of its exposure to foreign currency risk. The group is currently materially exposed to the USD. The sensitivity analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to is listed below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;USD:                                             &lt;span style="font-weight: bold;"&gt;3.6%&lt;/span&gt; (2025: 4.6%)&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;EUR:                                             &lt;span style="font-weight: bold;"&gt;6.2%&lt;/span&gt; (2025: 5.3%)&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;GBP:                                             &lt;span style="font-weight: bold;"&gt;6.0%&lt;/span&gt; (2025: 4.8%)&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on post-tax loss&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on other &lt;br/&gt; components of     equity&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;USD/AUD exchange     rate - change by &lt;span style="font-weight: bold;"&gt;3.6%&lt;/span&gt; (2025: 4.6%)*&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;201,668&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;389,932&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;111,193&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;234,216&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;EUR/AUD exchange rate - change     by &lt;span style="font-weight: bold;"&gt;6.2%&lt;/span&gt; (2025: 5.3%)*&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;17,225&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,073&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;17,225&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,385&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;GBP/AUD exchange rate - change     by &lt;span style="font-weight: bold;"&gt;6.0%&lt;/span&gt; (2025: 4.8%)*&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,119&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;11,133&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,119&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,232&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Holding all other variables     constant&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Profit is more sensitive to movements in the AUD/USD exchange rates in 2026 than 2025 because of the decreased amount of USD denominated cash and cash equivalents. The group&#x2019;s exposure to other foreign exchange movements is not material.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.9pt; text-align: justify; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Cash flow and fair value interest rate risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s main interest rate risk arises from cash and cash equivalents held, which expose the group to cash flow interest rate risk. During 2026 and 2025, the group&#x2019;s cash and cash equivalents at variable rates were denominated in Australian dollars.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to interest rate risk at the end of the reporting year and period, respectively, expressed in Australian dollars, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Financial instruments with cash flow risk&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Sensitivity&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to interest rate risk at the end of the reporting year and period, respectively, expressed in Australian dollars, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on post-tax loss&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on other &lt;br/&gt; components of     equity&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Interest     rates - change by &lt;span style="font-weight: bold;"&gt;743&lt;/span&gt; basis points (2025: 609 basis points)*&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;307,459&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,772,766&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;1,070,972&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;869,322&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Holding all other variables     constant&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The use of 7.43 percent (2025: 6.09 percent) was determined based on analysis of the Reserve Bank of Australia cash rate change, on an absolute value basis, at 30 June 2026 and the previous four balance dates. The average cash rate at these balance dates was 3.37 percent (2025: 2.62 percent). The average change to the cash rate between balance dates was 220.74 percent (2025: 232.74 percent). By multiplying these two values, the interest rate risk was derived. &lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;There has been an increase in the group&#x2019;s exposure to credit risk in 2026 due to decreased in cash and cash equivalents. The group&#x2019;s exposure to other classes of financial assets with credit risk is not material.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-align: justify; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Risk management&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Risk is minimized through investing cash and cash equivalents in financial institutions that maintain a high credit rating.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.9pt; text-indent: -0.25in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Impairment of financial assets&lt;/i&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Cash and cash equivalents are also subject to the impairment requirements of IFRS 9, and there was no identifiable impairment loss effecting cash and cash equivalents during the year. For more information refer to note 6(b)(viii).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Liquidity risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Liquidity risk arises from the possibility that the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The group manages this risk through the following mechanisms:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;preparing                                             forward looking cash flow analyses in relation to its operating, investing and financing                                             activities;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;obtaining                                             funding from a variety of sources;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;maintaining                                             a reputable credit profile;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;managing                                             credit risk related to financial assets;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;investing                                             cash and cash equivalents and deposits at call with major financial institutions; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;comparing                                             the maturity profile of financial liabilities with the realization profile of financial assets.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Maturities of financial liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The tables below analyze the group&#x2019;s financial liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual undiscounted cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Contractual maturities of financial liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Less than&lt;br/&gt;     6 months&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;6 - 12&lt;br/&gt;     months&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Between 1&lt;br/&gt;     and &lt;br/&gt;     2 years&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Between 2 &lt;br/&gt;     and &lt;br/&gt;     5 years&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Over &lt;br/&gt;     5 years&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total &lt;br/&gt;     contractual &lt;br/&gt;     cash flows&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Carrying &lt;br/&gt;     amount &lt;br/&gt;     liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;At 30 June 2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 30%; text-align: left;"&gt;Trade payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1138158821;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_455076162;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1306199751;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_928863346;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other financial liabilities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;101,937&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,758,913&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,871,952&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;8,896,778&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,144,199&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total non-derivatives&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,633,737&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,758,913&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,871,952&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;8,896,778&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,144,199&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;36,305,579&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;36,305,579&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 30 June 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Trade payables&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1581198739;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1980560945;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2122673013;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1367216253;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,363,259&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,058,078&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,039,178&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;11,585,395&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,052,414&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,704,252&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,058,078&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,039,178&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;11,585,395&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,052,414&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;41,439,317&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;41,439,317&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;There is a portion of other financial liabilities that is payable in shares. Refer to note 5(d) for further information.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="cref_1085778750" id="ixv-21438">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to foreign currency risk at the end of the reporting year and period, respectively, expressed in Australian dollar, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;30 June 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;USD &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;EUR &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;GBP &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;USD &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;EUR &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;GBP &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;89,600&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1418573340;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1231849584;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,994,099&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_262315310;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1721108780;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Trade receivables&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,211,798&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_681948505;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_997356148;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1489093636;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_321791850;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1653512947;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Trade payables&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,300,500&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;277,820&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;35,315&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;5,482,682&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;57,897&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;231,930&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total exposure&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,601,898&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;277,820&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;35,315&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,476,781&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;57,897&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;231,930&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34717"
      unitRef="uref_138071911">89600</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34718"
      unitRef="uref_138071911">2994099</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeReceivables
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34719"
      unitRef="uref_138071911">1211798</ifrs-full:TradeReceivables>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34720"
      unitRef="uref_138071911">4300500</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34721"
      unitRef="uref_1954685255">277820</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34722"
      unitRef="uref_1346866186">35315</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34723"
      unitRef="uref_138071911">5482682</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34724"
      unitRef="uref_1954685255">57897</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34725"
      unitRef="uref_1346866186">231930</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34726"
      unitRef="uref_138071911">5601898</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34727"
      unitRef="uref_1954685255">277820</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="cref_1502965910"
      decimals="0"
      id="ixv-34728"
      unitRef="uref_1346866186">35315</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34729"
      unitRef="uref_138071911">8476781</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34730"
      unitRef="uref_1954685255">57897</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk
      contextRef="cref_259034637"
      decimals="0"
      id="ixv-34731"
      unitRef="uref_1346866186">231930</ifrs-full:MaximumExposureToCreditRisk>
    <radx:ExposedForeignExchangeRiskPercentage
      contextRef="cref_218923996"
      decimals="3"
      id="ixv-34732"
      unitRef="uref_880450695">0.036</radx:ExposedForeignExchangeRiskPercentage>
    <radx:ExposedForeignExchangeRiskPercentage
      contextRef="cref_1885936551"
      decimals="3"
      id="ixv-34733"
      unitRef="uref_880450695">0.046</radx:ExposedForeignExchangeRiskPercentage>
    <radx:ExposedForeignExchangeRiskPercentage
      contextRef="cref_1769175827"
      decimals="3"
      id="ixv-34734"
      unitRef="uref_880450695">0.062</radx:ExposedForeignExchangeRiskPercentage>
    <radx:ExposedForeignExchangeRiskPercentage
      contextRef="cref_2044802928"
      decimals="3"
      id="ixv-34735"
      unitRef="uref_880450695">0.053</radx:ExposedForeignExchangeRiskPercentage>
    <radx:ExposedForeignExchangeRiskPercentage
      contextRef="cref_11673677"
      decimals="3"
      id="ixv-34736"
      unitRef="uref_880450695">0.06</radx:ExposedForeignExchangeRiskPercentage>
    <radx:ExposedForeignExchangeRiskPercentage
      contextRef="cref_1455051567"
      decimals="3"
      id="ixv-34737"
      unitRef="uref_880450695">0.048</radx:ExposedForeignExchangeRiskPercentage>
    <radx:ScheduleOfImpactOfForeignCurrencyRiskTableTextBlock contextRef="cref_1085778750" id="ixv-21652">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on post-tax loss&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on other &lt;br/&gt; components of     equity&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;USD/AUD exchange     rate - change by &lt;span style="font-weight: bold;"&gt;3.6%&lt;/span&gt; (2025: 4.6%)*&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;201,668&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;389,932&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;111,193&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;234,216&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;EUR/AUD exchange rate - change     by &lt;span style="font-weight: bold;"&gt;6.2%&lt;/span&gt; (2025: 5.3%)*&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;17,225&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,073&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;17,225&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,385&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;GBP/AUD exchange rate - change     by &lt;span style="font-weight: bold;"&gt;6.0%&lt;/span&gt; (2025: 4.8%)*&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,119&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;11,133&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;2,119&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,232&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Holding all other variables     constant&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</radx:ScheduleOfImpactOfForeignCurrencyRiskTableTextBlock>
    <radx:ExchangeRate
      contextRef="cref_334748240"
      decimals="3"
      id="ixv-34738"
      unitRef="uref_880450695">0.036</radx:ExchangeRate>
    <radx:ExchangeRate
      contextRef="cref_656615078"
      decimals="3"
      id="ixv-34739"
      unitRef="uref_880450695">0.046</radx:ExchangeRate>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_334748240"
      decimals="0"
      id="fc_1069442394"
      unitRef="uref_138071911">201668</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_656615078"
      decimals="0"
      id="fc_1492758934"
      unitRef="uref_138071911">389932</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_334748240"
      decimals="0"
      id="fc_334748240"
      unitRef="uref_138071911">111193</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_656615078"
      decimals="0"
      id="fc_656615078"
      unitRef="uref_138071911">234216</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ExchangeRate
      contextRef="cref_710217859"
      decimals="3"
      id="ixv-34744"
      unitRef="uref_880450695">0.062</radx:ExchangeRate>
    <radx:ExchangeRate
      contextRef="cref_1832352150"
      decimals="3"
      id="ixv-34745"
      unitRef="uref_880450695">0.053</radx:ExchangeRate>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_710217859"
      decimals="0"
      id="fc_2078799935"
      unitRef="uref_138071911">17225</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_1832352150"
      decimals="0"
      id="fc_1533432965"
      unitRef="uref_138071911">3073</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_710217859"
      decimals="0"
      id="fc_710217859"
      unitRef="uref_138071911">17225</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_1832352150"
      decimals="0"
      id="fc_1832352150"
      unitRef="uref_138071911">8385</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ExchangeRate
      contextRef="cref_249693967"
      decimals="3"
      id="ixv-34750"
      unitRef="uref_880450695">0.06</radx:ExchangeRate>
    <radx:ExchangeRate
      contextRef="cref_1912952120"
      decimals="3"
      id="ixv-34751"
      unitRef="uref_880450695">0.048</radx:ExchangeRate>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_249693967"
      decimals="0"
      id="fc_206936431"
      unitRef="uref_138071911">2119</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_1912952120"
      decimals="0"
      id="fc_2010432990"
      unitRef="uref_138071911">11133</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_249693967"
      decimals="0"
      id="fc_249693967"
      unitRef="uref_138071911">2119</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_1912952120"
      decimals="0"
      id="fc_1912952120"
      unitRef="uref_138071911">8232</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ScheduleOfExposureToInterestRateRiskTableTextBlock contextRef="cref_1085778750" id="ixv-21759">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to interest rate risk at the end of the reporting year and period, respectively, expressed in Australian dollars, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Financial instruments with cash flow risk&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,138,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;29,116,835&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:ScheduleOfExposureToInterestRateRiskTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_517081436"
      decimals="0"
      id="ixv-34757"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1848343351"
      decimals="0"
      id="ixv-34758"
      unitRef="uref_138071911">29116835</ifrs-full:CashAndCashEquivalents>
    <radx:FinancialInstrumentsWithCashFlowRisk
      contextRef="cref_517081436"
      decimals="0"
      id="ixv-34759"
      unitRef="uref_138071911">4138074</radx:FinancialInstrumentsWithCashFlowRisk>
    <radx:FinancialInstrumentsWithCashFlowRisk
      contextRef="cref_1848343351"
      decimals="0"
      id="ixv-34760"
      unitRef="uref_138071911">29116835</radx:FinancialInstrumentsWithCashFlowRisk>
    <radx:ScheduleOfImpactOfInterestRateRiskTableTextBlock contextRef="cref_1085778750" id="ixv-21833">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s exposure to interest rate risk at the end of the reporting year and period, respectively, expressed in Australian dollars, was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on post-tax loss&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Impact on other &lt;br/&gt; components of     equity&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Interest     rates - change by &lt;span style="font-weight: bold;"&gt;743&lt;/span&gt; basis points (2025: 609 basis points)*&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;307,459&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,772,766&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;1,070,972&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;869,322&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Holding all other variables     constant&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</radx:ScheduleOfImpactOfInterestRateRiskTableTextBlock>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_517081436"
      decimals="0"
      id="fc_97068733"
      unitRef="uref_138071911">307459</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnPosttaxLoss
      contextRef="cref_1848343351"
      decimals="0"
      id="fc_1659558259"
      unitRef="uref_138071911">1772766</radx:ImpactOnPosttaxLoss>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_517081436"
      decimals="0"
      id="fc_517081436"
      unitRef="uref_138071911">1070972</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ImpactOnOtherComponentsOfEquity
      contextRef="cref_1848343351"
      decimals="0"
      id="fc_1848343351"
      unitRef="uref_138071911">869322</radx:ImpactOnOtherComponentsOfEquity>
    <radx:ExposedInterestRateRisk
      contextRef="cref_1085778750"
      decimals="4"
      id="ixv-34766"
      unitRef="uref_880450695">0.0743</radx:ExposedInterestRateRisk>
    <radx:ExposedInterestRateRisk
      contextRef="cref_198500851"
      decimals="4"
      id="ixv-34767"
      unitRef="uref_880450695">0.0609</radx:ExposedInterestRateRisk>
    <radx:AverageCashInterestRateRiskPercentage
      contextRef="cref_1085778750"
      decimals="4"
      id="ixv-34768"
      unitRef="uref_880450695">0.0337</radx:AverageCashInterestRateRiskPercentage>
    <radx:AverageCashInterestRateRiskPercentage
      contextRef="cref_198500851"
      decimals="4"
      id="ixv-34769"
      unitRef="uref_880450695">0.0262</radx:AverageCashInterestRateRiskPercentage>
    <radx:AverageChangeToCashInterestRateRisk
      contextRef="cref_1085778750"
      decimals="4"
      id="ixv-34770"
      unitRef="uref_880450695">2.2074</radx:AverageChangeToCashInterestRateRisk>
    <radx:AverageChangeToCashInterestRateRisk
      contextRef="cref_198500851"
      decimals="4"
      id="ixv-34771"
      unitRef="uref_880450695">2.3274</radx:AverageChangeToCashInterestRateRisk>
    <radx:ScheduleOfMaturitiesOfFinancialLiabilitiesTableTextBlock contextRef="cref_1085778750" id="ixv-21997">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The tables below analyze the group&#x2019;s financial liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual undiscounted cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Contractual maturities of financial liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Less than&lt;br/&gt;     6 months&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;6 - 12&lt;br/&gt;     months&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Between 1&lt;br/&gt;     and &lt;br/&gt;     2 years&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Between 2 &lt;br/&gt;     and &lt;br/&gt;     5 years&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Over &lt;br/&gt;     5 years&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Total &lt;br/&gt;     contractual &lt;br/&gt;     cash flows&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold;"&gt;Carrying &lt;br/&gt;     amount &lt;br/&gt;     liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;At 30 June 2026&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 30%; text-align: left;"&gt;Trade payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1138158821;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_455076162;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1306199751;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_928863346;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 7%; font-weight: bold; text-align: right;"&gt;10,531,800&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other financial liabilities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;101,937&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,758,913&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,871,952&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;8,896,778&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,144,199&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;25,773,779&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total non-derivatives&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;10,633,737&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;6,758,913&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;4,871,952&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;8,896,778&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,144,199&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;36,305,579&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;36,305,579&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold;"&gt;At 30 June 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Trade payables&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1581198739;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1980560945;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2122673013;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1367216253;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9,340,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Other financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,363,259&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,058,078&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,039,178&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;11,585,395&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,052,414&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,098,324&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;10,704,252&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,058,078&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;8,039,178&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;11,585,395&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,052,414&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;41,439,317&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;41,439,317&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:ScheduleOfMaturitiesOfFinancialLiabilitiesTableTextBlock>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_2130818383"
      decimals="0"
      id="ixv-34772"
      unitRef="uref_138071911">10531800</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34773"
      unitRef="uref_138071911">10531800</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34774"
      unitRef="uref_138071911">10531800</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_2130818383"
      decimals="0"
      id="ixv-34775"
      unitRef="uref_138071911">101937</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1863492555"
      decimals="0"
      id="ixv-34776"
      unitRef="uref_138071911">6758913</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_308497697"
      decimals="0"
      id="ixv-34777"
      unitRef="uref_138071911">4871952</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1590527928"
      decimals="0"
      id="ixv-34778"
      unitRef="uref_138071911">8896778</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1399891170"
      decimals="0"
      id="ixv-34779"
      unitRef="uref_138071911">5144199</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34780"
      unitRef="uref_138071911">25773779</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34781"
      unitRef="uref_138071911">25773779</ifrs-full:OtherFinancialLiabilities>
    <radx:Nonderivatives
      contextRef="cref_2130818383"
      decimals="0"
      id="ixv-34782"
      unitRef="uref_138071911">10633737</radx:Nonderivatives>
    <radx:Nonderivatives
      contextRef="cref_1863492555"
      decimals="0"
      id="ixv-34783"
      unitRef="uref_138071911">6758913</radx:Nonderivatives>
    <radx:Nonderivatives
      contextRef="cref_308497697"
      decimals="0"
      id="ixv-34784"
      unitRef="uref_138071911">4871952</radx:Nonderivatives>
    <radx:Nonderivatives
      contextRef="cref_1590527928"
      decimals="0"
      id="ixv-34785"
      unitRef="uref_138071911">8896778</radx:Nonderivatives>
    <radx:Nonderivatives
      contextRef="cref_1399891170"
      decimals="0"
      id="ixv-34786"
      unitRef="uref_138071911">5144199</radx:Nonderivatives>
    <radx:Nonderivatives
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34787"
      unitRef="uref_138071911">36305579</radx:Nonderivatives>
    <radx:Nonderivatives
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-34788"
      unitRef="uref_138071911">36305579</radx:Nonderivatives>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_2071746334"
      decimals="0"
      id="ixv-34789"
      unitRef="uref_138071911">9340993</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34790"
      unitRef="uref_138071911">9340993</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34791"
      unitRef="uref_138071911">9340993</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_2071746334"
      decimals="0"
      id="ixv-34792"
      unitRef="uref_138071911">1363259</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_199907254"
      decimals="0"
      id="ixv-34793"
      unitRef="uref_138071911">2058078</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1158695048"
      decimals="0"
      id="ixv-34794"
      unitRef="uref_138071911">8039178</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1217755389"
      decimals="0"
      id="ixv-34795"
      unitRef="uref_138071911">11585395</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1665656946"
      decimals="0"
      id="ixv-34796"
      unitRef="uref_138071911">9052414</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34797"
      unitRef="uref_138071911">32098324</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34798"
      unitRef="uref_138071911">32098324</ifrs-full:OtherFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_2071746334"
      decimals="0"
      id="ixv-34799"
      unitRef="uref_138071911">10704252</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_199907254"
      decimals="0"
      id="ixv-34800"
      unitRef="uref_138071911">2058078</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_1158695048"
      decimals="0"
      id="ixv-34801"
      unitRef="uref_138071911">8039178</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_1217755389"
      decimals="0"
      id="ixv-34802"
      unitRef="uref_138071911">11585395</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_1665656946"
      decimals="0"
      id="ixv-34803"
      unitRef="uref_138071911">9052414</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34804"
      unitRef="uref_138071911">41439317</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:ContractualMaturitiesOfFinancialLiabilities
      contextRef="cref_1963669158"
      decimals="0"
      id="ixv-34805"
      unitRef="uref_138071911">41439317</radx:ContractualMaturitiesOfFinancialLiabilities>
    <radx:DisclosureOfCapitalManagementExplanatory contextRef="cref_1085778750" id="ixv-22353">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;11 Capital management&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Risk management&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group&#x2019;s objectives when managing capital are to&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;safeguard                                             its ability to continue as a going concern, so that it can continue to provide returns for                                             shareholders and benefits for other stakeholders, and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;maintain                                             an optimal capital structure to reduce the cost of capital.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In order to maintain or adjust the capital structure, the group may issue new shares or reduce its capital, subject to the provisions of the group&#x2019;s constitution. The capital structure of the group consists of equity attributed to equity holders of the group, comprising contributed equity, reserves and accumulated losses. By monitoring undiscounted cash flow forecasts and actual cash flows provided to the board by the group&#x2019;s management, the board monitors the need to raise additional equity from the equity markets.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; &lt;span style="-sec-ix-hidden:fc_1943161247;"&gt;No&lt;/span&gt; dividends were declared or paid to members for the year ended 30 June 2026 (30 June 2025: &lt;span style="-sec-ix-hidden:fc_611255203;"&gt;nil&lt;/span&gt;). The group&#x2019;s franking account balance was &lt;span style="-sec-ix-hidden:fc_1257405903;"&gt;nil&lt;/span&gt; at 30 June 2026 (30 June 2025: &lt;span style="-sec-ix-hidden:fc_1234535655;"&gt;nil&lt;/span&gt;). &lt;/p&gt;</radx:DisclosureOfCapitalManagementExplanatory>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory contextRef="cref_1085778750" id="ixv-22392">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;12 Interests in other entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s subsidiaries at 30 June 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;Place of&lt;br/&gt; business/&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Ownership interest held by&lt;br/&gt; the     group&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Ownership interest held by&lt;br/&gt; non-controlling     interests&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Name of entity&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;country of&lt;br/&gt; incorporation&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 40%; text-align: left;"&gt;Radiopharm Theranostics (USA) Inc&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;United States&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;100&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;100&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1156914257;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_385587549;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Radiopharm Ventures LLC&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;87.5&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;75&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;12.5&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;25&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Pharma15 Corporation&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;100&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_714264368;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_32722313;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;On 9 July 2022, Radiopharm Theranostics (USA) Inc. and The University of Texas MD Anderson Cancer Center formed Radiopharm Ventures, LLC, a joint venture to develop novel radiopharmaceutical therapeutic products for cancer. The joint venture will focus initially on developing products based on MD Anderson intellectual property.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Radiopharm Ventures, LLC is a limited liability company jointly owned by Radiopharm Theranostics (USA) Inc. (a wholly owned subsidiary of Radiopharm) (87.5%) and MD Anderson (12.5%). Radiopharm increased their ownership in October 2025 by committing an additional US$4m to the venture. The University of Texas MD Anderson Cancer Center has granted a license to Radiopharm Ventures for certain patent and technology rights for development and commercialization effective from 11 September 2022. The license may continue until the later of twenty years from the effective date or the end of the life of the licensed patents. The license may be terminated at any time by mutual written agreement. The agreement between Radiopharm Ventures and MD Anderson includes royalty and milestone payment obligations that arise from the development and/or commercialization of licensed products. The costs will be shared by Radiopharm Theranostics (USA) Inc and MD Anderson, and both parties will share ownership of the resultant intellectual property. At 30 June 2026, Radiopharm held control of the joint venture. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Non-controlling interests&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Set out below is summarized financial information for each subsidiary that has non-controlling interests that are material to the group. The amounts disclosed for each subsidiary are before inter-group eliminations.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Comparatives are not disclosed below as Radiopharm Ventures, LLC was established in the 2023 financial year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Radiopharm Ventures, LLC&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Summarized statement of financial position&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Current assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1894240016;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_252894350;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Current liabilities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1779423083;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_192894733;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Current net assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_585726619;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_250676638;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Non-current assets&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Non-current net assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Net assets&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;261,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,152,892&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Accumulated non-controlling interests&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(2,363,526&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,920,100&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Radiopharm Ventures, LLC&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Summarized statement of comprehensive loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Loss for the year&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(11,227,807&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,110,449&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total comprehensive loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(11,227,807&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,110,449&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Loss allocated to non-controlling interests&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(1,801,344&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,639.368&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="cref_1085778750" id="ixv-22400">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s subsidiaries at 30 June 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;Place of&lt;br/&gt; business/&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Ownership interest held by&lt;br/&gt; the     group&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Ownership interest held by&lt;br/&gt; non-controlling     interests&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Name of entity&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;country of&lt;br/&gt; incorporation&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;2026&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;2025&lt;br/&gt; %&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 40%; text-align: left;"&gt;Radiopharm Theranostics (USA) Inc&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center;"&gt;United States&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;100&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;100&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1156914257;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_385587549;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Radiopharm Ventures LLC&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;87.5&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;75&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;12.5&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;25&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Pharma15 Corporation&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center;"&gt;United States&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;100&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_714264368;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_32722313;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="cref_126621" id="ixv-34806">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_126621"
      decimals="2"
      id="ixv-34807"
      unitRef="uref_880450695">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_346654251"
      decimals="2"
      id="ixv-34808"
      unitRef="uref_880450695">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="cref_2048871378" id="ixv-34809">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_2048871378"
      decimals="3"
      id="ixv-34810"
      unitRef="uref_880450695">0.875</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_587244859"
      decimals="2"
      id="ixv-34811"
      unitRef="uref_880450695">0.75</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <radx:OwnershipInterestHeldByNoncontrollingInterests
      contextRef="cref_2048871378"
      decimals="3"
      id="ixv-34812"
      unitRef="uref_880450695">0.125</radx:OwnershipInterestHeldByNoncontrollingInterests>
    <radx:OwnershipInterestHeldByNoncontrollingInterests
      contextRef="cref_587244859"
      decimals="2"
      id="ixv-34813"
      unitRef="uref_880450695">0.25</radx:OwnershipInterestHeldByNoncontrollingInterests>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="cref_1639151071" id="ixv-34814">United States</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_1639151071"
      decimals="2"
      id="ixv-34815"
      unitRef="uref_880450695">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_766531602"
      decimals="2"
      id="ixv-34816"
      unitRef="uref_880450695">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_1098178729"
      decimals="3"
      id="ixv-34817"
      unitRef="uref_880450695">0.875</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="cref_175546384"
      decimals="3"
      id="ixv-34818"
      unitRef="uref_880450695">0.125</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <radx:ScheduleOfSummarizedBalanceSheetTextBlock contextRef="cref_1085778750" id="ixv-22530">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Comparatives are not disclosed below as Radiopharm Ventures, LLC was established in the 2023 financial year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Radiopharm Ventures, LLC&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Summarized statement of financial position&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Current assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1894240016;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_252894350;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Current liabilities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1779423083;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_192894733;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Current net assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_585726619;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_250676638;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Non-current assets&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;Non-current net assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;1,107,185&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,229,761&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Net assets&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;261,074&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,152,892&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Accumulated non-controlling interests&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(2,363,526&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,920,100&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:ScheduleOfSummarizedBalanceSheetTextBlock>
    <ifrs-full:NoncurrentAssets
      contextRef="cref_1773416733"
      decimals="0"
      id="ixv-34819"
      unitRef="uref_138071911">1107185</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="cref_1569279335"
      decimals="0"
      id="ixv-34820"
      unitRef="uref_138071911">1229761</ifrs-full:NoncurrentAssets>
    <radx:NoncurrentNetAssets
      contextRef="cref_1773416733"
      decimals="0"
      id="ixv-34821"
      unitRef="uref_138071911">1107185</radx:NoncurrentNetAssets>
    <radx:NoncurrentNetAssets
      contextRef="cref_1569279335"
      decimals="0"
      id="ixv-34822"
      unitRef="uref_138071911">1229761</radx:NoncurrentNetAssets>
    <ifrs-full:NetAssetsLiabilities
      contextRef="cref_1773416733"
      decimals="0"
      id="ixv-34823"
      unitRef="uref_138071911">261074</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="cref_1569279335"
      decimals="0"
      id="ixv-34824"
      unitRef="uref_138071911">1152892</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NoncontrollingInterests
      contextRef="cref_1773416733"
      decimals="0"
      id="ixv-34825"
      unitRef="uref_138071911">-2363526</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="cref_1569279335"
      decimals="0"
      id="ixv-34826"
      unitRef="uref_138071911">-1920100</ifrs-full:NoncontrollingInterests>
    <radx:ScheduleOfSummarizedStatementOfComprehensiveLossTextBlock contextRef="cref_1085778750" id="ixv-22659">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Radiopharm Ventures, LLC&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Summarized statement of comprehensive loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt;"&gt;Loss for the year&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(11,227,807&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,110,449&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total comprehensive loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(11,227,807&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(6,110,449&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Loss allocated to non-controlling interests&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(1,801,344&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,639.368&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:ScheduleOfSummarizedStatementOfComprehensiveLossTextBlock>
    <ifrs-full:ProfitLoss
      contextRef="cref_1302339560"
      decimals="0"
      id="ixv-34827"
      unitRef="uref_138071911">-11227807</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_965818673"
      decimals="0"
      id="ixv-34828"
      unitRef="uref_138071911">-6110449</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1302339560"
      decimals="0"
      id="ixv-34829"
      unitRef="uref_138071911">-11227807</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_965818673"
      decimals="0"
      id="ixv-34830"
      unitRef="uref_138071911">-6110449</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="cref_1302339560"
      decimals="0"
      id="ixv-34831"
      unitRef="uref_138071911">-1801344</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="cref_965818673"
      decimals="3"
      id="ixv-34832"
      unitRef="uref_138071911">-1639.368</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="cref_1085778750" id="ixv-22720">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;13 Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) AVb6 Integrin intellectual property&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group has the license agreement with TRIMT GmbH (TRIMT). The key financial terms of the license agreement includes payments of cash and shares in the group worth US$10 million which has been paid in the year ended 30 June 2022 and issued. The group has also incurred liabilities contingent on future events in respect of the license, which are summarized below: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Management has determined the amortised cost of contingent consideration by assessing the probability of each milestone being achieved and timing of achievement. Management&#x2019;s assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The amortized cost is measured as set out in note 9(b)(iv). The timeframe for measurement varies depending on the milestone and is aligned with industry information on the length of time taken to conduct oncological clinical trials.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone     Payments:&lt;/span&gt; Up to US$90m payable to TRIMT upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to TRIMT&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 83%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Commencement of Phase 3 diagnostic     clinical trial for (68Ga-TRIVEHEXIN) (Diagnostic)&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 8%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2m&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Any Marketing Approval     in Japan, China, Hong Kong or the United States of (68Ga-TRIVEHEXIN) for diagnostic application (Diagnostic)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 1 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Phase 2 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 2 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Phase 3 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 3 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Any Marketing Approval in the Territory other than     in Australia (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;30m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; As at 30 June 2026 &lt;span style="-sec-ix-hidden:fc_1979540956;"&gt;none&lt;/span&gt; of the above milestone have been achieved or paid (30 June 2025: &lt;span style="-sec-ix-hidden:fc_679673439;"&gt;none&lt;/span&gt;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties on net sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group is obliged to pay TRIMT royalties on net sales based on industry standard single digit royalty rates and also on sub licence revenues.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 23px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;(b)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;hu PSA Anti-body intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group has the license agreement with Diaprost AB. The key financial terms of the license agreement include upfront cash payments of US$7 million which has been paid in the year ending 30 June 2022. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In March 2025, Radiopharm signed an amendment with Diaprost and Fredax to increase the payment of Milestone Event 4 to US$12,500,000 which US$11,750,000 will be payable in cash and US$750,000 will be payable in shares of Radiopharm. All other amendments were minor in nature and had no monetary value. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has also incurred liabilities contingent on future events in respect of the license, which are summarised below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 21px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone Payments: &lt;/span&gt;Up to US$123.5m     payable to the Diaprost upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to Diaprost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: #CCEEFF;"&gt;&lt;td style="vertical-align: top; width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 83%; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The     earlier of (i) first ethics approval, or (ii) notice of allowance of Investigational New Drug application (Therapeutic) or (iii)     an equivalent of either of these that is sufficient to allow dosing in humans in any country in the Territory&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 8%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 1&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Phase 2&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;11m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 2B&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;12.5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Pivotal Study&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Upon the dosing of the final patient in a Pivotal Study&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FDA submission&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;7m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FDA approval&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;25m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;9.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;EMA approval&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;PMDA approval&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;11.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Second indication, approval at first of FDA, EMA, PMDA&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;12.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Approval at first of FDA, EMA, PMDA for Diagnostic     trials.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; As at 30 June 2026 milestone 1 had been achieved and paid (30 June 2025: &lt;span style="-sec-ix-hidden:fc_894107997;"&gt;none&lt;/span&gt;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 21px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties on net sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group is obliged to pay Diaprost AB royalties on sublicensing based on industry standard royalty rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;(c) NanoMab intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group has the license agreement with the NanoMab Technology Limited. The key financial terms of the license agreement includes payments of cash and shares in the group worth US$12.5 million which has been paid and issued in the year ending 30 June 2022. The group has also incurred liabilities contingent on future events in respect of the license, which are summarised below. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in; font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-right: 0.3in; text-align: justify; font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development     Milestone Payments: &lt;/span&gt;Up to US$18m payable in shares to the NanoMab upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center; border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to&lt;br/&gt;     Nanomab&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt;&lt;td style="vertical-align: top; width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 82%; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND     allowance by the U.S. FDA or the EMA or the NMPA (for either the HER-2 or the TROP-2 Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 9%; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND     allowance by the U.S. FDA or the EMA or the NMPA (for the PKT-7 Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.5m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 1 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 2 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 3 therapeutic clinical trial, or approval of a Licensed Product&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Payment to be made in the     form of ordinary shares in the company, based on the price of the 7 day VWAP prior to the announcement of the milestone on the ASX.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; As at 30 June 2026, milestone 3 for the first patient dosed in the first Phase 1 therapeutic clinical trial had been achieved and paid (30 June 2025: milestone 3). The group is also in the process of amending the agreement to have TROP2 removed from the milestone achievement after the sale of the asset. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Additionally, the group signed an amendment with NanoMab Technology Limited that included the additional milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to&lt;br/&gt;     Nanomab&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.1&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND     submission to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic) &#x2013; binding license agreement with a third-party to     improve Camelid PDL-1 therapeutic index&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.25m&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.2&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND submission     to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic) - IND submission for the Camelid PDL-1 New Formulation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.25m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 1 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 2 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 3 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Payment to be made in the     form of ordinary shares in the company, based on the price of the 7 day (VWAP) prior to the announcement of the milestone on the     ASX.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; As at 30 June 2026 milestone 2 for first patient dosed in the first Phase 1 therapeutic clinical trial was achieved or paid (30 June 2025: milestone 2). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties on net sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group is obliged to pay Nanomab royalties on net sales based on industry standard single digit royalty rates and also on sublicence revenues.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(d) Pivalate intellectual property&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group has the license agreement with Cancer Research Technologies Limited (CRT). The key financial terms of the license agreement include an upfront cash payment of &#xa3;180,000 which has been paid in the year ending 30 June 2022. The group has also incurred liabilities contingent on future events in respect of the license, which are summarized below: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone Payments: &lt;/span&gt;Up to &#xa3;35.78m     payable to CRT upon meeting various milestones: Diagnostic development milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Milestones&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;"&gt;Requirements&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Payment to&lt;br/&gt;     CRT&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;1.&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; text-align: left;"&gt;Phase 1 clinical trial commencement limited to each of the 1st indication&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;45k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;2.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 2 clinical trial commencement limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;225k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;3.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 3 clinical trial commencement limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;630k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;4.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of US Regulatory Approval&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;900k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;5.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of EU (or UK) Regulatory Approval&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;450k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;6.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;First commercial sale&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;900k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;7.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;10m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;630k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;8.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;50m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.15m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Therapeutic development milestones:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Milestones&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;"&gt;Requirements&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Payment to&lt;br/&gt;     CRT&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;1.&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; text-align: left;"&gt;Clearing of IND in the US or any country in Territory&#x202f;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;90k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;2.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 1 clinical trial/pivotal study commencement, limited to each of the 1st indication&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;225k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;3.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 2 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;630k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;4.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 3 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1.8m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;5.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of US Regulatory Approval&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.6m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;6.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of MA in the EU (or UK)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1.8m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;7.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;First commercial sale&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4.5m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;8.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;100m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.7m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;9.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;500m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13.5m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; As at 30 June 2026 &lt;span style="-sec-ix-hidden:fc_1753504482;"&gt;none&lt;/span&gt; of the above milestone have been achieved or paid (30 June 2025: &lt;span style="-sec-ix-hidden:fc_626167827;"&gt;none&lt;/span&gt;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#x25cf;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties on net sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group is obliged to pay CRT royalties on net sales based on industry standard single-digit royalty rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(f) Radiopharm Ventures LLC&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Radiopharm Ventures, LLC has entered into a technology commercialization agreement in order to complete research and development activities associated with the Mab license. The group has also incurred liabilities contingent on future events in respect of the license, which are summarized below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone     Payments:&lt;/span&gt; Up to US$72.28m payable to Mab upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;Event&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Requirements&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Payment to MD &lt;br/&gt; Anderson for &lt;br/&gt; Licenced &lt;br/&gt; products &lt;br/&gt; that target&lt;br/&gt;  B7-H3 &lt;br/&gt; and/or are &lt;br/&gt; covered by &lt;br/&gt; B7-H3 &lt;br/&gt; patent rights&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Payment to MD&lt;br/&gt;  Anderson for &lt;br/&gt; any other&lt;br/&gt;  licenced &lt;br/&gt; product&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%; text-align: left;"&gt;1&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 70%; text-align: left;"&gt;Initiation of Phase I Clinical Trial of a Licensed Product&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt; 75k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt; 50k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;2&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Initiation of Phase II Clinical Trial of a Licensed Product&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 275k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;200k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;3&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Initiation of Phase III Clinical Trial of a Licensed Product&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;525k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 400k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;4&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Filing of BLA (or equivalent in a non-US jurisdiction) for a Licensed Product&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 850k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 750k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;5&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA for a Licensed Product by the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.15m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.00m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;6&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the European Union equivalent of the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;4.00m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.00m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;7&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the Japanese equivalent of the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;8&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the Chinese equivalent of the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; As at 30 June 2026 milestone 1 for the B7-H3 target had been achieved or paid (30 June 2025: &lt;span style="-sec-ix-hidden:fc_665359121;"&gt;none&lt;/span&gt;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties on net sales&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group is obliged to pay MD Anderson royalties on net sales based on industry standard single digit royalty rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Commercialization Payments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group is obliged to pay MD Anderson the commercialization payments set forth below according to the following, schedule:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;"&gt;Commercialization Event&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Commercialization&lt;br/&gt;     Payment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Upon total worldwide Net Sales of all Licensed Products exceeding $250,000,000&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;5,000,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Upon total worldwide Net Sales of all Licensed Products exceeding $500,000,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Upon total worldwide Net Sales of all Licensed Products exceeding $1,000,000,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;25,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(g) Pharma15&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group has acquired Pharma15 with the key financial terms being an upfront payment of cash and shares of US$2m and also a deferred payment 1 year from acquisition of cash and shares of US$2m. The group has also incurred liabilities contingent on future events in respect of the license, which are summarized below: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone     Payments:&lt;/span&gt; Up to US$2.3m payable to Pharma15 upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Event&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 10%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 77%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FDA IND allowance for a therapeutic     product&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.3m&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Payment to be made in the     form of ordinary shares in the company, based on the price of the 7 day (VWAP) prior to the announcement of the milestone on the     ASX.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; As at 30 June 2026 &lt;span style="-sec-ix-hidden:fc_44444051;"&gt;none&lt;/span&gt; of the above milestone have been achieved or paid (30 June 2025: &lt;span style="-sec-ix-hidden:fc_805692997;"&gt;none&lt;/span&gt;). &lt;/p&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <radx:PaymentOfLicenseAgreementWithTRIMT
      contextRef="cref_1189307281"
      decimals="-6"
      id="ixv-34833"
      unitRef="uref_138071911">10000000</radx:PaymentOfLicenseAgreementWithTRIMT>
    <radx:DisclosureOfDevelopmentMilestonePaymentsExplanatory contextRef="cref_1085778750" id="ixv-22753">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone     Payments:&lt;/span&gt; Up to US$90m payable to TRIMT upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to TRIMT&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 83%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Commencement of Phase 3 diagnostic     clinical trial for (68Ga-TRIVEHEXIN) (Diagnostic)&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 8%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2m&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Any Marketing Approval     in Japan, China, Hong Kong or the United States of (68Ga-TRIVEHEXIN) for diagnostic application (Diagnostic)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 1 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Phase 2 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 2 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Phase 3 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 3 (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Any Marketing Approval in the Territory other than     in Australia (Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;30m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 21px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone Payments: &lt;/span&gt;Up to US$123.5m     payable to the Diaprost upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to Diaprost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: #CCEEFF;"&gt;&lt;td style="vertical-align: top; width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 83%; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The     earlier of (i) first ethics approval, or (ii) notice of allowance of Investigational New Drug application (Therapeutic) or (iii)     an equivalent of either of these that is sufficient to allow dosing in humans in any country in the Territory&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; width: 8%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 1&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Phase 2&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;11m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Last patient Phase 2B&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;12.5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First patient Pivotal Study&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Upon the dosing of the final patient in a Pivotal Study&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;15m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FDA submission&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;7m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FDA approval&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;25m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;9.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;EMA approval&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;PMDA approval&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;11.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Second indication, approval at first of FDA, EMA, PMDA&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;10m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;12.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Approval at first of FDA, EMA, PMDA for Diagnostic     trials.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in; font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-right: 0.3in; text-align: justify; font-size: 10pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development     Milestone Payments: &lt;/span&gt;Up to US$18m payable in shares to the NanoMab upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: center; border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to&lt;br/&gt;     Nanomab&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt;&lt;td style="vertical-align: top; width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 82%; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND     allowance by the U.S. FDA or the EMA or the NMPA (for either the HER-2 or the TROP-2 Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 9%; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND     allowance by the U.S. FDA or the EMA or the NMPA (for the PKT-7 Therapeutic)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.5m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 1 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: White;"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 2 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="background-color: rgb(204,238,255);"&gt;&lt;td style="vertical-align: top;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 3 therapeutic clinical trial, or approval of a Licensed Product&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Additionally, the group signed an amendment with NanoMab Technology Limited that included the additional milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestones&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment     to&lt;br/&gt;     Nanomab&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.1&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND     submission to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic) &#x2013; binding license agreement with a third-party to     improve Camelid PDL-1 therapeutic index&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.25m&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.2&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;IND submission     to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic) - IND submission for the Camelid PDL-1 New Formulation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.25m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 1 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 2 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;First     patient dosed in the first Phase 3 therapeutic clinical trial&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 4.7pt; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3m&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone Payments: &lt;/span&gt;Up to &#xa3;35.78m     payable to CRT upon meeting various milestones: Diagnostic development milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Milestones&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;"&gt;Requirements&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Payment to&lt;br/&gt;     CRT&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;1.&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; text-align: left;"&gt;Phase 1 clinical trial commencement limited to each of the 1st indication&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;45k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;2.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 2 clinical trial commencement limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;225k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;3.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 3 clinical trial commencement limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;630k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;4.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of US Regulatory Approval&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;900k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;5.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of EU (or UK) Regulatory Approval&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;450k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;6.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;First commercial sale&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;900k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;7.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;10m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;630k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;8.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;50m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.15m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Therapeutic development milestones:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Milestones&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;"&gt;Requirements&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Payment to&lt;br/&gt;     CRT&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%;"&gt;1.&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; text-align: left;"&gt;Clearing of IND in the US or any country in Territory&#x202f;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;90k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;2.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 1 clinical trial/pivotal study commencement, limited to each of the 1st indication&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;225k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;3.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 2 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;630k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;4.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Phase 3 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1.8m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;5.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of US Regulatory Approval&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.6m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;6.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Grant of MA in the EU (or UK)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1.8m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;7.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;First commercial sale&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4.5m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;8.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;100m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.7m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;9.&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Aggregate Net Sales worldwide exceeding &#xa3;500m&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#xa3;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13.5m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone     Payments:&lt;/span&gt; Up to US$72.28m payable to Mab upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;Event&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Requirements&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Payment to MD &lt;br/&gt; Anderson for &lt;br/&gt; Licenced &lt;br/&gt; products &lt;br/&gt; that target&lt;br/&gt;  B7-H3 &lt;br/&gt; and/or are &lt;br/&gt; covered by &lt;br/&gt; B7-H3 &lt;br/&gt; patent rights&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Payment to MD&lt;br/&gt;  Anderson for &lt;br/&gt; any other&lt;br/&gt;  licenced &lt;br/&gt; product&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 5%; text-align: left;"&gt;1&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 70%; text-align: left;"&gt;Initiation of Phase I Clinical Trial of a Licensed Product&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt; 75k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt; 50k&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;2&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Initiation of Phase II Clinical Trial of a Licensed Product&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 275k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;200k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;3&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Initiation of Phase III Clinical Trial of a Licensed Product&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;525k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 400k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;4&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Filing of BLA (or equivalent in a non-US jurisdiction) for a Licensed Product&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 850k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt; 750k&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;5&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA for a Licensed Product by the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.15m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.00m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;6&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the European Union equivalent of the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;4.00m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.00m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;7&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the Japanese equivalent of the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;8&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the Chinese equivalent of the FDA&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;US$&lt;/td&gt; &lt;td style="text-align: right;"&gt;2.50m&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Development Milestone     Payments:&lt;/span&gt; Up to US$2.3m payable to Pharma15 upon meeting various milestones:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Event&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Requirements&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Payment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 10%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 77%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FDA IND allowance for a therapeutic     product&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;US$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.3m&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</radx:DisclosureOfDevelopmentMilestonePaymentsExplanatory>
    <radx:PaymentForDevelopmentMilestoneToTRIMT
      contextRef="cref_816128912"
      decimals="-6"
      id="ixv-34834"
      unitRef="uref_138071911">90000000</radx:PaymentForDevelopmentMilestoneToTRIMT>
    <radx:Milestonepayment
      contextRef="cref_2125799627"
      decimals="-6"
      id="ixv-34835"
      unitRef="uref_138071911">2000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1430221635"
      decimals="-6"
      id="ixv-34836"
      unitRef="uref_138071911">3000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_761094825"
      decimals="-6"
      id="ixv-34837"
      unitRef="uref_138071911">5000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1411999849"
      decimals="-6"
      id="ixv-34838"
      unitRef="uref_138071911">10000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_562406285"
      decimals="-6"
      id="ixv-34839"
      unitRef="uref_138071911">10000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1217508044"
      decimals="-6"
      id="ixv-34840"
      unitRef="uref_138071911">15000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1739428878"
      decimals="-6"
      id="ixv-34841"
      unitRef="uref_138071911">15000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1533494348"
      decimals="-6"
      id="ixv-34842"
      unitRef="uref_138071911">30000000</radx:Milestonepayment>
    <radx:PaymentOfLicenseAgreementWithDiaprostAB
      contextRef="cref_1162615470"
      decimals="-6"
      id="ixv-34843"
      unitRef="uref_138071911">7000000</radx:PaymentOfLicenseAgreementWithDiaprostAB>
    <radx:PaymentsForMilestones
      contextRef="cref_1950371269"
      decimals="0"
      id="ixv-34844"
      unitRef="uref_138071911">12500000</radx:PaymentsForMilestones>
    <radx:PaymentsForMilestones
      contextRef="cref_1410443802"
      decimals="0"
      id="ixv-34845"
      unitRef="uref_138071911">11750000</radx:PaymentsForMilestones>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="cref_1350153857"
      decimals="0"
      id="ixv-34846"
      unitRef="uref_138071911">750000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <radx:PaymentForDevelopmentMilestoneToDiaprostAB
      contextRef="cref_1916309410"
      decimals="-5"
      id="ixv-34847"
      unitRef="uref_138071911">123500000</radx:PaymentForDevelopmentMilestoneToDiaprostAB>
    <radx:Milestonepayment
      contextRef="cref_485519371"
      decimals="-6"
      id="ixv-34848"
      unitRef="uref_138071911">3000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_566554721"
      decimals="-6"
      id="ixv-34849"
      unitRef="uref_138071911">5000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1705760710"
      decimals="-6"
      id="ixv-34850"
      unitRef="uref_138071911">11000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1017328493"
      decimals="-5"
      id="ixv-34851"
      unitRef="uref_138071911">12500000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_277748615"
      decimals="-6"
      id="ixv-34852"
      unitRef="uref_138071911">15000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_2032731225"
      decimals="-6"
      id="ixv-34853"
      unitRef="uref_138071911">15000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1509416075"
      decimals="-6"
      id="ixv-34854"
      unitRef="uref_138071911">7000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_444225272"
      decimals="-6"
      id="ixv-34855"
      unitRef="uref_138071911">25000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_844937145"
      decimals="-6"
      id="ixv-34856"
      unitRef="uref_138071911">10000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_789149418"
      decimals="-6"
      id="ixv-34857"
      unitRef="uref_138071911">5000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1085754203"
      decimals="-6"
      id="ixv-34858"
      unitRef="uref_138071911">10000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1769048956"
      decimals="-6"
      id="ixv-34859"
      unitRef="uref_138071911">5000000</radx:Milestonepayment>
    <radx:PaymentForDevelopmentMilestoneToTRIMT
      contextRef="cref_1916309410"
      decimals="0"
      id="ixv-34860"
      unitRef="uref_138071911">1</radx:PaymentForDevelopmentMilestoneToTRIMT>
    <radx:PaymentOfLicenseAgreementWithNanoMabTechnologyLTD
      contextRef="cref_1210940666"
      decimals="-5"
      id="ixv-34861"
      unitRef="uref_138071911">12500000</radx:PaymentOfLicenseAgreementWithNanoMabTechnologyLTD>
    <radx:PaymentForDevelopmentMilestoneToNanoMab
      contextRef="cref_1877994204"
      decimals="-6"
      id="ixv-34862"
      unitRef="uref_138071911">18000000</radx:PaymentForDevelopmentMilestoneToNanoMab>
    <radx:Milestonepayment
      contextRef="cref_108840067"
      decimals="-6"
      id="fc_108840067"
      unitRef="uref_138071911">5000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1098967680"
      decimals="-5"
      id="fc_1098967680"
      unitRef="uref_138071911">500000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_786639730"
      decimals="-6"
      id="fc_786639730"
      unitRef="uref_138071911">1000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_17840321"
      decimals="-6"
      id="fc_17840321"
      unitRef="uref_138071911">2000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1406080744"
      decimals="-6"
      id="fc_1406080744"
      unitRef="uref_138071911">3000000</radx:Milestonepayment>
    <radx:PaymentsForMilestones
      contextRef="cref_1877994204"
      decimals="0"
      id="ixv-34869"
      unitRef="uref_138071911">3</radx:PaymentsForMilestones>
    <radx:PaymentsForMilestones
      contextRef="cref_2015100241"
      decimals="0"
      id="ixv-34870"
      unitRef="uref_138071911">3</radx:PaymentsForMilestones>
    <radx:Milestonepayment
      contextRef="cref_225111429"
      decimals="-4"
      id="ixv-34871"
      unitRef="uref_138071911">250000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_868429"
      decimals="-4"
      id="fc_868429"
      unitRef="uref_138071911">250000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1939047493"
      decimals="-6"
      id="fc_1939047493"
      unitRef="uref_138071911">1000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1078079355"
      decimals="-6"
      id="fc_1078079355"
      unitRef="uref_138071911">2000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_748034023"
      decimals="-6"
      id="fc_748034023"
      unitRef="uref_138071911">3000000</radx:Milestonepayment>
    <radx:PaymentsForMilestones
      contextRef="cref_1405919732"
      decimals="0"
      id="ixv-34877"
      unitRef="uref_138071911">2</radx:PaymentsForMilestones>
    <radx:PaymentsForMilestones
      contextRef="cref_1405919732"
      decimals="0"
      id="ixv-34878"
      unitRef="uref_138071911">2</radx:PaymentsForMilestones>
    <radx:PaymentOfLicenseAgreementWithCRT
      contextRef="cref_986665818"
      decimals="-6"
      id="ixv-34879"
      unitRef="uref_1954685255">180000000000</radx:PaymentOfLicenseAgreementWithCRT>
    <radx:PaymentForDevelopmentMilestoneToCRT
      contextRef="cref_1954685255"
      decimals="-4"
      id="ixv-34880"
      unitRef="uref_1954685255">35780000</radx:PaymentForDevelopmentMilestoneToCRT>
    <radx:Milestonepayment
      contextRef="cref_1231890165"
      decimals="-6"
      id="ixv-34881"
      unitRef="uref_138071911">45000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_324120889"
      decimals="-6"
      id="ixv-34882"
      unitRef="uref_138071911">225000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_204932463"
      decimals="-6"
      id="ixv-34883"
      unitRef="uref_138071911">630000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_2041296158"
      decimals="-6"
      id="ixv-34884"
      unitRef="uref_138071911">900000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_2132565912"
      decimals="-6"
      id="ixv-34885"
      unitRef="uref_138071911">450000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_828513137"
      decimals="-6"
      id="ixv-34886"
      unitRef="uref_138071911">900000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1222400261"
      decimals="-6"
      id="ixv-34887"
      unitRef="uref_138071911">630000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_424525606"
      decimals="-4"
      id="ixv-34888"
      unitRef="uref_138071911">3150000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_10281060"
      decimals="-6"
      id="ixv-34889"
      unitRef="uref_138071911">90000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_754655235"
      decimals="-6"
      id="ixv-34890"
      unitRef="uref_138071911">225000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_2024565384"
      decimals="-6"
      id="ixv-34891"
      unitRef="uref_138071911">630000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1284817183"
      decimals="-5"
      id="ixv-34892"
      unitRef="uref_138071911">1800000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_892197224"
      decimals="-5"
      id="ixv-34893"
      unitRef="uref_138071911">3600000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_543436903"
      decimals="-5"
      id="ixv-34894"
      unitRef="uref_138071911">1800000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_407034768"
      decimals="-5"
      id="ixv-34895"
      unitRef="uref_138071911">4500000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1846050054"
      decimals="-5"
      id="ixv-34896"
      unitRef="uref_138071911">2700000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1902447576"
      decimals="-5"
      id="ixv-34897"
      unitRef="uref_138071911">13500000</radx:Milestonepayment>
    <radx:PaymentForDevelopmentMilestoneToRadiopharmVenturesLLC
      contextRef="cref_141722107"
      decimals="-4"
      id="ixv-34898"
      unitRef="uref_138071911">72280000</radx:PaymentForDevelopmentMilestoneToRadiopharmVenturesLLC>
    <radx:Milestonepayment
      contextRef="cref_191062219"
      decimals="-6"
      id="ixv-34899"
      unitRef="uref_138071911">75000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1009298097"
      decimals="-6"
      id="ixv-34900"
      unitRef="uref_138071911">50000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_2002430941"
      decimals="-6"
      id="ixv-34901"
      unitRef="uref_138071911">275000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1873235144"
      decimals="-6"
      id="ixv-34902"
      unitRef="uref_138071911">200000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1067645943"
      decimals="-6"
      id="ixv-34903"
      unitRef="uref_138071911">525000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_840661265"
      decimals="-6"
      id="ixv-34904"
      unitRef="uref_138071911">400000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_667332784"
      decimals="-6"
      id="ixv-34905"
      unitRef="uref_138071911">850000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1217481479"
      decimals="-6"
      id="ixv-34906"
      unitRef="uref_138071911">750000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_2107642178"
      decimals="-4"
      id="ixv-34907"
      unitRef="uref_138071911">5150000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1488830671"
      decimals="-4"
      id="ixv-34908"
      unitRef="uref_138071911">5000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_315987104"
      decimals="-4"
      id="ixv-34909"
      unitRef="uref_138071911">4000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1301684061"
      decimals="-4"
      id="ixv-34910"
      unitRef="uref_138071911">3000000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_157759423"
      decimals="-4"
      id="ixv-34911"
      unitRef="uref_138071911">3500000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_6539201"
      decimals="-4"
      id="ixv-34912"
      unitRef="uref_138071911">2500000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1184592063"
      decimals="-4"
      id="ixv-34913"
      unitRef="uref_138071911">3500000</radx:Milestonepayment>
    <radx:Milestonepayment
      contextRef="cref_1404515809"
      decimals="-4"
      id="ixv-34914"
      unitRef="uref_138071911">2500000</radx:Milestonepayment>
    <radx:PaymentsForMilestones
      contextRef="cref_141722107"
      decimals="0"
      id="ixv-34915"
      unitRef="uref_138071911">1</radx:PaymentsForMilestones>
    <ifrs-full:DisclosureOfProductsAndServicesExplanatory contextRef="cref_1085778750" id="ixv-23716">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group is obliged to pay MD Anderson the commercialization payments set forth below according to the following, schedule:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold;"&gt;Commercialization Event&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold;"&gt;Commercialization&lt;br/&gt;     Payment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Upon total worldwide Net Sales of all Licensed Products exceeding $250,000,000&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;5,000,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Upon total worldwide Net Sales of all Licensed Products exceeding $500,000,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Upon total worldwide Net Sales of all Licensed Products exceeding $1,000,000,000&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;25,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfProductsAndServicesExplanatory>
    <radx:NetSalesOfAllLicensedProductsExceedingValue
      contextRef="cref_1047837936"
      decimals="0"
      id="ixv-34916"
      unitRef="uref_138071911">250000000</radx:NetSalesOfAllLicensedProductsExceedingValue>
    <radx:CommercializationPayment
      contextRef="cref_1703580672"
      decimals="0"
      id="ixv-34917"
      unitRef="uref_138071911">5000000</radx:CommercializationPayment>
    <radx:NetSalesOfAllLicensedProductsExceedingValue
      contextRef="cref_1314667924"
      decimals="0"
      id="ixv-34918"
      unitRef="uref_138071911">500000000</radx:NetSalesOfAllLicensedProductsExceedingValue>
    <radx:CommercializationPayment
      contextRef="cref_412852398"
      decimals="0"
      id="ixv-34919"
      unitRef="uref_138071911">10000000</radx:CommercializationPayment>
    <radx:NetSalesOfAllLicensedProductsExceedingValue
      contextRef="cref_358410001"
      decimals="0"
      id="ixv-34920"
      unitRef="uref_138071911">1000000000</radx:NetSalesOfAllLicensedProductsExceedingValue>
    <radx:CommercializationPayment
      contextRef="cref_252680283"
      decimals="0"
      id="ixv-34921"
      unitRef="uref_138071911">25000000</radx:CommercializationPayment>
    <radx:PaymentOfLicenseAgreementWithPharma15
      contextRef="cref_1878796642"
      decimals="-6"
      id="ixv-34922"
      unitRef="uref_138071911">2000000</radx:PaymentOfLicenseAgreementWithPharma15>
    <radx:PaymentOfLicenseAgreementWithPharma15
      contextRef="cref_1178193810"
      decimals="-6"
      id="ixv-34923"
      unitRef="uref_138071911">2000000</radx:PaymentOfLicenseAgreementWithPharma15>
    <radx:PaymentForDevelopmentMilestoneToPharma15
      contextRef="cref_1878796642"
      decimals="-5"
      id="ixv-34924"
      unitRef="uref_138071911">2300000</radx:PaymentForDevelopmentMilestoneToPharma15>
    <radx:Milestonepayment
      contextRef="cref_2070317563"
      decimals="-5"
      id="ixv-34925"
      unitRef="uref_138071911">2300000</radx:Milestonepayment>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="cref_1085778750" id="ixv-23815">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;14 Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Research and development commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Pivalate intellectual property&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Under the License Agreement, a non-refundable annual license fee is payable to CRT of &#xa3;9,000 (A$17,500). This is payable within 30 days of the first, second, third and forth anniversaries of the effective date. The first three annual License fees has been paid as at 30 June 2026. Within 30 days of the fifth and each subsequent anniversary of the effective date and until the calendar year in which the first commercial sale of a licensed product occurs, Radiopharm shall pay to the CRT &#xa3;18,000 (A$35,000). &lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:LicenceFeeIncome
      contextRef="cref_1632162546"
      decimals="0"
      id="ixv-34926"
      unitRef="uref_1346866186">9000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="cref_1632162546"
      decimals="0"
      id="ixv-34927"
      unitRef="uref_1001896052">17500</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34928"
      unitRef="uref_1346866186">18000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34929"
      unitRef="uref_1001896052">35000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="cref_1085778750" id="ixv-23827">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;15 Related party transactions &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Key management personnel compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;30 June&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;2026&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2025&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2024&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left;"&gt;Short-term employee benefits&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;3,705,176&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3,828,342&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,009,786&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Post-employment benefits&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;124,588&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;119,513&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;126,649&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Long-term benefits&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1297016798;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;46,367&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;125,865&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,672,315&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,491,477&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,503,894&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif;"&gt;&lt;span style="font-weight: bold;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,502,079&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;5,485,699&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;6,766,194&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Detailed remuneration disclosures are provided in the remuneration report on pages 55 to 64.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Transactions with key management personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The following transactions occurred with key management personnel:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2026&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2025&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2024&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: italic; text-align: left;"&gt;Other transactions&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-left: 0.125in;"&gt;Forfeiture payments expense to key management personnel&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1778566947;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;46,367&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;125,865&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in;"&gt;Payments to director related entities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;171,176&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;415,909&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;605,390&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;171,176&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;462,276&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;731,255&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Forfeiture payments expense to key management personal&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The group has entered agreements to pay employees for forfeiture of long-term incentives with their former employment. At 30 June 2026 the group has recognized &lt;span style="-sec-ix-hidden:fc_1500336743;"&gt;nil&lt;/span&gt; as payable for the current year in cash. The expense is cumulative and vests dependent to the employees&#x2019; agreements with Radiopharm. At 30 June 2025, the group has recognized $46,367 as payable in cash and at 30 June 2024, the group recognized $490,335 as payable in cash. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(ii) Payments to director related entities&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; In the fiscal year of 2026, the Acclime Group invoiced Radiopharm for professional services such as financial reporting, capital management, company secretarial, accounting, bookkeeping, and payroll activities, amounting to $171,176 during the time that Mr. Hains, a Director of Acclime Australia, was a of Director of Radiopharm up to November 2025. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Loans to/from related parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; During the financial year ended 30 June 2024, Radiopharm received interest free loans amounting to $2,200,000 from director related entities. The loans were all repaid prior to 30 June 2024. There were &lt;span style="-sec-ix-hidden:fc_687879281;"&gt;no&lt;/span&gt; loans in fiscal 2026 (2025: &lt;span style="-sec-ix-hidden:fc_864590635;"&gt;nil&lt;/span&gt;). &lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory contextRef="cref_1085778750" id="ixv-23832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Key management personnel compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;30 June&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;2026&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2025&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;2024&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;$&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left;"&gt;Short-term employee benefits&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;3,705,176&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3,828,342&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,009,786&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Post-employment benefits&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;124,588&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;119,513&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;126,649&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Long-term benefits&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1297016798;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;46,367&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;125,865&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,672,315&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,491,477&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,503,894&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif;"&gt;&lt;span style="font-weight: bold;"&gt;Total&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;5,502,079&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;5,485,699&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;6,766,194&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34930"
      unitRef="uref_138071911">3705176</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34931"
      unitRef="uref_138071911">3828342</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34932"
      unitRef="uref_138071911">4009786</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34933"
      unitRef="uref_138071911">124588</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34934"
      unitRef="uref_138071911">119513</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34935"
      unitRef="uref_138071911">126649</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34936"
      unitRef="uref_138071911">46367</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34937"
      unitRef="uref_138071911">125865</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34938"
      unitRef="uref_138071911">1672315</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34939"
      unitRef="uref_138071911">1491477</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34940"
      unitRef="uref_138071911">2503894</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34941"
      unitRef="uref_138071911">5502079</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34942"
      unitRef="uref_138071911">5485699</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34943"
      unitRef="uref_138071911">6766194</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="cref_1085778750" id="ixv-23971">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The following transactions occurred with key management personnel:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;30 June&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2026&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2025&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2024&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: italic; text-align: left;"&gt;Other transactions&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-left: 0.125in;"&gt;Forfeiture payments expense to key management personnel&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1778566947;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;46,367&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;125,865&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in;"&gt;Payments to director related entities&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;171,176&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;415,909&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;605,390&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;171,176&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;462,276&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;731,255&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_403406822"
      decimals="0"
      id="ixv-34944"
      unitRef="uref_138071911">46367</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_1767159501"
      decimals="0"
      id="ixv-34945"
      unitRef="uref_138071911">125865</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_493839153"
      decimals="0"
      id="ixv-34946"
      unitRef="uref_138071911">171176</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_1783997132"
      decimals="0"
      id="ixv-34947"
      unitRef="uref_138071911">415909</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_1677041325"
      decimals="0"
      id="ixv-34948"
      unitRef="uref_138071911">605390</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34949"
      unitRef="uref_138071911">171176</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34950"
      unitRef="uref_138071911">462276</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:TransactionsOccurredWithKeyManagementPersonnel
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34951"
      unitRef="uref_138071911">731255</radx:TransactionsOccurredWithKeyManagementPersonnel>
    <radx:AmountPayableInCash
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-34952"
      unitRef="uref_138071911">46367</radx:AmountPayableInCash>
    <radx:AmountPayableInCash
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34953"
      unitRef="uref_138071911">490335</radx:AmountPayableInCash>
    <radx:PaymentsToDirectorRelatedEntities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-34954"
      unitRef="uref_138071911">171176</radx:PaymentsToDirectorRelatedEntities>
    <radx:TransfersUnderLoansFromEntityRelatedPartyTransaction
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-34955"
      unitRef="uref_138071911">2200000</radx:TransfersUnderLoansFromEntityRelatedPartyTransaction>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="cref_1085778750" id="ixv-24100">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;16 Share-based payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Employee Option Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The establishment of the &#x2018;Omnibus Incentive Plan&#x2019; (OIP) was renewed by shareholders at the annual general meeting held on 16 November 2023. The plan is designed to provide long-term incentives for employees (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board&#x2019;s discretion, and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The options issued under the plan have vesting conditions based on the achievement of service milestone, which are achieved if the holder remains with the group until the date is reached. The dates vary from the initial public offering up to 5 years from the grant dated. There are no performance or market conditions attached to any of the below options under the plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Set out below are summaries of all listed and unlisted options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; per&#160;share&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Number of&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Number of&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Number of&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;option&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;option&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;option&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 28%;"&gt;As at 1 July&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;0.13&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;237,595,186&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.31&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;77,473,719&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.36&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;58,678,263&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;214,480,666&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.05&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;164,772,115&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.11&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,795,456&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Forfeited during the year&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right;"&gt;0.12&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(43,830,802&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.01&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,650,648&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_158769521;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_847696160;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;As at 30 June&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right;"&gt;0.08&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;408,245,050&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.13&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;237,595,186&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.31&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;77,473,719&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Vested and exercisable at 30 June&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right;"&gt;0.16&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;140,210,497&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;68,176,817&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.46&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,931,239&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Share options outstanding at the end of the year have the following expiry date and exercise prices:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Grant date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expiry &lt;br/&gt; date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Exercise&lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June&lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June&lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June &lt;br/&gt; 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 16%;"&gt;2021-03-29&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 16%; text-align: right;"&gt;2025-11-25&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1418922926;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;1,900,022&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2021-04-05&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2025-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_763163625;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2021-04-26&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2025-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_569864081;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2021-06-27&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2021-07-28&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2021-08-02&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,666,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,666,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,666,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2021-12-21&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2025-12-21&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_265837238;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-03-02&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-05-27&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;740,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;740,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;740,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2022-04-22&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-06-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,666,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,666,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1700&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,425,675&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,137,976&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,137,976&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2022-11-16&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-12-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,800,004&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,800,004&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,800,004&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-11-16&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-06-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1700&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,366,927&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,366,927&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,366,927&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-02-07&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-02-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1551&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2023-05-18&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-06-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1980&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;200,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;200,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;200,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-06-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-05-31&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1400&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1772902389;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;505,598&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;505,598&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2023-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1120&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,658,514&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,658,514&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,176,190&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-07-24&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-24&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1210&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2023-11-16&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,113,668&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,113,668&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,113,668&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-12-13&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-12-13&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0760&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-06-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-05-31&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0320&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,300,838&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,300,838&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,300,838&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2024-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2029-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0410&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;25,904,884&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,480,627&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_217689316;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-08-23&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-09-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;24,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;24,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1475106504;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2024-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2029-06-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0410&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;59,290,690&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;59,290,690&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_224156013;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;2029-09-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;37,333,334&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;48,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_623896292;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2025-01-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;2028-12-13&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0270&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_825009300;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2025-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2030-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0250&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;86,250,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1474773609;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_340325290;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2025-08-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2030-08-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_845758456;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_734510058;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2025-11-20&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2030-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0250&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;99,294,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1693899775;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_186786133;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;2026-06-01&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2031-06-01&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,666,666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_504198348;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_884678054;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;408,245,050&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;237,594,698&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;79,774,557&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following options were granted outside of the OIP plan to non-employees, vesting immediately upon issue. The outstanding balance at the end of the year is detailed below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Grant date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expiry&lt;br/&gt; date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Exercise &lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options&lt;br/&gt; 30 June&lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June &lt;br/&gt; 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 16%;"&gt;2021-09-13&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 16%; text-align: right;"&gt;2024-11-25&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1015499212;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_987071452;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_301111933;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: right;"&gt;13,680,012&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.200&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,352,040&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,352,040&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,352,040&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-11-14&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.110&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-02-06&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-04-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.090&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,955,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,955,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,955,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2024-08-28&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-08-24&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.060&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;818,890,534&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;818,890,534&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1185254345;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;2025-12-09&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;2027-10-31&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.039&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,179,266,658&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,093,964,456&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;914,697,798&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;109,487,276&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Weighted average remaining contractual     life of options outstanding at end of year&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.02&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.12&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.98&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;i&gt;(i) Fair value of options granted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The model inputs for options granted during the year ended 30 June 2026 included:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expiry &lt;br/&gt; date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Exercise&lt;br/&gt; price ($)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;No. of&lt;br/&gt; options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share&lt;br/&gt; price at&lt;br/&gt; grant&lt;br/&gt; date     ($)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expected&lt;br/&gt; volatility&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Dividend&lt;br/&gt; yield&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Risk-free&lt;br/&gt; interest rate&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Fair value &lt;br/&gt; at grant&lt;br/&gt;  date ($)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 10%;"&gt;01/07/2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right;"&gt;01/07/2030&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.025&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;107,520,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.023&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;93.83&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3.43&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,731,072&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;01/08/2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;01/08/2030&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.060&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.023&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;94.32&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.65&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;80,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;20/11/2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;01/07/2030&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.025&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;99,294,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.025&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;98.58&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.76&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,479,480&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;09/12/2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;31/10/2027&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.039&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,179,266,658&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_782403807;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2083204664;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1542713733;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1187745178;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_872037522;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,391,080,658&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Expenses arising from share-based payment transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;2024 &lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Options issued&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;800,373&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,157,778&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,029,236&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="cref_1085778750" id="ixv-24112">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Set out below are summaries of all listed and unlisted options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;br/&gt; per&#160;share&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right;"&gt;Number of&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Number of&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right;"&gt;Number of&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;option&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;option&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;option&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 28%;"&gt;As at 1 July&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;0.13&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;237,595,186&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.31&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;77,473,719&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.36&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;58,678,263&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;214,480,666&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.05&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;164,772,115&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.11&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,795,456&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Forfeited during the year&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right;"&gt;0.12&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(43,830,802&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.01&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,650,648&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_158769521;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_847696160;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;As at 30 June&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right;"&gt;0.08&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;408,245,050&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.13&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;237,595,186&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.31&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;77,473,719&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Vested and exercisable at 30 June&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right;"&gt;0.16&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;140,210,497&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;68,176,817&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.46&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32,931,239&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="cref_530068751"
      decimals="2"
      id="ixv-34956"
      unitRef="uref_1453202449">0.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <radx:NumberOfSharesEmployeeOptionPlan
      contextRef="cref_530068751"
      decimals="0"
      id="ixv-34957"
      unitRef="uref_1634518116">237595186</radx:NumberOfSharesEmployeeOptionPlan>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="cref_926930741"
      decimals="2"
      id="ixv-34958"
      unitRef="uref_1453202449">0.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <radx:NumberOfSharesEmployeeOptionPlan
      contextRef="cref_926930741"
      decimals="0"
      id="ixv-34959"
      unitRef="uref_1634518116">77473719</radx:NumberOfSharesEmployeeOptionPlan>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="cref_875901779"
      decimals="2"
      id="ixv-34960"
      unitRef="uref_1453202449">0.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <radx:NumberOfSharesEmployeeOptionPlan
      contextRef="cref_875901779"
      decimals="0"
      id="ixv-34961"
      unitRef="uref_1634518116">58678263</radx:NumberOfSharesEmployeeOptionPlan>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="cref_135083310"
      decimals="2"
      id="ixv-34962"
      unitRef="uref_1453202449">0.02</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="cref_135083310"
      decimals="0"
      id="ixv-34963"
      unitRef="uref_880450695">214480666</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="cref_1034873053"
      decimals="2"
      id="ixv-34964"
      unitRef="uref_1453202449">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="cref_1034873053"
      decimals="0"
      id="ixv-34965"
      unitRef="uref_880450695">164772115</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="cref_1941222514"
      decimals="2"
      id="ixv-34966"
      unitRef="uref_1453202449">0.11</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="cref_1941222514"
      decimals="0"
      id="ixv-34967"
      unitRef="uref_880450695">18795456</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="cref_135083310"
      decimals="2"
      id="ixv-34968"
      unitRef="uref_1453202449">0.12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="cref_135083310"
      decimals="0"
      id="ixv-34969"
      unitRef="uref_880450695">43830802</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="cref_1034873053"
      decimals="2"
      id="ixv-34970"
      unitRef="uref_1453202449">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="cref_1034873053"
      decimals="0"
      id="ixv-34971"
      unitRef="uref_880450695">4650648</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="cref_450697764"
      decimals="2"
      id="ixv-34972"
      unitRef="uref_1453202449">0.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <radx:NumberOfSharesEmployeeOptionPlan
      contextRef="cref_450697764"
      decimals="0"
      id="ixv-34973"
      unitRef="uref_1634518116">408245050</radx:NumberOfSharesEmployeeOptionPlan>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="cref_530068751"
      decimals="2"
      id="ixv-34974"
      unitRef="uref_1453202449">0.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <radx:NumberOfSharesEmployeeOptionPlan
      contextRef="cref_530068751"
      decimals="0"
      id="ixv-34975"
      unitRef="uref_1634518116">237595186</radx:NumberOfSharesEmployeeOptionPlan>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="cref_926930741"
      decimals="2"
      id="ixv-34976"
      unitRef="uref_1453202449">0.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <radx:NumberOfSharesEmployeeOptionPlan
      contextRef="cref_926930741"
      decimals="0"
      id="ixv-34977"
      unitRef="uref_1634518116">77473719</radx:NumberOfSharesEmployeeOptionPlan>
    <radx:WeightedAverageExercisePricePerShareOptionVestedAndExercisable
      contextRef="cref_450697764"
      decimals="2"
      id="ixv-34978"
      unitRef="uref_1453202449">0.16</radx:WeightedAverageExercisePricePerShareOptionVestedAndExercisable>
    <radx:NumberOfOptionsVestedAndExercisable
      contextRef="cref_450697764"
      decimals="0"
      id="ixv-34979"
      unitRef="uref_880450695">140210497</radx:NumberOfOptionsVestedAndExercisable>
    <radx:WeightedAverageExercisePricePerShareOptionVestedAndExercisable
      contextRef="cref_530068751"
      decimals="2"
      id="ixv-34980"
      unitRef="uref_1453202449">0.3</radx:WeightedAverageExercisePricePerShareOptionVestedAndExercisable>
    <radx:NumberOfOptionsVestedAndExercisable
      contextRef="cref_530068751"
      decimals="0"
      id="ixv-34981"
      unitRef="uref_880450695">68176817</radx:NumberOfOptionsVestedAndExercisable>
    <radx:WeightedAverageExercisePricePerShareOptionVestedAndExercisable
      contextRef="cref_926930741"
      decimals="2"
      id="ixv-34982"
      unitRef="uref_1453202449">0.46</radx:WeightedAverageExercisePricePerShareOptionVestedAndExercisable>
    <radx:NumberOfOptionsVestedAndExercisable
      contextRef="cref_926930741"
      decimals="0"
      id="ixv-34983"
      unitRef="uref_880450695">32931239</radx:NumberOfOptionsVestedAndExercisable>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="cref_1085778750" id="ixv-24334">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Share options outstanding at the end of the year have the following expiry date and exercise prices:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Grant date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expiry &lt;br/&gt; date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Exercise&lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June&lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June&lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June &lt;br/&gt; 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 16%;"&gt;2021-03-29&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 16%; text-align: right;"&gt;2025-11-25&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1418922926;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;1,900,022&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2021-04-05&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2025-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_763163625;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2021-04-26&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2025-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_569864081;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,900,002&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2021-06-27&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2021-07-28&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,533,336&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2021-08-02&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,666,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,666,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,666,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2021-12-21&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2025-12-21&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_265837238;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-03-02&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-05-27&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;740,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;740,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;740,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2022-04-22&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-06-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,666,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,666,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1700&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,425,675&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,137,976&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,137,976&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2022-11-16&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-12-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.6000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,800,004&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,800,004&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,800,004&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-11-16&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-06-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1700&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,366,927&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,366,927&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;18,366,927&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-02-07&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-02-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1551&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;100,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2023-05-18&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-06-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1980&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;200,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;200,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;200,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-06-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-05-31&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1400&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1772902389;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;505,598&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;505,598&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2023-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1120&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,658,514&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,658,514&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,176,190&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-07-24&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-24&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1210&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2023-11-16&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.1100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,113,668&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,113,668&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,113,668&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-12-13&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-12-13&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0760&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-06-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2027-05-31&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0320&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,300,838&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,300,838&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,300,838&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2024-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2029-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0410&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;25,904,884&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,480,627&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_217689316;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-08-23&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-09-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;24,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;24,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1475106504;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2024-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2029-06-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0410&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;59,290,690&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;59,290,690&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_224156013;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;2029-09-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;37,333,334&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;48,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_623896292;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2025-01-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;2028-12-13&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0270&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;400,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_825009300;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2025-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2030-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0250&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;86,250,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1474773609;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_340325290;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2025-08-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2030-08-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_845758456;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_734510058;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2025-11-20&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2030-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0250&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;99,294,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1693899775;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_186786133;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;2026-06-01&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2031-06-01&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.0600&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,666,666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_504198348;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_884678054;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;408,245,050&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;237,594,698&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;79,774,557&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.1pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The following options were granted outside of the OIP plan to non-employees, vesting immediately upon issue. The outstanding balance at the end of the year is detailed below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Grant date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expiry&lt;br/&gt; date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Exercise &lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options&lt;br/&gt; 30 June&lt;br/&gt; 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June &lt;br/&gt; 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share options &lt;br/&gt; 30 June &lt;br/&gt; 2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 16%;"&gt;2021-09-13&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 16%; text-align: right;"&gt;2024-11-25&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1015499212;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_987071452;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 14%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_301111933;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: right;"&gt;13,680,012&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2022-11-25&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-11-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.200&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,352,040&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,352,040&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,352,040&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2023-11-14&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-07-01&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.110&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,500,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;2024-02-06&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2028-04-30&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.090&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,955,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,955,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8,955,224&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;2024-08-28&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2026-08-24&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.060&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;818,890,534&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;818,890,534&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1185254345;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;2025-12-09&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;2027-10-31&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;0.039&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,179,266,658&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2,093,964,456&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;914,697,798&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;109,487,276&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Weighted average remaining contractual     life of options outstanding at end of year&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.02&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.12&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;2.98&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_360264480" id="ixv-34984">2025-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1781408912"
      decimals="4"
      id="ixv-34985"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_548074793"
      decimals="0"
      id="ixv-34986"
      unitRef="uref_880450695">1900022</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1403356230"
      decimals="0"
      id="ixv-34987"
      unitRef="uref_880450695">1900002</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_816183465" id="ixv-34988">2025-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1130058759"
      decimals="4"
      id="ixv-34989"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_2017346239"
      decimals="0"
      id="ixv-34990"
      unitRef="uref_880450695">1900002</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1494728494"
      decimals="0"
      id="ixv-34991"
      unitRef="uref_880450695">1900002</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1443674035" id="ixv-34992">2025-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_2112097951"
      decimals="4"
      id="ixv-34993"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_501241957"
      decimals="0"
      id="ixv-34994"
      unitRef="uref_880450695">1900002</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1487221508"
      decimals="0"
      id="ixv-34995"
      unitRef="uref_880450695">1900002</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_198631103" id="ixv-34996">2026-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_51592759"
      decimals="4"
      id="ixv-34997"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_51592759"
      decimals="0"
      id="ixv-34998"
      unitRef="uref_880450695">2533336</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_931133148"
      decimals="0"
      id="ixv-34999"
      unitRef="uref_880450695">2533336</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_100673349"
      decimals="0"
      id="ixv-35000"
      unitRef="uref_880450695">2533336</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1739775018" id="ixv-35001">2026-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_930482778"
      decimals="4"
      id="ixv-35002"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_930482778"
      decimals="0"
      id="ixv-35003"
      unitRef="uref_880450695">2533336</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_2000660802"
      decimals="0"
      id="ixv-35004"
      unitRef="uref_880450695">2533336</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_121897300"
      decimals="0"
      id="ixv-35005"
      unitRef="uref_880450695">2533336</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_2054622152" id="ixv-35006">2026-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1805944749"
      decimals="4"
      id="ixv-35007"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1805944749"
      decimals="0"
      id="ixv-35008"
      unitRef="uref_880450695">8666678</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1857311806"
      decimals="0"
      id="ixv-35009"
      unitRef="uref_880450695">8666678</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1647359300"
      decimals="0"
      id="ixv-35010"
      unitRef="uref_880450695">8666678</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1100805626" id="ixv-35011">2025-12-21</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1954644021"
      decimals="4"
      id="ixv-35012"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1915052171"
      decimals="0"
      id="ixv-35013"
      unitRef="uref_880450695">400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1881161616"
      decimals="0"
      id="ixv-35014"
      unitRef="uref_880450695">400000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_119703658" id="ixv-35015">2027-05-27</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1756325082"
      decimals="4"
      id="ixv-35016"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1756325082"
      decimals="0"
      id="ixv-35017"
      unitRef="uref_880450695">740000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_777974110"
      decimals="0"
      id="ixv-35018"
      unitRef="uref_880450695">740000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1222503693"
      decimals="0"
      id="ixv-35019"
      unitRef="uref_880450695">740000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_327000077" id="ixv-35020">2027-06-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1924206269"
      decimals="4"
      id="ixv-35021"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1924206269"
      decimals="0"
      id="ixv-35022"
      unitRef="uref_880450695">1666500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1160084053"
      decimals="0"
      id="ixv-35023"
      unitRef="uref_880450695">1666500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1707518562"
      decimals="0"
      id="ixv-35024"
      unitRef="uref_880450695">2500000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_878367649" id="ixv-35025">2027-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_786507420"
      decimals="4"
      id="ixv-35026"
      unitRef="uref_1453202449">0.17</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_786507420"
      decimals="0"
      id="ixv-35027"
      unitRef="uref_880450695">12425675</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1674668432"
      decimals="0"
      id="ixv-35028"
      unitRef="uref_880450695">13137976</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_2068080987"
      decimals="0"
      id="ixv-35029"
      unitRef="uref_880450695">13137976</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_172805993" id="ixv-35030">2026-12-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1666552381"
      decimals="4"
      id="ixv-35031"
      unitRef="uref_1453202449">0.6</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1666552381"
      decimals="0"
      id="ixv-35032"
      unitRef="uref_880450695">3800004</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_927149939"
      decimals="0"
      id="ixv-35033"
      unitRef="uref_880450695">3800004</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1194433765"
      decimals="0"
      id="ixv-35034"
      unitRef="uref_880450695">3800004</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_412889581" id="ixv-35035">2027-06-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_875420284"
      decimals="4"
      id="ixv-35036"
      unitRef="uref_1453202449">0.17</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_875420284"
      decimals="0"
      id="ixv-35037"
      unitRef="uref_880450695">18366927</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_317774168"
      decimals="0"
      id="ixv-35038"
      unitRef="uref_880450695">18366927</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_362113034"
      decimals="0"
      id="ixv-35039"
      unitRef="uref_880450695">18366927</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1258967839" id="ixv-35040">2028-02-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1927572909"
      decimals="4"
      id="ixv-35041"
      unitRef="uref_1453202449">0.1551</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1927572909"
      decimals="0"
      id="ixv-35042"
      unitRef="uref_880450695">100000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1370650207"
      decimals="0"
      id="ixv-35043"
      unitRef="uref_880450695">100000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1608534073"
      decimals="0"
      id="ixv-35044"
      unitRef="uref_880450695">100000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_730857818" id="ixv-35045">2028-06-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1794744267"
      decimals="4"
      id="ixv-35046"
      unitRef="uref_1453202449">0.198</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1794744267"
      decimals="0"
      id="ixv-35047"
      unitRef="uref_880450695">200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1107392644"
      decimals="0"
      id="ixv-35048"
      unitRef="uref_880450695">200000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_407099329"
      decimals="0"
      id="ixv-35049"
      unitRef="uref_880450695">200000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1492498597" id="ixv-35050">2026-05-31</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1269655552"
      decimals="4"
      id="ixv-35051"
      unitRef="uref_1453202449">0.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_688984078"
      decimals="0"
      id="ixv-35052"
      unitRef="uref_880450695">505598</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_759987645"
      decimals="0"
      id="ixv-35053"
      unitRef="uref_880450695">505598</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_420995518" id="ixv-35054">2028-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_724216223"
      decimals="4"
      id="ixv-35055"
      unitRef="uref_1453202449">0.112</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_724216223"
      decimals="0"
      id="ixv-35056"
      unitRef="uref_880450695">3658514</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_270637834"
      decimals="0"
      id="ixv-35057"
      unitRef="uref_880450695">3658514</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_519685270"
      decimals="0"
      id="ixv-35058"
      unitRef="uref_880450695">7176190</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1391377859" id="ixv-35059">2028-07-24</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1275499145"
      decimals="4"
      id="ixv-35060"
      unitRef="uref_1453202449">0.121</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1275499145"
      decimals="0"
      id="ixv-35061"
      unitRef="uref_880450695">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1359085653"
      decimals="0"
      id="ixv-35062"
      unitRef="uref_880450695">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1266471380"
      decimals="0"
      id="ixv-35063"
      unitRef="uref_880450695">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1436931810" id="ixv-35064">2028-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1728794886"
      decimals="4"
      id="ixv-35065"
      unitRef="uref_1453202449">0.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1728794886"
      decimals="0"
      id="ixv-35066"
      unitRef="uref_880450695">10113668</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1596448726"
      decimals="0"
      id="ixv-35067"
      unitRef="uref_880450695">10113668</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1300933542"
      decimals="0"
      id="ixv-35068"
      unitRef="uref_880450695">10113668</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1008207822" id="ixv-35069">2028-12-13</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1899490176"
      decimals="4"
      id="ixv-35070"
      unitRef="uref_1453202449">0.076</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1899490176"
      decimals="0"
      id="ixv-35071"
      unitRef="uref_880450695">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_421970489"
      decimals="0"
      id="ixv-35072"
      unitRef="uref_880450695">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_749500879"
      decimals="0"
      id="ixv-35073"
      unitRef="uref_880450695">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1495591169" id="ixv-35074">2027-05-31</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_460571520"
      decimals="4"
      id="ixv-35075"
      unitRef="uref_1453202449">0.032</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_460571520"
      decimals="0"
      id="ixv-35076"
      unitRef="uref_880450695">2300838</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_927481683"
      decimals="0"
      id="ixv-35077"
      unitRef="uref_880450695">2300838</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_775859418"
      decimals="0"
      id="ixv-35078"
      unitRef="uref_880450695">2300838</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1072549679" id="ixv-35079">2029-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_893620482"
      decimals="4"
      id="ixv-35080"
      unitRef="uref_1453202449">0.041</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_893620482"
      decimals="0"
      id="ixv-35081"
      unitRef="uref_880450695">25904884</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1497542677"
      decimals="0"
      id="ixv-35082"
      unitRef="uref_880450695">30480627</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_284529348" id="ixv-35083">2026-09-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_685861082"
      decimals="4"
      id="ixv-35084"
      unitRef="uref_1453202449">0.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_685861082"
      decimals="0"
      id="ixv-35085"
      unitRef="uref_880450695">24000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1242036386"
      decimals="0"
      id="ixv-35086"
      unitRef="uref_880450695">24000000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_2119408009" id="ixv-35087">2029-06-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_2128956856"
      decimals="4"
      id="ixv-35088"
      unitRef="uref_1453202449">0.041</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_2128956856"
      decimals="0"
      id="ixv-35089"
      unitRef="uref_880450695">59290690</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_443616561"
      decimals="0"
      id="ixv-35090"
      unitRef="uref_880450695">59290690</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1827222556" id="ixv-35091">2029-09-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1796366748"
      decimals="4"
      id="ixv-35092"
      unitRef="uref_1453202449">0.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1796366748"
      decimals="0"
      id="ixv-35093"
      unitRef="uref_880450695">37333334</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_959946701"
      decimals="0"
      id="ixv-35094"
      unitRef="uref_880450695">48000000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_875875991" id="ixv-35095">2028-12-13</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_589083587"
      decimals="4"
      id="ixv-35096"
      unitRef="uref_1453202449">0.027</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_589083587"
      decimals="0"
      id="ixv-35097"
      unitRef="uref_880450695">400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_101105586"
      decimals="0"
      id="ixv-35098"
      unitRef="uref_880450695">400000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_65228173" id="ixv-35099">2030-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1396836075"
      decimals="4"
      id="ixv-35100"
      unitRef="uref_1453202449">0.025</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1396836075"
      decimals="0"
      id="ixv-35101"
      unitRef="uref_880450695">86250000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_900522248" id="ixv-35102">2030-08-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1854211896"
      decimals="4"
      id="ixv-35103"
      unitRef="uref_1453202449">0.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1854211896"
      decimals="0"
      id="ixv-35104"
      unitRef="uref_880450695">5000000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_72696819" id="ixv-35105">2030-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_520622503"
      decimals="4"
      id="ixv-35106"
      unitRef="uref_1453202449">0.025</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_520622503"
      decimals="0"
      id="ixv-35107"
      unitRef="uref_880450695">99294000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_341143700" id="ixv-35108">2031-06-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1089707227"
      decimals="4"
      id="ixv-35109"
      unitRef="uref_1453202449">0.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1089707227"
      decimals="0"
      id="ixv-35110"
      unitRef="uref_880450695">2666666</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1981733187"
      decimals="0"
      id="ixv-35111"
      unitRef="uref_880450695">408245050</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_234220556"
      decimals="0"
      id="ixv-35112"
      unitRef="uref_880450695">237594698</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1622593116"
      decimals="0"
      id="ixv-35113"
      unitRef="uref_880450695">79774557</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_981352347" id="ixv-35114">2024-11-25</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_611529629"
      decimals="0"
      id="ixv-35115"
      unitRef="uref_880450695">13680012</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_455539713" id="ixv-35116">2026-11-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_366531594"
      decimals="3"
      id="ixv-35117"
      unitRef="uref_1453202449">0.2</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_366531594"
      decimals="0"
      id="ixv-35118"
      unitRef="uref_880450695">79352040</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_160466343"
      decimals="0"
      id="ixv-35119"
      unitRef="uref_880450695">79352040</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_374893698"
      decimals="0"
      id="ixv-35120"
      unitRef="uref_880450695">79352040</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1685255" id="ixv-35121">2028-07-01</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1717370067"
      decimals="3"
      id="ixv-35122"
      unitRef="uref_1453202449">0.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1717370067"
      decimals="0"
      id="ixv-35123"
      unitRef="uref_880450695">7500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_619814595"
      decimals="0"
      id="ixv-35124"
      unitRef="uref_880450695">7500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1292143018"
      decimals="0"
      id="ixv-35125"
      unitRef="uref_880450695">7500000</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_317646948" id="ixv-35126">2028-04-30</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_871342575"
      decimals="3"
      id="ixv-35127"
      unitRef="uref_1453202449">0.09</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_871342575"
      decimals="0"
      id="ixv-35128"
      unitRef="uref_880450695">8955224</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_520762590"
      decimals="0"
      id="ixv-35129"
      unitRef="uref_880450695">8955224</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1088531607"
      decimals="0"
      id="ixv-35130"
      unitRef="uref_880450695">8955224</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_1551093248" id="ixv-35131">2026-08-24</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_591779329"
      decimals="3"
      id="ixv-35132"
      unitRef="uref_1453202449">0.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_591779329"
      decimals="0"
      id="ixv-35133"
      unitRef="uref_880450695">818890534</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_450007838"
      decimals="0"
      id="ixv-35134"
      unitRef="uref_880450695">818890534</ifrs-full:NumberOfOutstandingShareOptions>
    <radx:ExpiryDateOfOutstandingShareOptions contextRef="cref_782284377" id="ixv-35135">2027-10-31</radx:ExpiryDateOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="cref_1358652047"
      decimals="3"
      id="ixv-35136"
      unitRef="uref_1453202449">0.039</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1358652047"
      decimals="0"
      id="ixv-35137"
      unitRef="uref_880450695">1179266658</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1304073823"
      decimals="0"
      id="ixv-35138"
      unitRef="uref_880450695">2093964456</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_1672483521"
      decimals="0"
      id="ixv-35139"
      unitRef="uref_880450695">914697798</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="cref_17681198"
      decimals="0"
      id="ixv-35140"
      unitRef="uref_880450695">109487276</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="cref_675759352" id="ixv-35141">P3Y7D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="cref_1205521687" id="ixv-35142">P3Y1M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="cref_718193669" id="ixv-35143">P2Y11M23D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="cref_1085778750" id="ixv-25207">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The model inputs for options granted during the year ended 30 June 2026 included:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expiry &lt;br/&gt; date&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Exercise&lt;br/&gt; price ($)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;No. of&lt;br/&gt; options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Share&lt;br/&gt; price at&lt;br/&gt; grant&lt;br/&gt; date     ($)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Expected&lt;br/&gt; volatility&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Dividend&lt;br/&gt; yield&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Risk-free&lt;br/&gt; interest rate&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;Fair value &lt;br/&gt; at grant&lt;br/&gt;  date ($)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 10%;"&gt;01/07/2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: right;"&gt;01/07/2030&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.025&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;107,520,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.023&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;93.83&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3.43&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,731,072&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;01/08/2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;01/08/2030&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.060&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,000,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.023&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;94.32&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.65&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;80,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;20/11/2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;01/07/2030&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.025&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;99,294,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.025&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;98.58&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.76&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,479,480&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;09/12/2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;31/10/2027&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.039&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,179,266,658&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_782403807;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2083204664;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1542713733;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1187745178;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_872037522;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;1,391,080,658&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <radx:NumberOfOptionsGrantedExpiryDate contextRef="cref_126996007" id="ixv-35144">01/07/2030</radx:NumberOfOptionsGrantedExpiryDate>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="cref_126996007"
      decimals="3"
      id="ixv-35145"
      unitRef="uref_1453202449">0.025</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="cref_126996007"
      decimals="0"
      id="ixv-35146"
      unitRef="uref_880450695">107520000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="cref_126996007"
      decimals="3"
      id="ixv-35147"
      unitRef="uref_1453202449">0.023</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="cref_126996007"
      decimals="4"
      id="ixv-35148"
      unitRef="uref_880450695">0.9383</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="cref_126996007"
      decimals="4"
      id="ixv-35149"
      unitRef="uref_880450695">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="cref_126996007"
      decimals="4"
      id="ixv-35150"
      unitRef="uref_880450695">0.0343</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <radx:FairValueAtGrantDate
      contextRef="cref_126996007"
      decimals="0"
      id="ixv-35151"
      unitRef="uref_138071911">1731072</radx:FairValueAtGrantDate>
    <radx:NumberOfOptionsGrantedExpiryDate contextRef="cref_257140075" id="ixv-35152">01/08/2030</radx:NumberOfOptionsGrantedExpiryDate>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="cref_257140075"
      decimals="3"
      id="ixv-35153"
      unitRef="uref_1453202449">0.06</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="cref_257140075"
      decimals="0"
      id="ixv-35154"
      unitRef="uref_880450695">5000000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="cref_257140075"
      decimals="3"
      id="ixv-35155"
      unitRef="uref_1453202449">0.023</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="cref_257140075"
      decimals="4"
      id="ixv-35156"
      unitRef="uref_880450695">0.9432</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="cref_257140075"
      decimals="4"
      id="ixv-35157"
      unitRef="uref_880450695">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="cref_257140075"
      decimals="4"
      id="ixv-35158"
      unitRef="uref_880450695">0.0365</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <radx:FairValueAtGrantDate
      contextRef="cref_257140075"
      decimals="0"
      id="ixv-35159"
      unitRef="uref_138071911">80500</radx:FairValueAtGrantDate>
    <radx:NumberOfOptionsGrantedExpiryDate contextRef="cref_2001150217" id="ixv-35160">01/07/2030</radx:NumberOfOptionsGrantedExpiryDate>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="cref_2001150217"
      decimals="3"
      id="ixv-35161"
      unitRef="uref_1453202449">0.025</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="cref_2001150217"
      decimals="0"
      id="ixv-35162"
      unitRef="uref_880450695">99294000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="cref_2001150217"
      decimals="3"
      id="ixv-35163"
      unitRef="uref_1453202449">0.025</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="cref_2001150217"
      decimals="4"
      id="ixv-35164"
      unitRef="uref_880450695">0.9858</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="cref_2001150217"
      decimals="4"
      id="ixv-35165"
      unitRef="uref_880450695">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="cref_2001150217"
      decimals="4"
      id="ixv-35166"
      unitRef="uref_880450695">0.0376</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <radx:FairValueAtGrantDate
      contextRef="cref_2001150217"
      decimals="0"
      id="ixv-35167"
      unitRef="uref_138071911">1479480</radx:FairValueAtGrantDate>
    <radx:NumberOfOptionsGrantedExpiryDate contextRef="cref_682156036" id="ixv-35168">31/10/2027</radx:NumberOfOptionsGrantedExpiryDate>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="cref_682156036"
      decimals="3"
      id="ixv-35169"
      unitRef="uref_1453202449">0.039</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="cref_682156036"
      decimals="0"
      id="ixv-35170"
      unitRef="uref_880450695">1179266658</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35171"
      unitRef="uref_880450695">1391080658</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DisclosureOfExpensesExplanatory contextRef="cref_1085778750" id="ixv-35172">Expenses arising from share-based payment transactions&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; &#160;&#160;&#160;&#160;&#160;2024 &lt;br/&gt; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Options issued&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;800,373&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;2,157,778&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,029,236&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35173"
      unitRef="uref_138071911">800373</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35174"
      unitRef="uref_138071911">2157778</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-35175"
      unitRef="uref_138071911">3029236</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="cref_1085778750" id="ixv-25465">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;17 Remuneration of auditors&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Grant Thornton Audit Pty Ltd&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Audit and other assurance services&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Audit and review of financial statements&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;401,962&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;439,394&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Services related to NASDAQ and ATM registration&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;97,650&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;139,327&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Total remuneration for audit and other assurance services&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;499,612&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;578,721&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <radx:ScheduleOfPayableForServicesByTheAuditorTextBlock contextRef="cref_1085778750" id="ixv-25476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Audit and other assurance services&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026&lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Audit and review of financial statements&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;401,962&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;439,394&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Services related to NASDAQ and ATM registration&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;97,650&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;139,327&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Total remuneration for audit and other assurance services&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;499,612&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;578,721&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:ScheduleOfPayableForServicesByTheAuditorTextBlock>
    <ifrs-full:AuditorsRemuneration
      contextRef="cref_414897961"
      decimals="0"
      id="ixv-35176"
      unitRef="uref_138071911">401962</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="cref_825614241"
      decimals="0"
      id="ixv-35177"
      unitRef="uref_138071911">439394</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="cref_1346747018"
      decimals="0"
      id="ixv-35178"
      unitRef="uref_138071911">97650</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="cref_2100782799"
      decimals="0"
      id="ixv-35179"
      unitRef="uref_138071911">139327</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="cref_303504771"
      decimals="0"
      id="ixv-35180"
      unitRef="uref_138071911">499612</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="cref_1591042892"
      decimals="0"
      id="ixv-35181"
      unitRef="uref_138071911">578721</ifrs-full:AuditorsRemuneration>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="cref_1085778750" id="ixv-25525">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;18 Loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Reconciliations of loss used in calculating loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left;"&gt;Basic and diluted loss per share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Loss attributable to the ordinary equity holders of the     group used in calculating loss per share:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;From continuing operations&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;55,149,150&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;38,342,457&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;47,949,119&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Weighted average number of shares used as the denominator&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2026 &lt;br/&gt; Number&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2025&lt;br/&gt; Number&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2024&lt;br/&gt; Number&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Weighted average number     of ordinary shares used as the denominator in calculating basic and diluted loss per share&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right;"&gt;3,073,344,067&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;2,081,058,451&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;386,460,137&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;On the basis of the group&#x2019;s losses, the outstanding options as at 30 June 2026 are considered to be anti-dilutive and therefore were excluded from the diluted weighted average number of ordinary shares calculation.&lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="cref_1085778750" id="ixv-25530">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Reconciliations of loss used in calculating loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2026 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; border-bottom: Black 1.5pt solid;"&gt;30 June&lt;br/&gt; 2024 &lt;br/&gt; $&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left;"&gt;Basic and diluted loss per share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Loss attributable to the ordinary equity holders of the     group used in calculating loss per share:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;From continuing operations&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;55,149,150&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;38,342,457&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;47,949,119&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35182"
      unitRef="uref_1453202449">55149150</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35183"
      unitRef="uref_1453202449">55149150</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35184"
      unitRef="uref_1453202449">38342457</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35185"
      unitRef="uref_1453202449">38342457</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-35186"
      unitRef="uref_1453202449">47949119</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-35187"
      unitRef="uref_1453202449">47949119</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <radx:DisclosureOfWeightedAverageNumberOfSharesUsedAsTheDenominatorExplanatoryTextBlock contextRef="cref_1085778750" id="ixv-25596">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Weighted average number of shares used as the denominator&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;2026 &lt;br/&gt; Number&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2025&lt;br/&gt; Number&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;2024&lt;br/&gt; Number&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt;"&gt;Weighted average number     of ordinary shares used as the denominator in calculating basic and diluted loss per share&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right;"&gt;3,073,344,067&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;2,081,058,451&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right;"&gt;386,460,137&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</radx:DisclosureOfWeightedAverageNumberOfSharesUsedAsTheDenominatorExplanatoryTextBlock>
    <ifrs-full:WeightedAverageShares
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35188"
      unitRef="uref_1634518116">3073344067</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35189"
      unitRef="uref_1634518116">3073344067</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35190"
      unitRef="uref_1634518116">2081058451</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35191"
      unitRef="uref_1634518116">2081058451</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-35192"
      unitRef="uref_1634518116">386460137</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="cref_812473718"
      decimals="0"
      id="ixv-35193"
      unitRef="uref_1634518116">386460137</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="cref_1085778750" id="ixv-25650">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;19 Parent entity financial information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Summary financial information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The individual financial statements for the parent entity shows the following aggregate amounts:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;30 June &lt;br/&gt; 2026&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left;"&gt;Statement of financial position&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Current assets&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;21,648,230&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;39,621,179&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Non-current assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;65,272,919&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;40,000,365&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Total assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;86,921,149&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,621,544&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Current liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;16,967,577&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;14,091,574&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Non-current liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;20,537,925&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;29,653,015&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Total liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;37,505,502&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;43,744,588&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-style: italic; text-align: left;"&gt;Shareholders&#x2019; equity&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Issued capital&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Other equity&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64281204;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;Reserves&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Shares to be issued&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_350124766;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1324146248;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;13,873,018&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Equity Settled Payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64721603;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_15923225;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Retained earnings&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(174,390,743&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(154,728,303&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;49,415,647&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;35,876,956&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Loss for the year&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(39,945,543&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(32,205,611&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total comprehensive loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(39,945,543&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(32,205,611&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Guarantees entered into by the parent entity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The parent entity has not entered into any guarantees in relation to debts of its subsidiaries in the year ended 30 June 2026 (30 June 2025: &lt;span style="-sec-ix-hidden:fc_2089182294;"&gt;nil&lt;/span&gt;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Contingent liabilities of the parent entity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The parent entity had contingent liabilities at 30 June 2026 and 30 June 2025 identical to those of the group, as outlined in note 13.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(d) Contractual commitments for the acquisition of property, plant or equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; The parent entity has not entered into any contractual commitments for the acquisition of property, plant or equipment in the year ended 30 June 2026 (30 June 2025 &lt;span style="-sec-ix-hidden:fc_1621405148;"&gt;nil&lt;/span&gt;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(e) Determining the parent entity financial information&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The financial information for the parent entity has been prepared on the same basis as the consolidated financial statements, except as set out below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Investments in subsidiaries, associates and joint venture entities&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Investments in subsidiaries are accounted for at cost in the financial statements of Radiopharm Theranostics Limited&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="cref_1085778750" id="ixv-25658">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The individual financial statements for the parent entity shows the following aggregate amounts:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;30 June &lt;br/&gt; 2026&lt;br/&gt;     $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;30 June&lt;br/&gt; 2025 &lt;br/&gt; $&lt;/td&gt; &lt;td style="text-align: right; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left;"&gt;Statement of financial position&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Current assets&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; font-weight: bold; text-align: right;"&gt;21,648,230&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;39,621,179&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Non-current assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;65,272,919&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;40,000,365&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Total assets&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;86,921,149&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;79,621,544&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Current liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;16,967,577&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;14,091,574&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Non-current liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;20,537,925&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;29,653,015&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Total liabilities&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;37,505,502&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;43,744,588&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-style: italic; text-align: left;"&gt;Shareholders&#x2019; equity&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Issued capital&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;209,933,371&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;176,558,493&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Other equity&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64281204;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;849,544&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;Reserves&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Shares to be issued&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_350124766;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1324146248;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Share-based payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;13,873,018&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13,197,222&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-left: 0.125in; text-align: left;"&gt;Equity Settled Payments&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_64721603;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_15923225;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Retained earnings&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(174,390,743&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(154,728,303&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;49,415,647&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;35,876,956&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Loss for the year&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(39,945,543&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(32,205,611&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt;"&gt;Total comprehensive loss&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right;"&gt;(39,945,543&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(32,205,611&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:CurrentAssets
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35194"
      unitRef="uref_138071911">21648230</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35195"
      unitRef="uref_138071911">39621179</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35196"
      unitRef="uref_138071911">65272919</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35197"
      unitRef="uref_138071911">40000365</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35198"
      unitRef="uref_138071911">86921149</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35199"
      unitRef="uref_138071911">79621544</ifrs-full:Assets>
    <ifrs-full:CurrentLiabilities
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35200"
      unitRef="uref_138071911">16967577</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35201"
      unitRef="uref_138071911">14091574</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35202"
      unitRef="uref_138071911">20537925</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35203"
      unitRef="uref_138071911">29653015</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35204"
      unitRef="uref_138071911">37505502</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35205"
      unitRef="uref_138071911">43744588</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35206"
      unitRef="uref_138071911">209933371</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35207"
      unitRef="uref_138071911">176558493</ifrs-full:IssuedCapital>
    <ifrs-full:OtherEquityInterest
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35208"
      unitRef="uref_138071911">849544</ifrs-full:OtherEquityInterest>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35209"
      unitRef="uref_138071911">13873018</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35210"
      unitRef="uref_138071911">13197222</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:RetainedEarnings
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35211"
      unitRef="uref_138071911">-174390743</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35212"
      unitRef="uref_138071911">-154728303</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="cref_540356014"
      decimals="0"
      id="ixv-35213"
      unitRef="uref_138071911">49415647</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="cref_312638053"
      decimals="0"
      id="ixv-35214"
      unitRef="uref_138071911">35876956</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="cref_1345123180"
      decimals="0"
      id="ixv-35215"
      unitRef="uref_138071911">-39945543</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="cref_1018615720"
      decimals="0"
      id="ixv-35216"
      unitRef="uref_138071911">-32205611</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1345123180"
      decimals="0"
      id="ixv-35217"
      unitRef="uref_138071911">-39945543</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1018615720"
      decimals="0"
      id="ixv-35218"
      unitRef="uref_138071911">-32205611</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="cref_1085778750" id="ixv-25925">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;20 Summary of material accounting policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Basis of preparation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the &lt;i&gt;Corporations Act 2001&lt;/i&gt;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Radiopharm Theranostics Limited is a for-profit entity for the purpose of preparing the financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Compliance with IFRS&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The financial statements of the Radiopharm Theranostics Limited group also complies with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Historical cost convention&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The financial statements have been prepared on a historical cost basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Going concern&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; For the year ended June 30, 2026, the group incurred a total comprehensive loss of A$56,329,054 (2025: 37,878,423) and net cash outflows from operations of A$52,782,838 (2025: $36,645,477). As at June 30, 2026, the group held total cash and cash equivalents of A$4,138,074 and net assets of A$22,323,683. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest in resources in research and development activities for their clinical pipeline. These conditions mean that there is a material uncertainty on the group&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s ongoing viability and ability to continue as a going concern depends on its capacity to meet debts and commitments as they fall due. Based on current budget forecast assumptions, the group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. In addition, the group has the ability to employ cash management strategies such as delaying or reducing some operating activities and will be required to raise further capital subject to maintaining an active listing on the NASDAQ exchange as well as compliance with the group&#x2019;s obligations under ASX Listing Rule 7.1. The group&#x2019;s track record of successful capital raises provides confidence in their ability to secure funding if required.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The directors believe that the group can raise capital as required based on the success of previous capital raises and the continued development of the group&#x2019;s projects.&lt;br/&gt; &lt;br/&gt;  On July 24, 2026, the group announced a A$12.5 million institutional offer and launched a A$6 million Share Purchase Plan. The institutional offer comprises of to-tranche placement of approximately 448,839,531 new fully paid ordinary shares at A$0.015 per New Share to a Australian institutional and sophisticated investors; and 384,493,800 underlying ordinary shares at US$3.16 per ADS to a US Direct Registration Offering. The Share Purchase Plan offer closed on September 10, 2026 and A$3 million was raised during the process. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Based on the above, the directors are satisfied that the group is able to meet their commitments over the next 12 months, and for that reason the financial statements have been prepared on the basis that the group is a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Should the group be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements. The group will also be required to significantly reduce its operating activities and manage its costs. The financial statements do not include any adjustments relation to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessarily incurred should the group not continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iv) New standards and interpretations not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the group&#x2019;s financial statements are disclosed below. The group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;AASB 18 Presentation and     Disclosure in Financial Statements&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In June 2024, the AASB issued AASB 18, which replaces AASB 101 Presentation of Financial Statements. AASB 18 introduces new requirements for presentation within the statement of comprehensive income, including specified totals and subtotals. Furthermore, entities are required to classify all income and expenses within the statement of comprehensive income into one of five categories: operating, investing, financing, income taxes and discontinued operations, whereof the first three are new. It also requires disclosure of newly defined management-defined performance measures, subtotals of income and expenses and includes new requirements for aggregation and disaggregation of financial information based on the identified &#x2018;roles&#x2019; of the primary financial statements and the notes. In addition, narrow-scope amendments have been made to AASB 107 Statement of Cash Flows, which include changing the starting point from determining cash flows from operations under the indirect method, from &#x2018;profit or loss&#x2019; to &#x2018;operating profit or loss&#x2019; and removing the optionality around classification of cash flow from dividends and interest. In addition, there are consequential amendments to several other standards. AASB 18, and the amendments to the other standards, is effective for reporting periods beginning on or after 1 January 2027.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(v) Listing Rule 4.10.19&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In accordance with LR 4.10.19, the company has used the cash and assets in a form readily convertible to cash that it had at the time of admission to the Official listing of ASX Limited on 23 November 2021, in a way that is consistent with its business objectives, during the period from admission to 30 June 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Principles of consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Subsidiaries&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The acquisition method of accounting is used to account for business combinations by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Functional and presentation currency&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Items included in the financial statements of the group are measured using the currency of the primary economic environment in which the entity operates (&#x2018;the functional currency&#x2019;). The financial statements are presented in the Australian dollar ($), which is Radiopharm Theranostics Limited&#x2019;s functional and presentation currency. The subsidiaries of Radiopharm Theranostics Limited; Radiopharm Theranostics (USA) Inc and Radiopharm Ventures LLC both use USD as their functional currency. Upon consolidation, these USD amounts are converted to AUD for use in this report.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Transactions and balances&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within finance income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(d) Impairment of assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Intangible assets are tested at each reporting period for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting year. Assets are also assessed if they are ready-for-use each reporting period and will be commence amortization once ready-for-use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(e) Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(f) Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less loss allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off by reducing the carrying amount directly. An allowance account (provision for impairment of trade receivables) is used when there is objective evidence that the group will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization, and default or delinquency in payments (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount of the impairment allowance is the difference between the asset&#x2019;s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short-term receivables are not discounted if the effect of discounting is immaterial. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The amount of the impairment loss is recognized in profit or loss within other expenses. When a trade receivable for which an impairment allowance had been recognized becomes uncollectible in a subsequent year, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against other expenses in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(g) Assets classified as held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Assets are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;A loss is recognized for any initial or subsequent write-down of the asset to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset, but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset is recognized at the date of derecognition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(h) Investments and other financial assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Classification&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group classifies its financial assets in the following categories:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;those to be measured subsequently     at fair value (either through OCI or through profit or loss), and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;those to be measured at     amortized cost.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The classification depends on the entity&#x2019;s business model for managing the financial assets and the contractual terms of the cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Recognition and derecognition&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Measurement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iv) Financial instruments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Subsequent measurement of financial instruments depends on the group&#x2019;s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the group classifies its financial instruments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Amortized cost: Assets     that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest     are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest     rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses)     together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the consolidated statement     of profit or loss.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FVOCI: Assets that are     held for collection of contractual cash flows and for selling the financial assets, where the assets&#x2019; cash flows represent     solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except     for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in     profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified     from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in     finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses)     and impairment expenses are presented as separate line item in the consolidated statement of profit or loss.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FVPL: Assets that do not     meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured     at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the year in which it arises.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(v) Impairment&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group assesses on a forward looking basis the expected credit losses associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(i) Classification and measurement of financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Financial liabilities are initially measured at fair value and where applicable adjusted for transaction costs. Subsequently, financial liabilities are measured at amortized cost using the effective interest rate method unless the group has designated a financial liability at fair value through profit or loss with subsequent gains or losses recognised in profit or loss&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;All interest-related charges and, if applicable, changes in an instrument&#x2019;s fair value that are reported in profit or loss are included within finance costs or finance income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(j) Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Intangible assets are initially measured at cost. Following initial recognition, intangible assets are carried at historical cost, less any accumulated amortization and impairment losses. The useful lives of intangible assets that are available for use are assessed to be either finite or indefinite. Intangible assets with finite lives are amortized over the useful life and assessed for impairment whenever there is an indication of impairment. Amortization methods and periods for an intangible asset with a finite useful life is reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization method and/or period, as appropriate, which is a change in accounting estimate and applied prospectively. The amortization expense on intangible assets with finite lives is recognized in the consolidated statement of profit or loss and other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Acquisition of intangible assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has applied judgement in determining the accounting treatment for the acquisition of license agreements. License agreements have been determined to be stand-alone transactions, independent from any other agreement entered between the group and the licensor.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Future changes to probability of milestones becoming payable in subsequent periods will be captured in the consolidated statement of profit or loss and other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Contingent consideration on the acquisition of intangible assets is initially measured at fair value, and subsequently measured at&#160;amortized cost using the effective interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Future changes to probability of milestones becoming payable in subsequent periods, and other changes which impact the carrying amount of contingent consideration, will be captured in the consolidated statement of profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Research and development&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.85pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(iii) Amortization methods and useful lives&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Management has assessed capitalized patents, licenses and other rights as available for their intended use. These assets are amortized on a straight-line basis over the period of their expected benefit.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(k) Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting year. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(l) Contributed equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Ordinary shares are classified as equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(m) Loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-align: justify; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Basic loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Basic earnings per share is calculated by dividing:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-align: justify; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;the profit attributable to owners of the group, excluding     any costs of servicing equity other than ordinary shares&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;by the weighted average     number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the     year.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.9pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Diluted loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;the after income tax effect     of interest and other financing costs associated with dilutive potential ordinary shares, and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;the weighted average number     of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(n) &lt;i&gt;Revenue recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group recognizes revenue as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Revenue from contracts with customers&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Revenue is recognized at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the group: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognizes revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts or rebates, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the &#x2018;expected value&#x2019; or &#x2018;most likely amount&#x2019; method. This is based on their experience and considering industry information on clinical trial success rates and related parameters. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognized as a refund liability.&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <radx:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory contextRef="cref_1085778750" id="ixv-25930">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(a) Basis of preparation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the &lt;i&gt;Corporations Act 2001&lt;/i&gt;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Radiopharm Theranostics Limited is a for-profit entity for the purpose of preparing the financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Compliance with IFRS&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The financial statements of the Radiopharm Theranostics Limited group also complies with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Historical cost convention&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The financial statements have been prepared on a historical cost basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Going concern&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; For the year ended June 30, 2026, the group incurred a total comprehensive loss of A$56,329,054 (2025: 37,878,423) and net cash outflows from operations of A$52,782,838 (2025: $36,645,477). As at June 30, 2026, the group held total cash and cash equivalents of A$4,138,074 and net assets of A$22,323,683. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest in resources in research and development activities for their clinical pipeline. These conditions mean that there is a material uncertainty on the group&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group&#x2019;s ongoing viability and ability to continue as a going concern depends on its capacity to meet debts and commitments as they fall due. Based on current budget forecast assumptions, the group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. In addition, the group has the ability to employ cash management strategies such as delaying or reducing some operating activities and will be required to raise further capital subject to maintaining an active listing on the NASDAQ exchange as well as compliance with the group&#x2019;s obligations under ASX Listing Rule 7.1. The group&#x2019;s track record of successful capital raises provides confidence in their ability to secure funding if required.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The directors believe that the group can raise capital as required based on the success of previous capital raises and the continued development of the group&#x2019;s projects.&lt;br/&gt; &lt;br/&gt;  On July 24, 2026, the group announced a A$12.5 million institutional offer and launched a A$6 million Share Purchase Plan. The institutional offer comprises of to-tranche placement of approximately 448,839,531 new fully paid ordinary shares at A$0.015 per New Share to a Australian institutional and sophisticated investors; and 384,493,800 underlying ordinary shares at US$3.16 per ADS to a US Direct Registration Offering. The Share Purchase Plan offer closed on September 10, 2026 and A$3 million was raised during the process. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Based on the above, the directors are satisfied that the group is able to meet their commitments over the next 12 months, and for that reason the financial statements have been prepared on the basis that the group is a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Should the group be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements. The group will also be required to significantly reduce its operating activities and manage its costs. The financial statements do not include any adjustments relation to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessarily incurred should the group not continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iv) New standards and interpretations not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the group&#x2019;s financial statements are disclosed below. The group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;AASB 18 Presentation and     Disclosure in Financial Statements&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In June 2024, the AASB issued AASB 18, which replaces AASB 101 Presentation of Financial Statements. AASB 18 introduces new requirements for presentation within the statement of comprehensive income, including specified totals and subtotals. Furthermore, entities are required to classify all income and expenses within the statement of comprehensive income into one of five categories: operating, investing, financing, income taxes and discontinued operations, whereof the first three are new. It also requires disclosure of newly defined management-defined performance measures, subtotals of income and expenses and includes new requirements for aggregation and disaggregation of financial information based on the identified &#x2018;roles&#x2019; of the primary financial statements and the notes. In addition, narrow-scope amendments have been made to AASB 107 Statement of Cash Flows, which include changing the starting point from determining cash flows from operations under the indirect method, from &#x2018;profit or loss&#x2019; to &#x2018;operating profit or loss&#x2019; and removing the optionality around classification of cash flow from dividends and interest. In addition, there are consequential amendments to several other standards. AASB 18, and the amendments to the other standards, is effective for reporting periods beginning on or after 1 January 2027.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(v) Listing Rule 4.10.19&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;In accordance with LR 4.10.19, the company has used the cash and assets in a form readily convertible to cash that it had at the time of admission to the Official listing of ASX Limited on 23 November 2021, in a way that is consistent with its business objectives, during the period from admission to 30 June 2026.&lt;/p&gt;</radx:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35219"
      unitRef="uref_138071911">-56329054</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35220"
      unitRef="uref_138071911">-37878423</ifrs-full:ComprehensiveIncome>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_1085778750"
      decimals="0"
      id="ixv-35221"
      unitRef="uref_138071911">-52782838</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="cref_198500851"
      decimals="0"
      id="ixv-35222"
      unitRef="uref_138071911">-36645477</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="cref_1305557533"
      decimals="0"
      id="ixv-35223"
      unitRef="uref_138071911">4138074</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentAssets
      contextRef="cref_2001163503"
      decimals="0"
      id="ixv-35224"
      unitRef="uref_138071911">22323683</ifrs-full:OtherCurrentAssets>
    <radx:AmountOfInstitutionalOffer
      contextRef="cref_1360674854"
      decimals="-5"
      id="ixv-35225"
      unitRef="uref_138071911">12500000</radx:AmountOfInstitutionalOffer>
    <radx:AmountOfInstitutionalLaunched
      contextRef="cref_1360674854"
      decimals="-6"
      id="ixv-35226"
      unitRef="uref_138071911">6000000</radx:AmountOfInstitutionalLaunched>
    <ifrs-full:Equity
      contextRef="cref_17985243"
      decimals="0"
      id="ixv-35227"
      unitRef="uref_138071911">448839531</ifrs-full:Equity>
    <ifrs-full:ParValuePerShare
      contextRef="cref_17985243"
      decimals="3"
      id="ixv-35228"
      unitRef="uref_1453202449">0.015</ifrs-full:ParValuePerShare>
    <ifrs-full:Equity
      contextRef="cref_608536123"
      decimals="0"
      id="ixv-35229"
      unitRef="uref_138071911">384493800</ifrs-full:Equity>
    <ifrs-full:ParValuePerShare
      contextRef="cref_608536123"
      decimals="2"
      id="ixv-35230"
      unitRef="uref_1453202449">3.16</ifrs-full:ParValuePerShare>
    <ifrs-full:IssueOfEquity
      contextRef="cref_1085778750"
      decimals="-6"
      id="ixv-35231"
      unitRef="uref_138071911">3000000</ifrs-full:IssueOfEquity>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="cref_1085778750" id="ixv-26022">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(b) Principles of consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Subsidiaries&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The acquisition method of accounting is used to account for business combinations by the group.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="cref_1085778750" id="ixv-26064">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(c) Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Functional and presentation currency&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Items included in the financial statements of the group are measured using the currency of the primary economic environment in which the entity operates (&#x2018;the functional currency&#x2019;). The financial statements are presented in the Australian dollar ($), which is Radiopharm Theranostics Limited&#x2019;s functional and presentation currency. The subsidiaries of Radiopharm Theranostics Limited; Radiopharm Theranostics (USA) Inc and Radiopharm Ventures LLC both use USD as their functional currency. Upon consolidation, these USD amounts are converted to AUD for use in this report.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Transactions and balances&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within finance income.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="cref_1085778750" id="ixv-26083">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(d) Impairment of assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Intangible assets are tested at each reporting period for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting year. Assets are also assessed if they are ready-for-use each reporting period and will be commence amortization once ready-for-use.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="cref_1085778750" id="ixv-26090">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(e) Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory contextRef="cref_1085778750" id="ixv-26097">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(f) Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less loss allowance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt; Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off by reducing the carrying amount directly. An allowance account (provision for impairment of trade receivables) is used when there is objective evidence that the group will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization, and default or delinquency in payments (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount of the impairment allowance is the difference between the asset&#x2019;s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short-term receivables are not discounted if the effect of discounting is immaterial. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The amount of the impairment loss is recognized in profit or loss within other expenses. When a trade receivable for which an impairment allowance had been recognized becomes uncollectible in a subsequent year, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against other expenses in profit or loss.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <radx:MaximumOverdueDays contextRef="cref_1085778750" id="ixv-35232">P30D</radx:MaximumOverdueDays>
    <radx:DescriptionOfAccountingPolicyForAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory contextRef="cref_1085778750" id="ixv-26131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(g) Assets classified as held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Assets are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;A loss is recognized for any initial or subsequent write-down of the asset to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset, but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset is recognized at the date of derecognition.&lt;/p&gt;</radx:DescriptionOfAccountingPolicyForAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
    <radx:DescriptionOfAccountingPolicyInvestmentsAndOtherFinancialAssetsExplanatory contextRef="cref_1085778750" id="ixv-26140">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(h) Investments and other financial assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(i) Classification&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;The group classifies its financial assets in the following categories:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;those to be measured subsequently     at fair value (either through OCI or through profit or loss), and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;those to be measured at     amortized cost.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The classification depends on the entity&#x2019;s business model for managing the financial assets and the contractual terms of the cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Recognition and derecognition&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iii) Measurement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(iv) Financial instruments&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Subsequent measurement of financial instruments depends on the group&#x2019;s business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the group classifies its financial instruments:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Amortized cost: Assets     that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest     are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest     rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses)     together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the consolidated statement     of profit or loss.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FVOCI: Assets that are     held for collection of contractual cash flows and for selling the financial assets, where the assets&#x2019; cash flows represent     solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except     for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognized in     profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified     from equity to profit or loss and recognized in other gains/(losses). Interest income from these financial assets is included in     finance income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains/(losses)     and impairment expenses are presented as separate line item in the consolidated statement of profit or loss.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;FVPL: Assets that do not     meet the criteria for amortized cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured     at FVPL is recognized in profit or loss and presented net within other gains/(losses) in the year in which it arises.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(v) Impairment&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group assesses on a forward looking basis the expected credit losses associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk.&lt;/p&gt;</radx:DescriptionOfAccountingPolicyInvestmentsAndOtherFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="cref_1085778750" id="ixv-26245">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(i) Classification and measurement of financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Financial liabilities are initially measured at fair value and where applicable adjusted for transaction costs. Subsequently, financial liabilities are measured at amortized cost using the effective interest rate method unless the group has designated a financial liability at fair value through profit or loss with subsequent gains or losses recognised in profit or loss&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;All interest-related charges and, if applicable, changes in an instrument&#x2019;s fair value that are reported in profit or loss are included within finance costs or finance income.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="cref_1085778750" id="ixv-26272">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(j) Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Intangible assets are initially measured at cost. Following initial recognition, intangible assets are carried at historical cost, less any accumulated amortization and impairment losses. The useful lives of intangible assets that are available for use are assessed to be either finite or indefinite. Intangible assets with finite lives are amortized over the useful life and assessed for impairment whenever there is an indication of impairment. Amortization methods and periods for an intangible asset with a finite useful life is reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization method and/or period, as appropriate, which is a change in accounting estimate and applied prospectively. The amortization expense on intangible assets with finite lives is recognized in the consolidated statement of profit or loss and other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Acquisition of intangible assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group has applied judgement in determining the accounting treatment for the acquisition of license agreements. License agreements have been determined to be stand-alone transactions, independent from any other agreement entered between the group and the licensor.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Future changes to probability of milestones becoming payable in subsequent periods will be captured in the consolidated statement of profit or loss and other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Contingent consideration on the acquisition of intangible assets is initially measured at fair value, and subsequently measured at&#160;amortized cost using the effective interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Future changes to probability of milestones becoming payable in subsequent periods, and other changes which impact the carrying amount of contingent consideration, will be captured in the consolidated statement of profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Research and development&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.85pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(iii) Amortization methods and useful lives&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Management has assessed capitalized patents, licenses and other rights as available for their intended use. These assets are amortized on a straight-line basis over the period of their expected benefit.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory contextRef="cref_1085778750" id="ixv-26304">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(k) Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting year. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="cref_1085778750" id="ixv-26330">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(l) Contributed equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;Ordinary shares are classified as equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="cref_1085778750" id="ixv-26339">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;(m) Loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-align: justify; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;(i) Basic loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Basic earnings per share is calculated by dividing:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-align: justify; text-indent: -15.95pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;the profit attributable to owners of the group, excluding     any costs of servicing equity other than ordinary shares&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;by the weighted average     number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the     year.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.9pt; text-indent: 0pt;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;(ii) Diluted loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;the after income tax effect     of interest and other financing costs associated with dilutive potential ordinary shares, and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.95pt; text-indent: -16pt;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;the weighted average number     of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="cref_1085778750" id="ixv-26392">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;(n) &lt;i&gt;Revenue recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;The group recognizes revenue as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Revenue from contracts with customers&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Revenue is recognized at an amount that reflects the consideration to which the consolidated entity is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the group: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognizes revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts or rebates, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the &#x2018;expected value&#x2019; or &#x2018;most likely amount&#x2019; method. This is based on their experience and considering industry information on clinical trial success rates and related parameters. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognized as a refund liability.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:ExplanationOfFinancialEffectOfNonadjustingEventAfterReportingPeriod contextRef="cref_1085778750" id="ixv-26405">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;21 Events occurring after the reporting year&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt;"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt; On July 24, 2026, the Company announced an A$12.5 million institutional offer and launched A$6 million Share Purchase Plan. The institutional offer comprises of two-tranche placement of approximately 448,839,531 new fully paid ordinary shares at A$0.015 per New Share to an Australian international institutional and sophisticated investors; and 384,493,800 underlying ordinary shares at US$3.16 per ADS to a US Direct Registration Offering. The Share Purchase Plan offer closed on 10 September 2026 and a further A$3m was raised. &lt;/p&gt;</ifrs-full:ExplanationOfFinancialEffectOfNonadjustingEventAfterReportingPeriod>
    <radx:AmountUsed
      contextRef="cref_1391050674"
      decimals="-5"
      id="ixv-35233"
      unitRef="uref_138071911">12500000</radx:AmountUsed>
    <radx:AmountUsed
      contextRef="cref_1449520954"
      decimals="-6"
      id="ixv-35234"
      unitRef="uref_138071911">6000000</radx:AmountUsed>
    <radx:IssueOfOrdinaryShares
      contextRef="cref_1391050674"
      decimals="0"
      id="ixv-35235"
      unitRef="uref_1634518116">448839531</radx:IssueOfOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="cref_208507239"
      decimals="3"
      id="ixv-35236"
      unitRef="uref_1453202449">0.015</ifrs-full:ParValuePerShare>
    <radx:UnderlyingOrdinaryShares
      contextRef="cref_1453202449"
      decimals="0"
      id="ixv-35237"
      unitRef="uref_1634518116">384493800</radx:UnderlyingOrdinaryShares>
    <radx:UnderlyingOrdinarySharesPricePerShare
      contextRef="cref_1453202449"
      decimals="2"
      id="ixv-35238"
      unitRef="uref_1453202449">3.16</radx:UnderlyingOrdinarySharesPricePerShare>
    <radx:AmountUsed
      contextRef="cref_138071911"
      decimals="0"
      id="ixv-35239"
      unitRef="uref_138071911">3</radx:AmountUsed>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_803299973"
          xlink:label="fc_803299973"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_367163782"
          xlink:label="fc_367163782"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1679625513"
          xlink:label="fc_1679625513"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_838689820"
          xlink:label="fc_838689820"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_223383173"
          xlink:label="fc_223383173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1512562005"
          xlink:label="fc_1512562005"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_290225396"
          xlink:label="fc_290225396"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_71955621"
          xlink:label="fc_71955621"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1493941943"
          xlink:label="fc_1493941943"
          xlink:type="locator"/>
        <link:footnote id="fref_128785213" xlink:label="fref_128785213" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accrued receivables Accrued receivables comprise $15,877,895 from the Australian Taxation Office in relation to the R&amp;D tax incentive (30 June 2025: $10,171,532).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_803299973"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_367163782"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1679625513"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_838689820"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_223383173"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1512562005"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_290225396"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_71955621"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1493941943"
          xlink:to="fref_128785213"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_508051551"
          xlink:label="fc_508051551"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_496556634"
          xlink:label="fc_496556634"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2014217810"
          xlink:label="fc_2014217810"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1906481532"
          xlink:label="fc_1906481532"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1397869314"
          xlink:label="fc_1397869314"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_104051111"
          xlink:label="fc_104051111"
          xlink:type="locator"/>
        <link:footnote id="fref_1124768100" xlink:label="fref_1124768100" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">the tax rate is driven                                             by 21.1% for the federal rate and 6.5% for the new York sate rate</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_508051551"
          xlink:to="fref_1124768100"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_496556634"
          xlink:to="fref_1124768100"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2014217810"
          xlink:to="fref_1124768100"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1906481532"
          xlink:to="fref_1124768100"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1397869314"
          xlink:to="fref_1124768100"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_104051111"
          xlink:to="fref_1124768100"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_569852528"
          xlink:label="fc_569852528"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1430126581"
          xlink:label="fc_1430126581"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1458693029"
          xlink:label="fc_1458693029"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1351611906"
          xlink:label="fc_1351611906"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1503119618"
          xlink:label="fc_1503119618"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1477221416"
          xlink:label="fc_1477221416"
          xlink:type="locator"/>
        <link:footnote id="fref_1281992523" xlink:label="fref_1281992523" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Payment to be made in the     form of ordinary shares in the company, based on the price of the 7-day volume weighted average price (VWAP) prior to the announcement     of the milestone on the ASX.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_569852528"
          xlink:to="fref_1281992523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1430126581"
          xlink:to="fref_1281992523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1458693029"
          xlink:to="fref_1281992523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1351611906"
          xlink:to="fref_1281992523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1503119618"
          xlink:to="fref_1281992523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1477221416"
          xlink:to="fref_1281992523"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_612133084"
          xlink:label="fc_612133084"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1304397351"
          xlink:label="fc_1304397351"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1016384458"
          xlink:label="fc_1016384458"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_701424536"
          xlink:label="fc_701424536"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1843483613"
          xlink:label="fc_1843483613"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1870684131"
          xlink:label="fc_1870684131"
          xlink:type="locator"/>
        <link:footnote id="fref_353944298" xlink:label="fref_353944298" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The NeoIndicate asset was     handed back to the university during the financial year, resulting in the unwinding of contingent consideration for its milestone     payments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_612133084"
          xlink:to="fref_353944298"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1304397351"
          xlink:to="fref_353944298"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1016384458"
          xlink:to="fref_353944298"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_701424536"
          xlink:to="fref_353944298"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1843483613"
          xlink:to="fref_353944298"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1870684131"
          xlink:to="fref_353944298"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1781282920"
          xlink:label="fc_1781282920"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_357496978"
          xlink:label="fc_357496978"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_371904715"
          xlink:label="fc_371904715"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_81216337"
          xlink:label="fc_81216337"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1403551223"
          xlink:label="fc_1403551223"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1118738496"
          xlink:label="fc_1118738496"
          xlink:type="locator"/>
        <link:footnote id="fref_1138865372" xlink:label="fref_1138865372" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Pharma15 asset was     fully impaired during the year and as a result the likelihood of milestones being met for the progression of the asset has been also     reduced to nil.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1781282920"
          xlink:to="fref_1138865372"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_357496978"
          xlink:to="fref_1138865372"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_371904715"
          xlink:to="fref_1138865372"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_81216337"
          xlink:to="fref_1138865372"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1403551223"
          xlink:to="fref_1138865372"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1118738496"
          xlink:to="fref_1138865372"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1701782481"
          xlink:label="fc_1701782481"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2094687344"
          xlink:label="fc_2094687344"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_422900191"
          xlink:label="fc_422900191"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_358279390"
          xlink:label="fc_358279390"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1912404370"
          xlink:label="fc_1912404370"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2112481639"
          xlink:label="fc_2112481639"
          xlink:type="locator"/>
        <link:footnote id="fref_2133402036" xlink:label="fref_2133402036" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Leave obligations</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1701782481"
          xlink:to="fref_2133402036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2094687344"
          xlink:to="fref_2133402036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_422900191"
          xlink:to="fref_2133402036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_358279390"
          xlink:to="fref_2133402036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1912404370"
          xlink:to="fref_2133402036"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2112481639"
          xlink:to="fref_2133402036"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_249693967"
          xlink:label="fc_249693967"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_334748240"
          xlink:label="fc_334748240"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2078799935"
          xlink:label="fc_2078799935"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_656615078"
          xlink:label="fc_656615078"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_206936431"
          xlink:label="fc_206936431"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_710217859"
          xlink:label="fc_710217859"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1832352150"
          xlink:label="fc_1832352150"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1492758934"
          xlink:label="fc_1492758934"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1912952120"
          xlink:label="fc_1912952120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2010432990"
          xlink:label="fc_2010432990"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1533432965"
          xlink:label="fc_1533432965"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1069442394"
          xlink:label="fc_1069442394"
          xlink:type="locator"/>
        <link:footnote id="fref_692164228" xlink:label="fref_692164228" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Holding all other variables     constant</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_249693967"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_334748240"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2078799935"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_656615078"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_206936431"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_710217859"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1832352150"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1492758934"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1912952120"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2010432990"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1533432965"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1069442394"
          xlink:to="fref_692164228"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1848343351"
          xlink:label="fc_1848343351"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_97068733"
          xlink:label="fc_97068733"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1659558259"
          xlink:label="fc_1659558259"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_517081436"
          xlink:label="fc_517081436"
          xlink:type="locator"/>
        <link:footnote id="fref_284161166" xlink:label="fref_284161166" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Holding all other variables     constant</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1848343351"
          xlink:to="fref_284161166"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_97068733"
          xlink:to="fref_284161166"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1659558259"
          xlink:to="fref_284161166"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_517081436"
          xlink:to="fref_284161166"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_17840321"
          xlink:label="fc_17840321"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_108840067"
          xlink:label="fc_108840067"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_786639730"
          xlink:label="fc_786639730"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1406080744"
          xlink:label="fc_1406080744"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1098967680"
          xlink:label="fc_1098967680"
          xlink:type="locator"/>
        <link:footnote id="fref_326747161" xlink:label="fref_326747161" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Payment to be made in the     form of ordinary shares in the company, based on the price of the 7 day VWAP prior to the announcement of the milestone on the ASX.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_17840321"
          xlink:to="fref_326747161"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_108840067"
          xlink:to="fref_326747161"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_786639730"
          xlink:to="fref_326747161"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1406080744"
          xlink:to="fref_326747161"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1098967680"
          xlink:to="fref_326747161"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_748034023"
          xlink:label="fc_748034023"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1078079355"
          xlink:label="fc_1078079355"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_868429"
          xlink:label="fc_868429"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1939047493"
          xlink:label="fc_1939047493"
          xlink:type="locator"/>
        <link:footnote id="fref_1171308972" xlink:label="fref_1171308972" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Payment to be made in the     form of ordinary shares in the company, based on the price of the 7 day (VWAP) prior to the announcement of the milestone on the     ASX.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_748034023"
          xlink:to="fref_1171308972"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1078079355"
          xlink:to="fref_1171308972"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_868429"
          xlink:to="fref_1171308972"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1939047493"
          xlink:to="fref_1171308972"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
